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100 years after its first description, Ewing sarcoma (EwS), the second most common bone-
associated cancer in children and young adults, is still poorly understood. Neither the cell of 
origin is known, nor the detailed mechanism of expression regulation by the pathognomic 
fusion oncogene. Similarly, factors causing overt clinical heterogeneity and 
advanced/targeted therapeutic strategies for patients with non-localized disease remain to be 
identified.  
An apparent paradox of EwS is its clinical heterogeneity compared to its silent landscape of 
genomic mutations. The only highly recurrent mutation in EwS is the characteristic fusion 
oncogene composed of EWSR1 and an ETS-transcription factor. Interactions of this single 
driver with the genome have been described and associated with gene expression regulation 
several times, but always in a small number of cell line models. This thesis aimed at creating 
a multidimensional dataset on a large number of EwS cell line models with and without fusion 
oncogene knockdown, the Ewing Sarcoma Cell Line Atlas (ESCLA), to both enable further 
investigations of expression regulation in EwS and model heterogeneity.  
In 18 well-characterized EwS cell lines, with three distinct fusion types, an inducible shRNA 
construct targeting the fusion oncogene was stably integrated. The whole genomes of the 
cell lines were sequenced with relatively long reads (150 bp) and >30 coverage. For the 
respective fusion and the histone marks H3K27ac, H3K27me3 and H3K4me3 chromatin 
immunoprecipitation with subsequent next-generation sequencing (ChIP-Seq) was 
performed. The transcriptome of the cells with and without fusion knockdown was assessed 
by ClariomD DNA microarrays, as was the protein expression by mass spectrometry and the 
CpG island methylation by MethylationEPIC BeadChip arrays. 
Whole genome sequencing enabled genotyping of several polymorphic potentially fusion 
binding microsatellites with GGAA motif. ChIP-Seq data were in line with previous 
publications and identified 50 additional consensus fusion binding sites. Transcriptome and 
proteome data strongly correlated with each other and displayed expression rearrangement 
upon fusion knockdown. Only for CpG methylation not any uniform effect of fusion oncogene 
knockdown was observed. 
Cell lines with distinct fusion types, EWSR1-FLI1 type 1, 2 and EWSR1-ERG, were for the 
first time systematically compared to each other. Neither expression regulation, nor 
methylation profile were dependent on the respective fusion. However, the fusion types 
differed in their rate of chromoplexy as developmental process. All EWSR1-ERG fusions and 
 
 
55% of EWSR1-FLI1 type 1 fusions developed from chromoplexy, whereas all EWSR1-FLI1 
type 2 fusions were the result of reciprocal translocation. 
Binding of the fusion to GGAA motifs appeared as multifactorial and still poorly understood 
process. Among others, high numbers of consecutive GGAA motifs, additional nearby motifs 
and microsatellites as well as and copy number gains correlated with fusion binding 
probability. Genes differentially expressed upon fusion knockdown differed from not affected 
genes in their distance to the next fusion bound GGAA mSat, the number of nearby GGAA 
mSats, and in the presence of transcription factor bindings sites for NFAT5, NFYC, and E2F2 
in their promoters. All these transcription factors were also regulated by the fusion oncogene. 
A set of 22 genes were identified to be regulated to different extends in the 18 cell line 
models upon fusion knockdown. This heterogeneity in regulation was in line with 
heterogeneous expression in patients, which correlated with overall survival. These genes 
were mainly associated with cell-cycle progression and cell division, transcription factors and 
targets of those. Yet, evaluated and identified parameters of EWSR1-ETS mediated gene 
expression regulation were not sufficient to fully explain inter-cell line differences in gene 
regulation.  
Several studies demonstrated previously an interaction between the fusion oncogene and 
GGAA microsatellites, but were limited to few loci. Previous whole exome sequencing 
projects missed out on these relevant regulatory regions. Reporter assays in vitro revealed 
enhancer activity of GGAA microsatellites, but in an artificial only mono-allelic approach. 
Studies and experiments on gene regulation in EwS with only two to three cell lines could 
hardly model heterogeneity. The here generated ESCLA overcame these obstacles, and 
supported, refined and expanded previously elaborated models of fusion oncogene mediated 
gene regulation genome wide.  
In conclusion, a multidimensional and comprehensive dataset was generated on a collection 
of EwS cell line models clearly outnumbering previous studies. Moreover, the dataset has 
already enabled first novel insights on the mechanisms and dependencies of fusion mediated 
gene regulation and modelled heterogeneity. The generated cell lines and the ESCLA likely 
constitute a rich resource for the Ewing sarcoma research community. Additionally, the 
capability of the dataset to model heterogeneity might enforce research on personalized 
medicine and the development of new treatment strategies for so far incurable advanced 
disease patients. 
 




1.1. General and clinical aspects of Ewing sarcoma  
Ewing sarcoma (EwS) is an aggressive bone and soft-tissue cancer (Grünewald et al., 2018). 
EwS mainly affects children and young adults with an incidence of 0.155 per 100,000 in 
Caucasians, thus constituting the second most common bone-associated sarcoma at 
younger ages after osteosarcoma (Kaatsch et al., 2016). Moreover, EwS occurs rarely at 
higher ages (Jawad et al., 2009). Males are more frequently affected than females (1.5 
times) (Jawad et al., 2009). The most common EwS bone cancer sites are the lower 
extremities and the pelvis (Grünewald et al., 2018). Soft-tissue EwS occurs more frequent in 
elder patients, rather located in the trunk than in the extremities (Applebaum et al., 2011). 
First symptoms are intermittent local and regional pain, palpable swelling and only rarely 
fever and pathological fracture (Grünewald et al., 2018; PDQ Pediatric Treatment Editorial 
Board, 2002).  
After assessment of symptoms, physical examination and radiography, EwS is diagnosed 
(molecular-)pathologically (Grünewald et al., 2018; PDQ Pediatric Treatment Editorial Board, 
2002). However, diagnosing EwS is still challenging (Orth et al., 2020). Although EwS was 
first described by its eponym James Ewing in 1920 referring to its histology as "diffuse 
endothelioma of bone", a round cell sarcoma of unknown origin with small polyhedral cells, 
hyperchromatic nuclei and pale cytoplasm without inter-cellular stroma (Ewing, 2006), the 
histology (Figure 1) is not unique to EwS. Several other cancers share the small-round-cell 
histology, even differential diagnoses like neuroblastoma and rhabdomyosarcoma (Carter 
and Patel, 2019; Hung et al., 2017; Sbaraglia et al., 2020). The standard 
immunohistochemical marker for EwS is CD99 (Ambros et al., 1991). However, it has been 
shown several times that CD99 is highly sensitive for EwS, but also unspecific (Baldauf et al., 
2018a; Orth et al., 2020; Zaccarini et al., 2018). Other proposed auxiliary markers like PAX7 
(Baldauf et al., 2018b; Charville et al., 2017) and NKX2-2 (Hung et al., 2016) lack specificity. 
Friend leukemia integration 1 transcription factor, FLI1, also lacks specificity and additional 
sensitivity as it is rarely expressed in those EwS, which are not positive for EWSR1-FLI1 
(Crompton et al., 2014; Rossi et al., 2004). The recently introduced immunohistochemical 
markers BCL11B and GLG1 are highly specific, but capture only 63% of EwS (Baldauf et al., 
2018a; Orth et al., 2020). Thus, further diagnostic procedures are based on the detection of 
the pathognomonic EWSR1-ETS fusion. The standard tool is fluorescence in situ 
hybridization for EWSR1 breakapart (Machado et al., 2009). Nevertheless, EWSR1 
breakapart occurs also in morphological mimics of EwS like desmoplastic small round cell 
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tumor (DSRCT) and angiomatoid fibrous histiocytoma (Papp et al., 2017). Elsewise, the 
fusion can be detected via quantitative real-time PCR, whose reliability is highly dependent 
on the seleted primers, or RNASeq (Antonescu, 2014).  
Standard treatment comprises neoadjuvant chemotherapy, often combinations with/of 
cyclophosphamide, doxorubicin and etoposide, followed by radiotherapy and/or resection 
(Gaspar et al., 2015; PDQ Pediatric Treatment Editorial Board, 2002). The further treatment 
should be adapted to histological response (Bosma et al., 2019). Prognosis is moderate in 
case of metastasis-free disease with a five-year survival rate of about 70%. Unfortunately, in 
about 25% of cases metastases have already formed at the time of diagnosis, leading to a by 
far worse survival rate (30%) (Bosma et al., 2018; Gaspar et al., 2015; Kridis et al., 2017). 
Noteworthy, the chemotherapeutics administered in young age and during development bear 
risks for permanent and late occurring adverse effects (Ginsberg et al., 2010; Longhi et al., 
2012). Unfortunately, more advanced and specific treatments were not established in 
standard clinical protocols. However, several candidate drugs, like clofarabine (Çelik et al., 
2018), and potential targets were described, for instance inhibition of PARP1 (Brenner et al., 
2012), PRKCB (Surdez et al., 2012), HDAC enzymes (Pattenden et al., 2016), and CDK12 
(Iniguez et al., 2018). 
 
 
Figure 1: Histology of EwS. HE staining; bar indicates 50 µm. From the Atlas of Genetics and 
Cytogenetics in Oncology and Haematology (URL http://AtlasGeneticsOncology.org; PMID 23161685). 
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The cell of origin is still, even 100 years after the first description of EwS, a matter of debate. 
Analyses on the morphology, histological markers, transcriptome and epigenome, as well as 
the site of tumor growth suggest that EwS develops from mesenchymal stem cells (Gordon 
et al., 2016; Sheffield et al., 2017; Tirode et al., 2007). However, very recently this 
assumption was questioned again in a report favoring pluripotent stem and neural crest cells 
as origin of EwS (Miller et al., 2020).  
 
 
1.2. Genomic aspects of EwS 
Genetically, EwS harbors a pathognomic aberrant fusion transcription factor. This fusion 
transcription factor results from in-frame translocation of the N-terminal part of the 
constitutively transcribed EWS RNA-binding protein 1 (EWSR1, chr22q12.2) to the C-
terminal part of a member of the ETS transcription factor family. In rare cases, EWSR1 is 
replaced by FUS, another member of the FET protein family (Chen et al., 2016; Tsuda et al., 
2020). The most common fusion partner for EWSR1 is the ETS transcription factor FLI1 
(chr11q24.3; 85%) (Delattre et al., 1992; Sorensen et al., 1994). EWSR1-FLI1 fusions (EF1) 
are differentiated by the last EWSR1 and first FLI1 exon in the fusion, most frequently 
EWSR1 exon 7 and FLI1 exon 6 (type 1) or EWSR1 exon 7 and FLI1 exon 5 (type 2) 
(Giovannini et al., 1994). Fusions to ETS-related gene (ERG; chr21q22.2), EWSR1-ERG 
(EErg) constitute another 10% of EwS fusion oncogenes (Sorensen et al., 1994; Zucman et 
al., 1993). Already at the time of the first EErg fusion description, it has been stated that this 
fusion cannot be the product of a simple balanced translocation, as the fusion partners are 
localized on opposite strands (Desmaze et al., 1997; Zucman et al., 1993). Recently, 
chromoplexy, a process involving multiple rearrangement loops over several chromosomes, 
was described as the developmental process for 42% of EwS fusion, especially for EErg 
(Anderson et al., 2018; Baca et al., 2013). Another rather seldom mutational process 
resulting in EwS fusion is chromothripsis (Anderson et al., 2018; Stephens et al., 2011). 
Despite the fusion oncogenes, EwS presents a mainly unaltered genome. Copy number 
gains of chromosome 1q (18%), 8 (47%) and 12 (21%) are recurrently observed, as is loss of 
chromosome 16q (17%) (Mackintosh et al., 2012; Tirode et al., 2014). CDKN2A deletions are 
also common in EwS (12%). TP53 mutations occur in about 7%, STAG2 mutations in about 
17%. Mutations in the coding sequence of STAG2 are actually the most frequent somatic 
mutations in EwS despite the fusion oncogene. STAG2, and even more coincidence with 
TP53 mutations are associated with poor outcome (Tirode et al., 2014). 
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Knockdown experiments of EF1 resulted in impaired proliferation and invasion, and higher 
rates of apoptosis (Chansky et al., 2004; Patel et al., 2012). Several further knockdown 
experiments for the EwS fusions were performed, mainly to identify a multitude of regulated 
and potential target genes (Smith et al., 2006; Tirode et al., 2007). Expression of the fusion in 
other cell types than EwS leads to various phenotypes indicating dependency of the cellular 
context for the action of EF1 (Kovar, 2005). For instance, while NIH3T3 cells were 
transformed (Arvand and Denny, 2001; May et al., 1993), mesenchymal stem cells from 
bone marrow were blocked in differentiation upon EF1 expression (Torchia et al., 2003). 
Expression of EF1 in human embryonic stem cells resulted in a similar transcriptomic profile 
to EwS (Gordon et al., 2016).  
Therefore, these studies and the absence of other highly recurrent somatic mutations 
indicate that the fusion oncogene is the major driver of EwS. Differences in the biology of the 
distinct fusions were not extensively investigated. But a study on two type 1 and one type 2 
cell line and one type 3 (EWSR1 exon 10 to FLI1 exon 6) found only 41 genes to be 
differentially expressed (Bandrés et al., 2005). Different fusion types were discussed to have 
impact on prognosis (de Alava et al., 1998). However, this hypothesis was later rejected (Le 
Deley et al., 2010). 
 
 
1.3. Gene regulation in EwS 
Contrary to the genome, the epigenome (Sheffield et al., 2017), transcriptome, and proteome 
are massively rewired in EwS compared to normal tissues, likely by the fusion oncogene. 
Previous studies could demonstrate that EF1 binds to microsatellites (mSats) with GGAA 
motif in ChIP experiments, resulting in enhancer activity (Gangwal et al., 2008; Guillon et al., 
2009; Riggi et al., 2014; Wei et al., 2010). A mSat is defined as the repetitive sequential 
occurrence of motifs in the genome, the motif is two to six bases long (dependent on authors 
up to 10), and the minimal number of repeats is two to five (Richard et al., 2008). The 
repetitive motifs affect the DNA structure which leads to slippage during replication and 
finally to a high variability in mSat length (Mirkin, 2007). GGAA mSats are packed in 
nucleosomes, not transcribed and without any known function in normal tissues. Actually, 
mSats were for a long time believed to be genetic junk (Gangwal et al., 2008). However, 
there is growing evidence that mSats have impact on gene expression and constitute for 
15% of all inherited gene regulation by nearby common genomic variants (Fotsing et al., 
2019; Gymrek et al., 2016). The accessibility of GGAA mSats for EF1 binding and the 
presence of histone marks for open chromatin is actually dependent on EF1 (Patel et al., 
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2012; Riggi et al., 2014; Tomazou et al., 2015). Knockdown of EF1 leads to a chromatin 
state more similar to mesenchymal stem cells. Vice versa, expression of EF1 in 
mesenchymal stem cells resulted in a chromatin state more similar to EwS (Riggi et al., 
2014). Moreover, in embryonic and multipotent stem cells, mSats are often likewise 
accessible as in EwS, indicating a permissive milieu for EwS fusion and, again, stem cells as 
presumable origin of EwS (Gomez et al., 2016). An EF1 dependent enhancer activity of 
GGAA mSats has been shown in several reporter assays (Dallmayer et al., 2019; Marchetto 
et al., 2020; Monument et al., 2014; Musa et al., 2019). Partly, GGAA mSats bound by the 
fusion oncogene depict even super-enhancer properties (Baldauf et al., 2018a), which are 
described to mediate cell identity (Whyte et al., 2013). Interestingly, the number of 
consecutive GGAA repeats correlates with the enhancer activity of the respective mSat 
(Gangwal et al., 2008). The minimal number of GGAA repeats for EF1 dependent enhancer 
activity is controversial. A minimum of four repeats for binding and five for enhancer activity 
(Gangwal et al., 2008) were described in reporter assays, in ChIP data four repeats were 
already sufficient for enhancer activity (Riggi et al., 2014). The highest enhancer activity was 
reported for 24 repeats, followed by a dip in enhancer activity before another peak at around 
50 repeats (Monument et al., 2014). 
 
 
Figure 2: The current model of EWSR1-FLI1 mediated gene expression. 
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The mechanism, how EWSR1-ETS (EEts) confers de novo enhancer activity to otherwise 
nucleosomal GGAA mSats is not fully elucidated. Binding of EF1 to the genome is 
dependent on the presence of the DNA binding domain of the ETS transcription factor (May 
et al., 1993; Welford et al., 2001). However, the fused transcription factor lacks one of 
normally two p300 binding domains, a transcriptional coactivator. Thus, monomeric EF1, 
which has been shown to bind to single GGAA motifs (Guillon et al., 2009; Riggi et al., 2014), 
recruits far less of this transcriptional coactivator (Riggi et al., 2014). Hence, one explanation 
for the EEts mediated enhancer activity at GGAA mSats might be that simply more EEts 
binds. Nevertheless, EWSR1 is highly important for the EEts mediated enhancer activity, and 
several interaction partners were described that might close the gap between the known 
fusion binding to GGAA mSats and the consequent gene regulation (Figure 2). EWSR1 is 
hypothesized to co-activate ETS transcription factors (Kedage et al., 2016). Additionally, 
EWSR1 is important for the open chromatin structure at GGAA mSats. A prion-like domain in 
EWSR1 binds the BAF chromatin remodelling complex thus recruiting BAF to GGAA mSats 
and open the chromatin structure (Boulay et al., 2017). Currently, an interaction of EWSR1 
and RING1B, another interactor with p300, has been shown to be necessary for target 
location of the fusion (Sánchez-Molina et al., 2020). Furthermore, EWSR1 colocalizes with 
LSD1, whose expression is important for EEts mediated enhancer function (Theisen et al., 
2020). Interestingly, fusion-EWSR1 even interacts with wildtype EWSR1, thus interfering with 
its regulatory activity, ultimately increasing transcription (Gorthi et al., 2018). 
 
 
1.4. The relevance of gene regulation by the EwS-specific fusion 
oncogene 
The first clinical relevance of EF1 binding to a specific GGAA mSat has been shown in 2015 
in the context of EwS susceptibility. Susceptibility highly varies between ethnicities. Africans 
depict a susceptibility by factor 9-10 less than Europeans (Jawad et al., 2009). In 2012, 
higher length of the NR0B1 associated mSat in Africans was reported. However, this finding 
was not sufficient to explain lower susceptibility as NR0B1 has been shown to promote EwS 
(Beck et al., 2012). Finally, a high diversity of the single nucleotide polymorphism (SNP) 
rs79965208 (T to A) has been shown, with a frequency of 64% in Caucasians, but only 25% 
in Africans. The A allele instead of a T creates a GGAA motif connecting two adjacent 
mSats, thus generating one long GGAA mSat nearby the susceptibility gene EGR2 
(Grünewald et al., 2015). Despite EGR2 expression as susceptibility marker, six SNPs 
associated with susceptibility were identified in genome-wide association studies, most of 
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them closely located to GGAA repeats (Machiela et al., 2018). In 2019, the relevance of the 
repeat number of an EEts-bound GGAA mSat for EwS prognosis was reported as a 
correlation with the prognostically unfavorable MYBL2 expression (Musa et al., 2019). 
Noteworthy, MYBL2 acts likely via AURKB. The same gene has been reported to mediate 
the enhancer activity of RING1B/EF1 complexes (Musa et al., 2019; Sánchez-Molina et al., 
2020) 
To further understand the biology of EwS, find prognostic markers, and inroads for new 
therapeutic approaches, several targets of the fusion oncogene were identified and 
evaluated for their functional relevance. NR0B1 was the first identified direct target of an 
EF1-bound GGAA mSat that is necessary for cell line growth (Gangwal et al., 2008; Kinsey 
et al., 2006). Similar results were published for CCK (Carrillo et al., 2007), FOXM1 
(Christensen et al., 2013) and NKX2-2, which is closely located to one of the six susceptibility 
SNPs (Smith et al., 2006). Additionally, knockdown of PRKCB impaired many genes affected 
by EF1, hinting towards PRKCB as a major downstream effector of EF1 (Surdez et al., 
2012). The expression of STEAP1 was associated with oxidative stress in EwS which 
promotes aggressiveness (Grunewald et al., 2012). Another EEts driven gene upregulating 
oxidative stress, SOX6, was recently identified (Marchetto et al., 2020). One of the few 
investigated EF1 repressed targets is SPRY1. Reexpression of SPRY1 reduces EwS cell 
proliferation as it inhibits the fibroblast growth factor receptor (Cidre-Aranaz et al., 2017). 
Another gene suppressed in EwS is LOX, which acts as tumor suppressor in EwS (Agra et 
al., 2013). 
 
In sum, previous reports on EwS identified the pathognomonic EEts fusion as the major 
driver of EwS, which affects the expression of several genes by binding to GGAA mSats, 
thereby converting otherwise closed chromatin structure to de novo enhancers. Besides the 
quiet genomic landscape, EwS is clinically heterogeneous, partly depicting favorable and 
partly fatal prognosis. Little is known about the heterogeneity causing factor. Current studies 
focus on different fusion expression levels resulting in different EwS behavior from a more 
proliferative to more invasive state (Aynaud et al., 2020; Franzetti et al., 2017). Thus, further 
insights into EEts mediated gene regulation are urgently needed to better understand clinical 
heterogeneity and find inroads to advanced and personalized therapeutic strategies. For 
several reasons, previous studies were restricted to further clarifying EwS heterogeneity. 
Only a limited number of cell lines was tested (most often two), which cannot be sufficient to 
represent heterogeneity in patients. Moreover, most previous studies were based exclusively 
on EF1 positive EwS, not addressing potential commonalities or differences between fusion 
~ 8 ~ 
 
types. Furthermore, analyses on EEts mediated enhancer activity were mainly performed in 
a mono-allelic approach.  
To overcome these obstacles, this thesis aimed at the generation of a multi-dimensional and 
comprehensive dataset of a relatively high number of EwS cell line models in fusion-high and 
-low state to assess commonalities between cell lines with distinct fusions, further investigate 
gene regulation genome wide, and to identify heterogeneously regulated clinically relevant 
genes as potential inroads for personalized medicine.  
Three distinct fusion types were represented by 18 cell lines. All cell lines were transduced 
with an inducible shRNA targeting the respective fusion. The cells were characterized on the 
genome, transcriptome, proteome and methylome level. Furthermore, fusion binding to the 
genome and histone marks were assessed. These components constituted the Ewing 
Sarcoma Cell Line Atlas (ESCLA).  
The ESCLA enabled first insights into several factors influencing fusion binding to GGAA 
mSats and expression regulation, confirming previously reported targets and dependencies 
and extending those with new identified targets, binding sites, and structure-effect 
associations. 22 heterogeneously regulated and survival correlated genes were identified, of 
which most were associated with cell-cycle progression. 
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2. Research objectives and scientific aims 
 
2.1. Research objectives 
EwS lacks highly recurrent mutations except for the pathognomonic chimeric EWSR1-ETS 
transcription factor. Hence, the reason for clinically overt inter-patient heterogeneity might not 
be mutations, but rather germline variations in polymorphic EWSR1-ETS binding sites. This 
thesis focused on deciphering the genetic architecture of preferred EWSR1-ETS binding 
sites and parameters affecting the binding. The results should further elucidate gene 
regulatory mechanisms in EwS and hint towards heterogeneously regulated clinically 
relevant genes as potential targets for personalized medicine. The analyses were based on 
the construction of a relatively large cohort of EwS cell lines and a comprehensive 




2.2. Scientific aims 
1st aim:  Generation of EwS cell lines with inducible knockdown of the fusion oncogene. 
2nd aim:  Generation of a multidimensional and comprehensive dataset on the EwS cell 
lines including data on genome, fusion binding to the genome, transcriptome, 
proteome and methylome. 
3rd aim:  Comparison of EwS cell lines with distinct fusion types based on the dataset. 
4th aim:  Demonstration and further investigation of EwS fusion binding and gene 
expression regulation in the dataset. 
5th aim:  Identification of differentially expressed and clinically relevant genes as 
potential biomarkers for personalized medicine. 
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3. Materials and Methods 
 
3.1. Materials 
3.1.1. Cell lines 
Article Specification Supplier 
A673 EwS cell line ATCC, Manassas, VA, USA 
CHLA10 EwS cell line Children's Oncology Group, Monrovia, CA, USA 
CHLA25 EwS cell line Children's Oncology Group, Monrovia, CA, USA 
CHLA99 EwS cell line Children's Oncology Group, Monrovia, CA, USA 
COGE352 EwS cell line Children's Oncology Group, Monrovia, CA, USA 
ES7 EwS cell line Delattre, O., Paris, France 
EW1 EwS cell line Delattre, O., Paris, France 
EW16 EwS cell line Delattre, O., Paris, France 
EW17 EwS cell line Delattre, O., Paris, France 
EW18 EwS cell line Delattre, O., Paris, France 
EW22 EwS cell line Delattre, O., Paris, France 
EW24 EwS cell line Delattre, O., Paris, France 
EW3 EwS cell line Delattre, O., Paris, France 
EW7 EwS cell line Delattre, O., Paris, France 
LAP35 EwS cell line Delattre, O., Paris, France 
MHHES1 EwS cell line DSMZ, Braunschweig, Germany 
MIC EwS cell line Delattre, O., Paris, France 
ORS EwS cell line Delattre, O., Paris, France 
POE EwS cell line Delattre, O., Paris, France 
RDES EwS cell line DSMZ, Braunschweig, Germany 
RH1 EwS cell line Delattre, O., Paris, France 
SBKMSKS1 EwS cell line Burdach, S., Munich, Germany (Grunewald et al., 
2012) 
SKES1 EwS cell line DSMZ, Braunschweig, Germany 
SKNMC EwS cell line DSMZ, Braunschweig, Germany 
SKNPLI EwS cell line Delattre, O., Paris, France 
SKPNDW EwS cell line Delattre, O., Paris, France 
TC106 EwS cell line Children's Oncology Group, Monrovia, CA, USA 
TC205 EwS cell line Children's Oncology Group, Monrovia, CA, USA 
TC32 EwS cell line Children's Oncology Group, Monrovia, CA, USA 
TC71 EwS cell line Children's Oncology Group, Monrovia, CA, USA 
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HEK293T Human embryonic 
kidney cell line 
DSMZ, Braunschweig, Germany 
SAOS2 Osteosarcoma cell line DSMZ, Braunschweig, Germany 








Stellar Competent Cells Clontech, TaKaRa, Saint-Germain-en-Laye, France 
 
3.1.4. Media and supplements for cell culture 
Article Manufacturer 
Accutase Sigma-Aldrich, Taufkirchen, Germany 
Collagen solution from bovine skin Sigma-Aldrich, Taufkirchen, Germany 
Doxycycline Merck, Darmstadt, Germany 
Doxycycline (for mice) Belapharm, Vechta, Germany 
Fetal bovine serum Sigma-Aldrich, Taufkirchen, Germany 
OptiMEM medium Thermo Fisher, Waltham, MA, USA 
Penicilin / Streptomycin (10.000 U/ml, 
10.000µg/ml) 
Biochrom, Berlin, Germany 
Phosphate Buffered Saline Biochrom, Berlin, Germany 
Plasmocure InvivoGen, San Diego, CA, USA 
Puromycin InvivoGen, San Diego, CA, USA 
RPMI 1640 medium with stable glutamin, 2 
g/L NaHCO3 
Biochrom, Berlin, Germany 
Trypsin/EDTA (10X) Biochrom, Berlin, Germany 
 
3.1.5. siRNAs, shRNAs, vectors, and transfection reagents 
Article Description/Target sequence Manufacturer 
siRNA_EF1_TypeII_1 5'-CAGAGTTCACTGCTGGCCTAT-3' eurofins Genomics, 
Ebersberg, Germany 
siRNA_EF1_TypeII_2 5'-AGCAGAGTTCACTGCTGGCCT-3' eurofins Genomics, 
Ebersberg, Germany 
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shRNA_Control 5’-CAACAAGATGAAGAGCACCAA-3’ eurofins Genomics, 
Ebersberg, Germany 
shRNA_EF1_Carillo 5'-GCAGCAGAACCCTTCTTATGA-3' eurofins Genomics, 
Ebersberg, Germany 
shRNA_EF1_Tirode 5'-AAGGCAGCAGAACCCTTCTTA-3' eurofins Genomics, 
Ebersberg, Germany 
shRNA_EWSR1-ERG 5’-GCTACGGGCAGCAGAATTTAC-3’ eurofins Genomics, 
Ebersberg, Germany 
shRNA_FLI1_Ex5 5'-AGTTCACTGCTGGCCTATAAT-3' eurofins Genomics, 
Ebersberg, Germany 
shRNA_FLI1_Ex9 5'-CTTTGGAGCCGCATCACAATA-3' eurofins Genomics, 
Ebersberg, Germany 
pCMV_EF1_puro Vector Surdez, D., Paris, 
France 
Tet-pLKO-puro Vector Addgene, Watertown, 
MA, USA 
D8.9 Packaging plasmid Creative Biogene, 
Shirley, NY, USA 
VSVG Packaging plasmid Addgene, Watertown, 
MA, USA 
HiPerFect Transfection reagent Qiagen, Venlo, 
Netherlands 
Lipofectamin LTX and 
Plus Reagent 
Transfection reagent Thermo Fisher, 
Waltham, MA, USA 
 
3.1.6. Primers 
All primers were retrieved from Eurofin Genomics, Ebersberg, Germany. 











CDKN1A_Fw 5'-ACTGACTCATCACTACTCCCTC-3' ChIP-PCR 
CDKN1A_Rv 5'-GTGTGCTATTCCCGCCAG-3' ChIP-PCR 
CUL1_Fw 5'-TCCTCCCTTCTAGAAAGAGCTGAC-3' ChIP-PCR 
CUL1_Rv 5'-AGGCCCGAAACCACAGAGCATAAA-3' ChIP-PCR 
GATA2 _Fw 5'-CTCAGGACCCATGGAAGTATTG-3' ChIP-PCR 
GATA2_Rv 5'-CTGCAATCCTCTTAGCCTCTAG-3' ChIP-PCR 
IGF2_Fw 5'-AGTGCTCGGAATGTTTGGGAACTG-3' ChIP-PCR 
IGF2_Rv 5'-AGTTACCAGGAGGTGCTCAAGTGT-3' ChIP-PCR 
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Sec14L2_Fw 5'-GCCCCCGCTGATGCACTTCC-3' ChIP-PCR 
Sec14L2_Rv 5'-AAGTGCGCCAGCAGAGCCAG-3' ChIP-PCR 
Myco-F1 5'-ACACCATGGGAGCTGGTAAT-3' Mycoplasma PCR 
Myco-F1t 5'-ACACCATGGGAGTTGGTAAT-3' Mycoplasma PCR 
Myco-F2 5'-GTTCTTTGAAAACTGAAT-3' Mycoplasma PCR 
Myco-F2a 5'-ATTCTTTGAAAACTGAAT-3' Mycoplasma PCR 
Myco-F2cc 5'-GCTCTTTCAAAACTGAAT-3' Mycoplasma PCR 
Myco-R1 5'-CTTCATCGACTTTCAGACCCAAGGCAT-3' Mycoplasma PCR 
Myco-R1ac 5'-CTTCATCGACTTCCAGACCCAAGGCAT-3' Mycoplasma PCR 
Myco-R1cat 5'-CCTCATCGACTTTCAGACCCAAGGCAT-3' Mycoplasma PCR 
Myco-R1tt 5'-CTTCTTCGACTTTCAGACCCAAGGCAT-3' Mycoplasma PCR 
Myco-R2 5'-GCATCCACCAAAAACTCT-3' Mycoplasma PCR 
Myco-R2at 5'-GCATCCACCAAATACTCT-3' Mycoplasma PCR 
Myco-R2ca 5'-GCATCCACCACAAACTCT-3' Mycoplasma PCR 
EF1_Fw 5’-GCCAAGCTCCAAGTCAATATAGC-3’ qRT-PCR, PCR (fusion 
oncogene transcript) 
EF1_Rv 5’-GAGGCCAGAATTCATGTTATTGC-3’ qRT-PCR, PCR (fusion 
oncogene transcript) 
ERG_Fw 5’-CGAACGAGCGCAGAGTTAT-3’ qRT-PCR (wt gene) 
ERG_Rv 5’-ACGTCTGGAAGGCCATATTC-3’ qRT-PCR (wt gene) 
EWSR1_Fw 5’-CAGCCAAGCTCCAAGTCAATA-3’ qRT-PCR (wt gene) 




EWSR1-ERG_Rv 5’-CTGTGGAAGGAGATGGTTGAG-3’ qRT-PCR 
FLI1_TV1-3_Fw 5’-TGGATGGCAAGGAACTGTG-3’ qRT-PCR (wt gene) 
FLI1_TV1-3_Rv 5’-CGGTGTGGGAGGTTGTATTA-3’ qRT-PCR (wt gene) 
FLI1_TV4_Fw 5'-CATCACCATCCCACCGTC-3' qRT-PCR (wt gene) 
FLI1_TV4_Rv 5'-TCTGAAACATCGTGGGTAGC-3' qRT-PCR (wt gene) 
RPLP0_Fw 5’-GAAACTCTGCATTCTCGCTTC-3’ qRT-PCR 
RPLP0_Rv 5’-GGTGTAATCCGTCTCCACAG-3’ qRT-PCR 
ERG_Rv2 5’-TTGGGTTTGCTCTTCCGCTC-3’ PCR (fusion oncogene 
transcript) 
FLI1-EWS#1_Fw 5'-AATACAACCTCCCACACCGA-3' PCR, reverse fusion 
FLI1-EWS#1_Rv 5'-ACTCCTGCCCATAAACACCC-3' PCR, reverse fusion 
FLI1-EWS#2_Fw 5'-GTGCTGTTGTCACACCTCAG-3' PCR, reverse fusion 
FLI1-EWS#2_Rv 5'-GTTCTCTCCTGGTCCGGAAA-3' PCR, reverse fusion 
FLI1-FLI1_Fw 5'-AATACAACCTCCACACCGA-3' PCR, reverse fusion 
FLI1-FLI1_Rv 5'-CTTACTGATCGTTTGTGCCCC-3' PCR, reverse fusion 
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Tet-pLKO_Fw 5'-GGCAGGGATATTCACCATTAT-3' colony PCR 
















ERG (EPR3864) Rabbit, 
monoclonal 
ChIP ab92513 Abcam, Cambridge, UK 
FLI1 Rabbit, 
polyclonal 
ChIP ab15289 Abcam, Cambridge, UK 
H3K27ac Rabbit, 
polyclonal 
ChIP ab4729 Abcam, Cambridge, UK 
H3K27me3 Rabbit, 
polyclonal 








ABC HRP Kit) 
Horse, 
polyclonal 
IHC PK-6200 Vector Laboratories, 
Burlingame, CA, USA 
PAX7 Mouse, 
monclonal 













IHC MP-7401 Vector Laboratories, 











434R Cell Marque, Rocklin, 
USA 




sc-32233 Santa Cruz 
Biotechnology, Dallas, 
TX, USA 




254M Cell Marque, Rocklin, 
USA 






W402B Promega, Maddison, 
WI, USA 






R1364HRP OriGene Technologies, 
Rockville, MD, USA 
 




Antigen retrieval AR-10 solution DCS Innovative, Hamburg, Germany 
High-Capacity cDNA Reverse Transcription Kit Thermo Fisher, Waltham, MA, USA 
iDeal ChIP-seq kit for Transcription Factors Diagenode, Seraing, Belgium 
NucleoSpin Gel and PCR Clean-up Macherey-Nagel, Düren, Germany 
NucleoSpin RNA Macherey-Nagel, Düren, Germany 
NucleoSpin Tissue genomic DNA prep kit Macherey-Nagel, Düren, Germany 
ProTaqs I and V Antigen-Enhancer Quartett, Berlin, Germany 
PureYield Plasmid Midiprep System Promega, Maddison, WI, USA 
Qubit dsDNA HS Assay Kit  Thermo Fisher, Waltham, MA, USA 
SYBR SELECT Master Mix Thermo Fisher, Waltham, MA, USA 




AgeI HF New England Biolabs, Frankfurt (Main), Germany 
Complete Protease Inhibitor Mini Roche, Mannheim, Germany 
EcoRI HF New England Biolabs, Frankfurt (Main), Germany 
GoTaq Hot Start Polymerase  Promega, Maddison, WI, USA 
Proteinase Inhibitor Cocktail Sigma-Aldrich, Taufkirchen, Germany 
RNAse cocktail Thermo Fisher, Waltham, MA, USA 
T4 DNA ligase Thermo Fisher, Waltham, MA, USA 
Taq DNA polymerase New England Biolabs, Frankfurt (Main), Germany 
 
3.1.10. Chemicals and reagents 
Article Manufacturer/supplier 
Acetic acid (100%) Neolab, Heidelberg, Germany 
Acrylamid, Rotiphorese Gel 30 Bisacrylamid Roth, Karlsruhe, Germany 
AEC+ chromogen Agilent Technologies, Santa Clara, CA, USA 
Agarose Sigma-Aldrich, Taufkirchen, Germany 
Ammonium persulfate (APS) Sigma-Aldrich, Taufkirchen, Germany 
Ampicillin Sigma-Aldrich, Taufkirchen, Germany 
Aqua bidest Kerndl, Weißenfeld, Germany 
Bradford Bio-Rad, Munich, Germany 
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Bromphenol blue Sigma-Aldrich, Taufkirchen, Germany 
Buffer for T4 ligase (10X) Thermo Fisher, Waltham, MA, USA 
Buffer GoTag Green Promega, Maddison, WI, USA 
Buffer Smart Cut New England Biolabs, Frankfurt (Main), 
Germany 
Chloroform/isoamylalcohol 24/1 Sigma-Aldrich, Taufkirchen, Germany 
Crystal violet Sigma-Aldrich, Taufkirchen, Germany 
DAB+ chromogen Agilent Technologies, Santa Clara, CA, USA 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, Taufkirchen, Germany 
Dithiothreitol (DTT) Sigma-Aldrich, Taufkirchen, Germany 
DNA Ladder 1kbp Roth, Karlsruhe, Germany 
DNA Ladder GeneRuler 100 bp Plus  Thermo Fisher, Waltham, MA, USA 
dNTPs Sigma-Aldrich, Taufkirchen, Germany 
Ethanol (denaturated >99.8%) Roth, Karlsruhe, Germany 
Ethidiumbromide solution Sigma-Aldrich, Taufkirchen, Germany 
Ethylenediaminetetraacetic acid (EDTA) Roth, Karlsruhe, Germany 
Formalin (4%) Sigma-Aldrich, Taufkirchen, Germany 
Gelatin from procine skin, powder Sigma-Aldrich, Taufkirchen, Germany 
Geltrex LDEV-Free Reduced Growth Factor 
Basement Membrane Matrix 
Thermo Fisher, Waltham, MA, USA 
Glycerol Roth, Karlsruhe, Germany 
Glycine Roth, Karlsruhe, Germany 
Hematoxylin Gill's Formula Vector Laboratories, Burlingame, CA, USA 
HRP Substrate Immobilion Merck, Darmstadt, Germany 
Isopropanol Sigma-Aldrich, Taufkirchen, Germany 
LB Broth (Miller) Sigma-Aldrich, Taufkirchen, Germany 
LB Broth Agar (Lennox) Sigma-Aldrich, Taufkirchen, Germany 
Magnesium chloride (MgCl2) New England Biolabs, Frankfurt (Main), 
Germany 
Methanol Sigma-Aldrich, Taufkirchen, Germany 
Milk powder, non-fat dried Roth, Karlsruhe, Germany 
Nonidet P40 Thermo Fisher, Waltham, MA, USA 
Phenol/chloroform/isoamylalcohol 25/24/1 Thermo Fisher, Waltham, MA, USA 
PageRuler Prestained Protein Ladder Thermo Fisher, Waltham, MA, USA 
RNAseZap Sigma-Aldrich, Taufkirchen, Germany 
Sodium acetate buffer solution 3M Sigma-Aldrich, Taufkirchen, Germany 
Sodium chloride (NaCl) Roth, Karlsruhe, Germany 
Sodium deoxycholate Sigma-Aldrich, Taufkirchen, Germany 
Sodium dodecyl sufate (SDS) Sigma-Aldrich, Taufkirchen, Germany 
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Sodium orthovanadate (Na3VO4) Sigma-Aldrich, Taufkirchen, Germany 
Sucrose Sigma-Aldrich, Taufkirchen, Germany 
SYBR Safe DNA gel stain Thermo Fisher, Waltham, USA 
Tetramethylethylenediamine (TEMED) Roth, Karlsruhe, Germany 
TRIS Roth, Karlsruhe, Germany 
TRIS HCl Sigma-Aldrich, Taufkirchen, Germany 
Triton X-100 Sigma-Aldrich, Taufkirchen, Germany 
Trypan blue solution Sigma-Aldrich, Taufkirchen, Germany 
Tween-20 Sigma-Aldrich, Taufkirchen, Germany 
Water, DNAse und RNAse free Roth, Karlsruhe, Germany 
 
3.1.11. Consumeables 
Type Specification Manufacturer/supplier 
Autoclavation tape 
 
Hartenstein, Würzburg, Germany 
Cell culture flasks T25, T75, T150 TPP, Trasadingen, Switzerland 
Cell culture multiwell 
plates 
96, 24, 12, 6 wells TPP, Trasadingen, Switzerland 
Cell scraper 
 
Hartenstein, Würzburg, Germany 
Centrifugation tubes 15 ml, 50 ml Greiner Bio-One, Kremsmünster, 
Austria 
Counting chambers C-Chip NanoEntek, Waltham, MA, USA 
Counting chambers for Countess cell counter Thermo Fisher, Waltham, MA, USA 
Cryo tubes 2 ml, CryoGen CLEARLine Hartenstein, Würzburg, Germany 
Filters for syringes Rotilabo 0.45µm, 0.22µm Roth, Karlsruhe, Germany 
Gloves  Nitril NextGen MeiTrade, Krimpen aan den Ijseel, 
Netherlands 
Purple Nitrile Kimberly-Clark Professional, 
Koblenz-Rheinhafen, Germany 
Injection needles size 18, Sterican Braun, Melsungen, Germany 
Multi-dispenser tips 0.5 ml, 5 ml, sterile Hartenstein, Würzburg, Germany 
Nitrocellulose Amersham Protran 0.45  GE Healthcare, Freiburg, Germany 
Parafilm M laboratory film Hartenstein, Würzburg, Germany 
Pasteur pipettes 
 
Kimble Chase, Meiningen, 
Germany 
PCR plates FrameStar 480/96 clear, white 4titude, Wotton, UK 
PCR Tubes 8 Well PCR Tube Strip, 
attached caps 
4titude, Wotton, UK 
Petri dishes 10 cm Greiner Bio-One, Kremsmünster, 
Austria 
Pipette tips 10 µl, 20 µl, 100 µl, 200 µl, 1250 Biozym, Hessisch Oldendorf, 
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µl, SafeSeal SurPhop filter tips Germany 
Protective Coat S2 SplashCoat pro+ DACH, Raststatt, Germany 
Reaction tubes 1.5 ml, 2 ml Eppendorf, Hamburg, Germany 
 
1.5 ml, DNA lobind Eppendorf, Hamburg, Germany 
 
1.5 ml, protein lobind Eppendorf, Hamburg, Germany 
Scalpel Fig.21, ratiomed Hartenstein, Würzburg, Germany 
Serological pipettes 5 ml, 10 ml, 25 ml Corning, Wiesbaden, Germany 
Sonication tubes 1.5 ml TPX microtubes for 
Bioruptor Plus 
Diagenode, Seraing, Belgium 
Syringes 5 ml, Inject Braun, Melsungen, Germany 
Whatman paper 
 
Hartenstein, Würzburg, Germany 
 
3.1.12. Instruments 
Type Specification Manufacturer/supplier 
Aspiration pump Vacusafe Integra, Biebertal, Germany 
 
table device FTA-1 Hartenstein, Würzburg, Germany 
Autoclave Varioklav HP Labortechnik, Oberschleißheim, 
Germany 
Bacteria incubator Kelvitron T Heraeus, Hanau, Germany 
Bacteria shaker Certomat IS Braun, Melsungen, Germany 
Camera µ850SW Olympus, Tokio, Japan 
Cell counter Countess Thermo Fisher, Waltham, MA, USA 
Centrifuge Rotina 420R Hettich, Tuttlingen, Germany 
 
cooling Centrifuge5417R Eppendorf, Hamburg, Germany 
 
Heraeus Megafuge8R Thermo Fisher, Waltham, MA, USA 
 
for PCR plates 
Universal320 
Hettich, Tuttlingen, Germany 
Fluorometer Qubit 3.0 Thermo Fisher, Waltham, MA, USA 
Freezer -80°C B 35-50 Fryka, Esslingen, Germany 
 
Froma -86°C ULT Freezer Thermo Fisher, Waltham, MA, USA 
Freezing container Mr. Frosty Hartenstein, Würzburg, Germany 
Gel chambers 
 
PEQLAB, Erlangen, Germany 
Heating circulator EO Julabo, Seelbach, Deutschland 
Ice machine SPR 80 Nordcap, Bremen, Germany 
Incubator Forma Scientific CO2 Water 
Jacketed Incubator 
Thermo Fisher, Waltham, MA, USA 
Laminar Flow HeraSafe Laminar Flow Thermo Fisher, Waltham, MA, USA 
 
Safe2000 Thermo Fisher, Waltham, MA, USA 
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Maxisafe2020 Thermo Fisher, Waltham, MA, USA 
Microscope Axiovert 200 Carl Zeiss, Oberkochen, Germany 
 
Axioplan2 Carl Zeiss, Oberkochen, Germany 
 
Primo Vert Carl Zeiss, Oberkochen, Germany 
Mini centrifuge 
 
Labnet, Edison, NJ, USA 
 
DW-41 Qualiton, Korea 
Multidispenser HandyStep electronig Brand, Wertheim, Germany 
Nitrogen tank Arpege 70 Air Liquide, Düsseldorf, Germany 
Orbital shaker Unimax 1010 DT Heidolph Instruments, Schwabach, 
Germany 
PCR Cycler vapo.protect Eppendorf, Hamburg, Germany 
 
T100 Thermal Cycler Bio-Rad, Munich, Germany 
pH meter WTW pH-197 Xylem Analytics, Weilheim, Germany 
Pipette Controller Pipetboy2 Integra, Biebertal, Germany 
 
accu-jet pro Brand, Wertheim, Germany 
Pipettes Pipetman 2, 10, 20, 100, 
200, 1000 µl 
Gilson, Middleton, WI, USA 
 
PipetmanG 2, 10, 20, 100, 
200, 1000 µl 
Gilson, Middleton, WI, USA 
Plate reader Varioskan Thermo Fisher, Waltham, MA, USA 
Power supply PowerPac 200 Bio-Rad, Munich, Germany 
qPCR Cycler CFX Connect Real-Time 
System 
Bio-Rad, Munich, Germany 
Rotation wheel SB3 Stuart, Staffordshire, UK 
Scale BL150 Sartorius, Göttingen, Germany 
 
Analytical Lab Balance Sartorius, Göttingen, Germany 
Sonicator Bioruptor Plus Diagenode, Seraing, Belgium 
 
VCX 130 Sonics, Newtown, CT, USA 
Spectrophotometer NanoDrop ND-1000 
Spectophotometer 
PEQLAB, Erlangen, Germany 
Thermoblock ThermoStat plus Eppendorf, Hamburg, Germany 
Thermomixer Thermomixer compact Eppendorf, Hamburg, Germany 
Ultracentrifuge 4K15C Sigma-Aldrich, Taufkirchen, Germany 
UV working table FT-20E/365 Thermo Fisher, Waltham, MA, USA 
 
MultiImage Light Cabinet Alpha Innotech, Kasendorf, Germany 
Vacuum manifold 
 
Promega, Maddison, WI, USA 
Vacuum pump WOB-L Welch, Fürstenfeldbruck, Germany 
Vortexer Vortex-Genie2 Scientific Industries, Bohemia, NY, USA 
Water bath 
 
Köttermann, Uetze, Germany 
Western blot Vertical Electrophoresis Cell Thermo Fisher, Waltham, MA, USA 






Odyssey LI-COR, Homburg, Germany 
Western blot 
transfer system 
Mini Trans-Blot Cell Thermo Fisher, Waltham, MA, USA 
 
3.1.13. Software 
Specific bioinformatic packages are cited in the respective Methods section. 
Program Distributor 
Bio-Rad CFX Manager Bio-Rad, Munich, Germany 
GraphPad PRISM 8 GraphPad Software, San Diego, CA, 
USA 
Microsoft Office 2010 Microsoft, Redmond, WA, USA 
Transcriptome Analysis Console 4.0 Thermo Fisher, Waltham, MA, USA 




3.2.1. Cell culture standards 
3.2.1.1. Standard culture conditions 
All cell lines were cultured in cell culture flasks and plates in RPMI 1640 full medium at 37°C 
in a fully humidified 5% CO2 atmosphere. 
 
RPMI 1640 full medium: RPM 1640 with stable glutamine + 10% fetal calf serum (FCS) + 
100 U/ml penicillin + 100 µg/ml streptomycin 
 
When working with cell lines with doxycycline inducible constructs, FCS tested to be 
tetracycline-free was used exclusively. 
Most cells were at least semi-adherent to the culture flasks. When culture dish coating was 
demanded for adherence, gelatin or collagen coating was used. Both coating strategies were 
interchangeable, but collagen coating appeared superior for long-term culture (e.g. single cell 
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cloning). Generally, culture dishes were coated with gelatin for CHLA25, EW3, and TC106, 
with collagen for CHLA10, EW24, and MIC.  
For gelatin coating, 2% sterile collagen was melted in water bath at 37°C, 5 µl per cm² 
culture surface were filled into the culture flasks/dishes, and incubated for 30 min at 37°C. 
Excess liquid was aspirated and cell surface dried for 15 min before using the culture 
flasks/dishes. 
For collagen coating, collagen from calf skin (3 mg/ml) was diluted 1:45 in phosphate-
buffered saline (PBS) on ice, 40 µl per cm² culture surface were filled into the culture 
flasks/dishes. After 30 min incubation at 37°C, liquid was aspirated, and culture flasks/dishes 
were ready to use.  
To exclude any mycoplasma contamination, which might affect assays and readouts, 
supernatant of all cells was frozen whenever they were used for an assay. In case of a 
detection of mycoplasma in the supernatant (see Mycoplasma PCR), infected cells were 
cultured with 1:3,000 Plasmocure in RPMI 1640 full medium for at least seven days and 
retested after expansion of the cells without further treatment. In case of a persistent 
contamination, the treatment was prolonged incrementally. 
 
3.2.1.2. Subculturing/harvesting cells 
Cells were subcultured every 2-5 days before total confluence. For subculturing/harvesting 
cells, supernatant was aspirated and cell surface washed with PBS to clean from debris and 
trypsin-blocking magnesium or calcium ions. Then, cells were detached by trypsin proteolysis 
for up to 5 min at 37°C, trypsin activity was stopped by addition of medium, cells were 
resuspended in trypsin-medium-mixture, and spinned down at 360 g. The supernatant was 
removed and the cell pellet was resuspended in full medium. Cells were subcultured in ratios 
1:2 to 1:10. 
 
3.2.1.3. Freezing cells 
For cell storage, freshly detached and centrifugated cells were resuspended in freezing 
solution, transferred into cryo tubes, slowly cooled down by one degree per minute to -80°C 
in Mr. Frosty freezing containers and then transferred to liquid nitrogen. 
 
Freezing solution: 45% vol RPMI full medium, 45% vol FCS, 10% vol DMSO 
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3.2.1.4. Counting cells 
For counting cells, freshly harvested cell suspension was mixed with trypan blue and 10 µl 
were transferred into a Neubauer counting chamber. The average count of vital cells, 
meaning cells without trypan staining (trypan exclusion method), in all 4x4 squares was 
multiplied with the dilution factor (cells in trypan blue) and the chamber factor 104 to calculate 
the actual cell number per millilitre cell suspension. 
For automated cell count, the Countess Automated Cell Counter was used with 
manufacturer's disposable counting chambers and a 1:1 dilution of cell suspension and 
trypan blue. The threshold between living and dead cells was adjusted for each cell line 
individually by adapting the parameters circularity and size. 
 
3.2.2. Transient RNAi mediated protein knockdown 
To reduce expression of the EF1 type 2 fusion oncogene, RNA interference (RNAi) was 
employed: The posttranscriptional expression regulation via endogenous micro RNA 
(miRNA) was mimicked by synthetic small interfering RNA (siRNA) transferred into cells 
using a transfection reagent. In the transfected cells, the siRNA complexes with the RNA-
induced-silencing complex (RISC), binds to complementary transcript finally leading to 
degradation of the bound mRNA and subsequent reduced translation and protein expression 
(Novina and Sharp, 2004). 
siRNAs were prediluted to 20 µM. In RPMI medium without further supplements the 
transfection reagent and the siRNA were mixed (see Table 1), incubated for 12 min to enable 
complex formation of the siRNA with the transfection reagent, and then 313 µl mixture were 
transferred to cells freshly seeded in 10 cm² dishes in 1.687 ml full medium (fast forward 
transfection).  
 
Table 1: Volumes for siRNA transfection mix. 313 µl mix are added to cells growing in a 10 cm² 
dish. 
Final siRNA concentration 10 nM 25 nM 50 nM 
Medium, supplement free (µl) 337.1 337.3 329.5 
siRNA (20 µM stock) (µl)  6.9 5.18 10.35 
HiPerFect transfection reagent (µl) 1.04 2.59 5.18 
 
For lower concentrations of siRNA, lower amounts of cell toxic transfection reagent are 
needed. Hence, cells were first transfected with low siRNA concentrations (10 nM and 
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25 nM). To increase the RNAi effect, in a second experiment 25 nM and 50 nM were used 
and cells were retransfected according to this protocol after 48 h. 
 
3.2.3. Lentiviral transduction of shRNA 
While the RNAi effect of siRNAs is only intermediary, as the siRNA gets used up and 
degraded, stable RNAi can be achieved by genomic integration of a short hairpin RNA 
(shRNA) sequence. Transcribed shRNA acts like endogenous miRNA.  
 
 
Figure 3: Vector map of the Tet-pLKO-puro vector with its components and restriction sites 
 
For genomic integration of a shRNA sequence, together with a transcription activating 
promoter, a lentiviral system was employed. The shRNA integrated into the Tet-pLKO-puro 
vector was packed into a replication incompetent lentivirus, which infected the target cells, 
and utilizing its lentiviral enzymes reverse transcriptase and integrase, integrated stably the 
Tet-pLKO-puro sequence between two long terminal repeats (yellow in Figure 3) into the 
genome. 
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The Tet-pLKO-puro vector (Figure 3) comprises an ampicillin resistance cassette for 
selection of bacteria containing the vector, a puromycin resistance cassette which is 
integrated into the genome of the target cells for selection of successfully transduced cells, 
and a tet-responsive element, which enables tetracycline mediated activation of the 
transcription of the shRNA (Wiederschain et al., 2009). The latter feature was the main 
reason for selecting this vector system: While other vector systems result in constitutive 
expression of the shRNA construct, which might impair cell growth in vitro and in vivo or 
might even make it impossible, the shRNA integrated from the Tet-pLKO-puro vector is not 
expressed until induction by simple addition of doxycycline (Dox) to the culture medium or 
drinking water of mice. 
shRNAs against different EWSR1-ETS fusion oncogenes were designed and their 
knockdown efficiency was predicted with the gpp web portal of the Broad Institute 
(Cambridge, MA, USA). Sequences were selected on the criteria 100% sequence match, 
highest adjusted score (predicted knockdown performance and cloneability adjusted for 
predicted off-target effects), and least predicted additional human target sequences 
(especially those, which are expressed in the target cell type EwS). Additionally, a non-
targeting control shRNA was used. shRNA sequences (top and bottom) were ordered with 
the correct overhangs for ligation with the digested TET-pLKO-puro vector. Both sequences 
were reconstituted to 100 pmol/µl in nuclease-free water. For annealing of the sequences, 
11.25 µl of top and bottom shRNA were mixed with 2.5 µl of 10X annealing buffer, the 
sample was heated up to 95°C and slowly cooled down by 1°C/min to 14°C. 1 µl annealed 
shRNA was diluted in 399 µl of 0.5X annealing buffer for further use. 
 
10X annealing buffer: 100 mM Tris-HCl, 1 M NaCl, pH adjusted to 7.4 
 
Two times 4 µg TET-pLKO-vector-puro (10,633 bp) was double digested with 2 µl EcoRI HF 
(20 U) and 1 µl AgeI HF (20 U) in 1x smart cut buffer for 15 min at 37°C, each. Digestion was 
inactivated at 65°C for 20 min. Both samples were pooled and DNA was precipitated by 
addition of 140 µl nuclease-free water, 20 µl sodium acetate (3 M), 440 µl of cold EtOH 
(100%) and freezing at -80°C for at least 45 min. The precipitated DNA was spinned down at 
4°C and 20,000 g for 30 min. The pellet was washed with 1 ml 70% EtOH during 15 min 
further centrifugation. Then, the pellet was tried at 37°C and resuspended in 12 µl nuclease-
free water. 
Successful digestion was controlled by loading the DNA on a 1% agarose gel, where the 
1,800 bp stuffer (light blue in Figure 3) and the 8,834 bp linear plasmid appeared nicely 
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separated. The lane at 8 kbp was cut out and cleaned up. DNA concentration was measured 
with NanoDrop spectrophotometer and adjusted to 25 ng/µl. 
For ligation of shRNA and TET-pLKO-puro vector 1 µl vector DNA, 1 µl diluted and annealed 
shRNA, 1.5 µl 10X ligation buffer, 1 µl T4 DNA ligase and 10.5 µl nuclease-free water were 
mixed and incubated at room temperature for 30 min. 
For expansion of the ligated vector, stellar competent cells were transformed. 50 µl of stellar 
competent cells thawed on ice were mixed with 3 µl of ligation mix, incubated on ice for 
30 min, and then heat shocked for 60 sec at 42°C. After 2 further min of incubation on ice, 
447 µl prewarmed SOC medium was added to the bacteria. The bacteria were incubated at 
37°C for 1 h on a thermomixer with 300 rpm, concentrated by centrifugation at 8,700 g for 
5 min and resuspension in 100 µl SOC medium, and half plated on agar plates with ampicillin 
(100 µg/ml). Agar plates were incubated at 37°C over night. 
 
Table 2: Components of colony PCR 
 Stock conc. Amount (µl) Final conc. 
Nuclease-free water NA 27.25 NA 
GoTaq green buffer 5x 10 1x 
MgCl2 25 mM 6 3 mM 
dNTPs 10 mM 1 200 µM 
Primer mix (TetpLKO-FW/-Rv) 10 µM, each 2.5 0.5 µM, each 
GoTaq Polymerase 5 U/µl 0.25 1.25 U/ 50 µl 
Colony solution NA 3  NA 
 
Table 3: Thermal protocol for colony PCR 
Step # Description Temperature (°C) Time (s) Comment 
1 Initiation 95 600  
2 Denaturation 98 10  
3 Annealing 59-49 30 Decrease 1°C/2 cycles 
4 Extension 72 60 Return to step 2, 20 times 
5 Denaturation 98 10  
6 Annealing 56 30  
7 Extension 72 60 Return to step5, 20 times 
8 Final extension 72 600  
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A colony-polymerase chain reaction (PCR) was performed to test for successful integration 
of the vector into the bacteria. Single colonies were picked and incubated in 100 µl LB with 
100 µg/ml ampicillin for 1.5 h, 37°C, 300 rpm. The PCR was run with components described 
in Table 2 and thermal conditions described in Table 3. 
On a 1.5% agarose gel, the presence of an amplified shRNA insert (about 420 bp) was 
controlled. 
The remaining colony material in LB was transferred into 50 ml LB medium with 100 µg/ml 
ampicillin for bacteria growth over night at 37°C and 180 rpm. 
500 µl bacteria culture were mixed with 500 µl glycerol (50%) and frozen as stock. The 
plasmid was extracted from the bacteria with the PureYield Plasmid Midiprep System using 
manufacturer's protocol. Bacteria in LB were spinned down at 5,000 g for 10 min, pellet was 
resuspended in 3 ml Resuspension Solution, and lysed with additional 3 ml Lysis Solution. 
After 3 min incubation time, 5 ml Neutralization Solution were added. The mixture was 
centrifuged at 15,000 g for 20 min. The supernatant was transferred into a Clearing Column 
on top of a Binding Column on a vacuum manifold. After all liquid was aspirated, the Binding 
Column was washed with 5 ml Endotoxin Removal Wash and 20 ml Column Wash Solution. 
Then, plasmid was eluted with 600 µl nuclease-free water during centrifugation at 2,000 g for 
5 min. DNA concentration was assessed with a spectrophotometer.  
The shRNA sequence was controlled for correctness by sanger sequencing at Eurofins 
Genomics (Ebersberg, Germany) using forward (TetpLKO-Seq-Fw) or (if forward primer was 
not sufficient to generate a read over the shRNA) reverse sequencing primer (TetpLKO-Seq-
Rv). 
For packaging of the Tet-pLKO-puro vector with shRNA into lentivirus, 2x106 HEK293T cells 
were plated at day 0 on T75 culture flask in 10 ml medium. At day 1, 4,600 µl OptiMEM, 
10 µg plasmid DNA, 10 µg D8.9 and 3 µg VSVG were mixed with 46 µl Plus transfection 
reagent. After 10 min incubation, 60 µl Lipofectamine LTX transfection reagent were added. 
After 25 min incubation, the transfection mix was added to the HEK293T cells. Four hours 
later the medium was altered to normal medium; eight further hours later, the medium was 
changed to 5 ml medium with 30% FCS. At day 3, about 36 h after the last medium change, 
the virus containing supernatant of the HEK293T cells was filtered with 0.45 µm pore size to 
eliminate cellular components.  
For infection of target cells, 1 ml of supernatant was added to about 25% confluent, actively 
proliferating cells in T25. After reaching confluence, the cells were transferred into a T75 
culture flask supplemented with puromycin (lowest lethal dose (LLD) or maximum 1 µg/ml). A 
culture flask with non-infected cells was used to test for successful selection. 
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The LLD of puromycin for non-transfected cells was identified by seeding wild type cells in 12 
well plates with medium supplemented with the puromycin concentrations 0, 0.5, 1, 2, 5, and 
10 µg/ml for 48 h and microscopical assessment of the toxic effect. LLD was either 0.5 µg/ml 
(identified for A673, CHLA10, EW7, EW24, MIC, RH1, SKNMC, TC32, TC71) or 1 µg/ml.  
 
3.2.4. Transient EWSR1-FLI1 overexpression 
For transient EWSR1-FLI1 overexpression to test antibody specificity in western blot 
analysis, cells on 10 cm² culture dishes were transfected with pCMV_EF1_puro (carrying the 
cDNA for EWSR1-FLI1 type 1, from Didier Surdez, Institut Curie, Paris, France) using 
LTX/Plus transfection reagents: For three transfections 3 µg DNA in 600 µl OptiMEM were 
incubated with 6 µl Plus reagent for 10 min. 7.5 µl LTX reagent were added, after another 
25 min incubation 191.1 µl transfection mix were added to the cells cultured in 1809 µl 
medium. The medium was changed to fresh full RPMI medium after 4.5 h. After 48 h the 
cells were harvested: One quarter was scratched from the culture dish and lysed in RA1 
buffer for RNA isolation, the left cells were lysed in RIPA buffer for western blot analysis. 
 
3.2.5. Single cell cloning 
To receive isogenic clones of transduced cell lines for better reproducibility, cells were 
seeded at very low density. First, the supernatant of the cells was kept as conditioned 
medium, passed through a 0.45 µm filter to remove cellular components and filled up to 
18 ml with fresh full medium. Then cells were harvested, resuspended in 5 ml medium and 
counted. The cell suspension volume corresponding to 96 cells was calculated. By 1:10 
dilution the volume was increased until it was manageable. Then 96 cells were transferred 
into the 18 ml medium with condition medium. 150 µl of this suspension (0.8 cells/well) were 
seeded per well of a 96 well plate. The growth of single colonies was microscopically 
controlled and corresponding wells were marked. When colonies reached nearly confluence, 
supernatant was removed, cells were detached with Accutase at room temperature and 
transferred into 12-well culture plate, then subsequently transferred to larger culture dishes 
for testing of knockdown-inducibility, freezing and direct use. 
 
3.2.6. Mice experiments and tissue microarray (TMA) generation 
Mice experiments were conducted with allowance of the government of Upper Bavaria (ROB-
2532.Vet_02-15-184) and in accordance with the 3R principle (replacement, reduction and 
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refinement). NOD/scid/gamma immunodeficient mice were kept in individually sterile 
ventilated cages in the certified mouse facility of the Institute of Pathology of the LMU 
Munich. Cages were only opened under a laminar flow. Mice at the age of at least eight 
weeks were xenotransplanted with EwS cells with Dox-inducible fusion oncogene knockdown 
by subcutaneous injection of 2.5x106 EwS cells in 100 µl 1:1 mix PBS and Geltrex into the 
right flank after shaving of the injection site. Per cell line/experiment 12 mice were 
xenotransplanted. The welfare of the mice was controlled daily. Tumor size was controlled 
every two days with a caliper. Additionally, each mouse was controlled for any changes in 
body condition, social behavior, appearance, breathing, or dehydration, diarrhoe/rectum 
prolapse, tumor ulceration/invasive tumor growth/pain/high tumor volume (average diameter 
> 15 mm), weight loss, increased abdominal volume and abnormal grimace (Mouse Grimace 
Scale). Whenever symptoms in any category were observed, a score up to 7 (most severe) 
was given for each category. When the sum score was at least 7, the stress for the mouse 
was assessed as too high and the mouse was sacrified by cervical translocation. When 
tumors reached an average diameter of 10 mm, mice were alternately assigned to 
treated/control group. The treated group received 2 mg/ml Dox (for induction of shRNA 
integrated into the genome of xenotransplanted cells) in 50 mg/ml sucrose drinking water. 
The control group received 50 mg/ml sucrose drinking water. Mice were marked with ear 
punches. 96 h after assignment to any group, mice were sacrified by cervical dislocation and 
tumors were immediately isolated. Two fractions per tumor were snap-frozen in liquid 
nitrogen for RNA isolation. The remaining tumor was put into formalin for fixation. After 
fixation, tumors were dehydrated and embedded into paraffin blocks. From the snap frozen 
samples, RNA was isolated, reverse transcribed and a quantitative real-time PCR was 
performed to identify the tumors with the highest and lowest expression of the fusion 
oncogene. The three tumors with the highest and lowest mRNA expression of the fusion 
oncogene were used for construction of TMAs. Three cores (1 mm diameter) per tumor were 
transferred into a TMA scaffold. 4 µm sections were cut, stained with haematoxylin and eosin 
and via immunohistochemistry for several potentially regulated proteins. 
 
3.2.7. Immunohistochemistry (IHC) 
Sections of the TMA generated from EwS xenotransplanted in mice were stained for FLI1 
and fusion oncogene targets at the immunohistochemical facility of the Pathology of the LMU 
Munich. For antigen retrieval, microwave treatment was performed with the antigen retrieval 
AR-10 solution for FLI1, the antigen retrieval ProTaqs I and V Antigen-Enhancer for pMYBL2 
and PAX7, and the Target Retrieval Solution S1699 for SOX6. Endogenous peroxidases 
were blocked with 7.5% H2O2 and blocking serum for 20 min. As primary antibodies, anti-
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FLI1 (254M, 1:120), anti-pMYBL2 (ab76009, 1:100), anti-PAX7 (PAX7-c, 1:180) and anti-
SOX6 (HPA003908, 1:1,600) were used. As secondary antibody, peroxidase-conjugated 
anti-rabbit/-mouse IgG antibody were used: MP-7401 for FLI1, pMYBL2 and SOX6, and 
PK6200 for PAX7. Slides were stained with AEC+ (SOX6) and DAB+chromogen and 
counterstained with haematoxylin Gill’s Formula. Immunoreactivity was semi-quantified with 
a modified immunoreactivity score (IRS) as employed for hormone receptor status (Remmele 
and Stegner, 1987): Staining intensity was scored in four categories, from no to strong 
staining, represented by score 0 to 3. The stained portion of cells was scored in five 
categories from 0-19% in steps of 20% to 80-100%, represented by score 0-4. The product 
of both scores resembled the final IRS. 
 
3.2.8. DNA isolation 
Genomic DNA was isolated using the NucleoSpin Tissue kit. About 107 cells were pre-lysed 
in 200 µl Buffer T1, mixed with 25 µl Proteinase K (proteinase from the kit diluted in 
proteinase buffer) and 200 µl Buffer B3. After protein digestion at 70°C for 15 min, 210 µl 
ethanol (96-100%) were added for DNA precipitation and the sample was loaded on a 
collection tube. After centrifugation for 1 min at 11,000 g, the tube's membrane was washed 
with 500 µl Buffer BW, and 600 µl Buffer B5, each washing step performed with 1 min 
centrifugation at 11,000 g. The membrane was dried by two further minutes centrifugation 
and the DNA was eluted from the membrane with 40 µl nuclease-free water. DNA was 
quantified using 1 µl eluted DNA on a NanoDrop spectrophotometer. 
 
3.2.9. RNA isolation, reverse transcription and qRT-PCR 
3.2.9.1. RNA isolation 
RNA was isolated using the NucleoSpin RNA kit with a slightly modified manufacturer's 
protocol: Cells were lysed in 350 µl RA1 lysis buffer and roughly mixed with 350 µl ethanol 
(70%) to enable membrane binding. The mixture was transferred into a collection tube. RNA 
was bound to the membrane during centrifugation at 11,000 g at 4°C for 1 min. The 
membrane was desalted with 350 µl MDB. Potentially contaminating genomic DNA was 
digested with 95 µl 1:10 in rDNAse buffer diluted rDNAse for 15 min at room temperature. 
rDNAse was stopped by washing with 200 µl RAW2 buffer. The membrane was washed 
twice with RA3 buffer, 600 µl and 250 µl. For the last washing step, the centrifugation time 
was increased to 2 min to dry the membrane. RNA was eluted in 40 µl nuclease-free water. 
RNA was quantified using 1 µl eluted RNA on a NanoDrop spectrophotometer. 
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3.2.9.2. Reverse transcription 
RNA was reverse transcribed to cDNA using the High Capacity cDNA Reverse Transcription 
Kit. Per reaction 2 µl 10x RT Buffer, 2 µl 10x RT Random Primers, 0.7 µl 25x dNTPs and 
0.7 µl of MultiScribe Reverse Transcriptase were filled up to 20 µl volume with 1 µg RNA and 
nuclease-free water. The thermal conditions indicated in Table 4 were applied. 
 
Table 4: Thermal protocol for reverse transcription 
Step # Description Temperature (°C) Time (s) 
1 Primer annealing 25 10 
2 Reverse transcription 37 120 
3 Inactivation of the reverse transcriptase 85 5 
 
Resulting cDNA was diluted 1:10 in nuclease-free water and stored at -20°C. 
 
3.2.9.3. Primer design and test 
As primer design tool the online Realtime PCR Tool from Integrated DNA Technologies 
(Coralville, IA, USA) was used with mRNA sequences retrieved from NCBI (Bethesda, MD, 
USA). Primer pairs were tested in an in silico PCR with the UCSC browser and with BLAT for 
their specificity. Exon-exon spanning primers were preferred, as eventually contaminating 
genomic DNA would not be sufficiently amplified in a qRT-PCR protocol with such primers to 
cause any bias on the results. When several isoforms of a gene were known, primers binding 
all isoforms were preferred. 
For testing the primers, qRT-PCR was performed with cDNA of cells with known high 
expression of the target sequence. The cDNA was used undiluted and in six subsequent 1:2 
dilutions (maximum dilution 1:64). When displaying the dilution on an x-axis in log2-
transformation (0 to -6) and the Cq values on the y-axis, the optimal slope would be 1 
(meaning for each duplication of the PCR product one additional cycle is needed). The 
average actually observed slope x was used in the formula 2


 to calculate the primer 
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3.2.9.4. Quantitative real-time polymerase chain reaction (qRT-PCR) 
qRT-PCR combines PCR and quantification. DNA gets denaturated at high temperature, 
then primers complementary to a specific sequence can bind to the single-stranded DNA 
(annealing), which builds the starting point for DNA polymerisation. By cyclic repetition of 
these steps, DNA flanked by the primers gets exponentially amplified. A fluorescent dye 
binding to double stranded DNA indicates the amplification. The cycle number, when the 
fluorescence signal passes a threshold, is depicted as Cq (quantification cycle) value. 
Per reaction 7.5 µl SYBR Select Master Mix (including buffer, polymerase, nucleotides and 
fluorescent dye) were mixed with 6.75 µl of the 1:10 pre-diluted cDNA and 0.75 µl of forward-
/reverse-primer mix (conc. 10 nmol/ml, each). 96 well PCR plates were used. Standard PCR 
plates were clear. When high Cq values were expected (>30), white plates were utilized to 
avoid any risk of cross-signaling. qRT-PCR was performed in a CFX Connect Real-Time 
System cycler using the protocol indicated in Table 5. 
 
Table 5: Thermal protocol for qRT-PCR 





1 Polymerase heat activation 95 120  
2 Denaturation 95 10  
3 Annealing and elongation 60 30 Plate read, go to step 2 
for 49 times 
4 Final denaturation 95 30  
5 Cooling before melting curve 65 30  
6 Melting curve 65-95 5 Plate read and increment 
of 0.5°C, repeat 
 
To quantify the qRT-PCR products, the ΔΔCq method was used. First, the Cq value of each 
sample and primer pair was normalized to the Cq value of the same sample and the primer 
pair for the housekeeping gene RPLP0. Then, the resulting ΔCq values were compared to 
the ΔCq value of a control sample. As with each PCR cycle the product is doubled, a high 
ΔΔCq means that more PCR product doubling was necessary for signal detection, hence 
less cDNA and less transcript was present in the sample. 
  
~ 32 ~ 
 
∆	
  = 	
  − 	
  
∆∆	
  = ∆	
  − ∆	 
  
 !"#$%   &'( ))$*+  ,  
[%] = 2
∆∆01234567859:479  ∙ 100 
 
3.2.10. Western blot 
3.2.10.1. Sample preparation 
For quantification of proteins in cell lines, subconfluent grown cells were lysed in 100 µl cold 
RIPA buffer per 10 cm² culture surface, after washing off the proteins from the medium with 
PBS. All cell material was scratched into a collection tube, shaken for 30 min on ice, and 
spinned down at 11,000 g for 5 min. The supernatant was kept as cell debris free protein 
sample. 
 
RIPA buffer: 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium 
dodecyl sulfate (SDS), 50 mM Tris-HCl, pH adjusted to 8; directly before use add 15 µl 
protease inhibitor cocktail and 5 µl Na3VO4 (200 mM) to 980 µl RIPA buffer 
Na3VO4: 200 mM in ddH2O, pH adjusted to 10, boiled until clear 
 
Total protein per sample was estimated with the colorimetric Bradford protein assay. The 
Bradford assay was performed in a 96-well culture dish. For each control and sample 100 µl 
of 1:5 Bradford solution diluted with ddH2O were added to different wells. For controls and 
samples 1 µl volume was used. As controls BSA dilutions containing 0.125 µg, 0.25 µg, 
0.5 µg, 0.75 µg, 1 µg, 1.5 µg, and 2 µg BSA per microlitre were applied. After 5 min 
incubation on an orbital shaker, absorption at 595 nm was measured on a plate reader. 
Using the controls, a linear function between protein concentration and absorption was 
calculated in Microsoft Office Excel as standard curve. Based on this standard curve, the 
protein concentration of the samples was calculated. 
 
3.2.10.2. SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Per sample, 15-30 µg protein were used for SDS-PAGE. To the corresponding volume of the 
sample, 1/4 volume of loading dye was added and the sample was denaturated at 95°C for 
5 min for disruption of tertiary structures. 
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Loading dye: 312.5 mM Tris-HCl, 10% SDS, 50% glycerol, bromphenol blue; filtered; before 
use add 250 µl of 1 M DTT to 1 ml loading dye 
 
For all proteins tested here, a 10% resolving gel was suitable. All ingredients of the 
polyacrylamide gel (Table 6) were mixed and filled into the gel cassette up to 5 mm below 
the end of the comb. For a clear horizontal line between the resolving and stacking gel, the 
resolving gel was covered with isopropanol during polymerisation. After polymerisation of the 
resolving gel, isopropanol was removed, the stacking gel ingredients were mixed and added 
on top of the resolving gel, and the comb was stuck on top of the gel cassette. 
 
Table 6: Composition of the polyacrylamide gel 
 Resolving gel (10%) (µl) Stacking gel (µl) 
ddH2O 2,925 3,543 
1.5 M TrisHCl (pH 8.8) 1,950 NA 
1 M TrisHCl (pH 6.8) NA 860 
30% Acrylamide/Bisacrylamide 2,500 500 
10% SDS 75 47.5 
10% APS 40 40 
TEMED 10 10 
 
1.5 M TrisHCl: Add 45.4 g Tris to 250 ml ddH2O, adjust pH to 8.8 
1 M TrisHCl: Add 30.3 g Tris to 250 ml ddH2O, adjust pH to 6.8 
10% APS: dissolve 10 g APS in 100 ml ddH2O 
10% SDS: dissolve 10 g SDS in 100 ml ddH2O 
 
After polymerisation of the stacking gel, the gel cassette was assembled with the electrode 
chamber in a tank. Running buffer was added to the upper chamber, which is faced by the 
upper and open part of the gel cassette, and to the lower part. The comb was removed and 
in the thus built gel pockets the sample or a protein ladder (2 µl) were added. Electrophoresis 
run for 90 min at 120 V. The running front was controlled to reach the end of the gel at this 
time. Afterwards, the gel cassette was opened and the wet blotting system assembled. 
Running buffer: 3 g/L Tris base, 14.4 g/L glycine, 0.1% SDS 
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3.2.10.3. Electroblotting 
A wet transfer system was applied. Whatman paper was soaked in transfer buffer. The gel 
was placed with orientation front-downside on the paper, then the buffer-soaked 
nitrocellulose membrane was placed on top, carefully avoiding any air bubble, before another 
Whatman paper was laid on top. This stack was placed into a holding system between two 
foams and put into the transfer chamber filled with transfer buffer. The membrane faced the 
anode, while the gel faced the cathode. This way, the negatively charged proteins will follow 
the electric current in direction to the anode, getting immobilised in the nitrocellulose 
membrane. Transfer was performed for 90 min at constant 2 A. To avoid overheating, the 
system was continuously cooled. 
 
Transfer buffer: 3 g/L Tris base, 14.4 g/L glycine, 20% vol methanol 
 
Afterwards, the transfer system was disassembled. For control of equal loading and 
successful transfer of the proteins on the membrane, the membrane was shortly stained with 
Ponceau S. Excess staining was washed off with ddH2O. By three times short washing of the 
membrane in TBS-T on an orbital shaker, the membrane was decolorized again.  
 
10x TBS: Add 24 g Tris base and 88 g NaCl to 1 L ddH2O, adjust pH to 7.3 
1x TBS: dilute 10x TBS 1:10 in ddH2O (final conc. 20 mM Tris, 150 mM NaCl) 
TBS-T: Add 1 ml Tween-20 to 1L 1x TBS 
 
3.2.10.4. Protein detection 
To avoid unspecific antibody binding, the membrane was blocked with 5% milk or 5% BSA 
(filtered, depending on the preference for the respective antibody) in TBS-T for 1 h. The 
membrane was then incubated with the protein specific antibody (Table 7) in milk or BSA at 
4°C over night. 
After washing the membrane and eliminating unbound antibodies with TBS-T (three times, 
10 min, each), the membrane was incubated with a horseradish peroxidase (HRP) coupled 
antibody specific for the species of the primary antibody for 1 h. 
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Table 7: Antibodies for western blot 
Target Antibody Species Dilution In BSA/milk Primary/secondary 
GAPDH Santa Cruz 32233 Mouse 1:2,000 milk primary 
FLI1 Cell Marque 254M Mouse 1:1,000 BSA primary 
ERG Cell Marque 434R Rabbit 1:2,000 milk primary 
Anti-
mouse 
Promega W402B Goat 1:3,000 milk secondary 
Anti-rabbit OriGene EU 
R1364HRP 
Goat 1:5,000 milk secondary 
 
The unbound secondary antibody was removed by three further washing steps with TBS-T, 
before detection of chemiluminescence. An electrochemiluminescence reagent was directly 
pipetted on the membrane and the signal generated by the cleavage of this reagent by the 
HRP was detected and quantified with the LI-COR Odyssey imaging system. 
  
3.2.11. Mycoplasma PCR 
To rule out mycoplasma contamination in cell culture, a nested PCR protocol was used. To 
this end, supernatant was taken from cultured cells after at least three days of cell growth 
close to confluency. The supernatant was denaturated at 95°C for 5 min and then spinned 
down to avoid any cellular components in the PCR. 
The primers are listed in Table 8. Each primer was diluted to 100 µM according to 
manufacturers' protocol. In one volume primer mix each primer was diluted 1:10 (hence each 
primer constitutes to 10% of the total volume of the primer mix). In the primer mix for the first 
PCR the forward primers were diluted 1:5, (constituting 20% of final volume, each), to 
balance the concentration of forward and reverse primers.  
In the first PCR, 1 µl of cell supernatant and the corresponding primer mix were combined 
with the remaining components of the PCR mix (see Table 9). PCR was run with the thermal 
program depicted in Table 10. 
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Table 8: Primers for mycoplasma PCR 
 Oligoname Sequence 5'-3' 













Table 9: Components of the mycoplasma PCR. SN: supernatant 
 Stock conc. Amount (µl) Final conc. 
Nuclease-free water NA 1st 18.75/2nd 18.55 NA 
Taq Buffer (MgCl2 free) 10x 2.5 1x 
MgCl2 25 mM 1.5 1.25 mM 
dNTPs 10 mM 0.5 200 µM 
Primer mix 80 µM/ 60 µM 1st 0.625/2nd 0.825 2 µM 
Taq Polymerase 5 U/µl 0.125 0.625 U/25 µl 
SN/1st PCR product NA 1  NA 
 
Table 10: Thermal protocol of the mycoplasma PCR 
Step # Description Temperature (°C) Time (s) Comment 
1 Initiation 95 120  
2 Denaturation 95 30  
3 Annealing  52 (1st), 45 (2nd) 60  
4 Elongation 68 60 Go to step 2, 39 times 
5 Final elongation 68 420  
 
Then the PCR was repeated, using the product of the first PCR and the second primer mix 
and the annealing temperature of 45°C (see Table 8-10). 
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The product of the second PCR run was mixed with 5 µl 6x gel loading buffer and run with a 
positive and negative control in a 1.5% agarose gel with 100 bp DNA ladder. 
 
3.2.12. PCR for fusion oncogene 
To test, which fusion type is present in EwS cell lines, primers for both EWSR1 and ETS 
transcription factor were used in a PCR with cDNA of the cells. The components are listed in 
Table 11. A thermal protocol was applied adjusted to the melting temperature of the primers, 
and the product length (Table 12). 
 
Table 11: Components of the fusion oncogene PCR 
 Stock conc. Amount (µl) Final conc. 
Nuclease-free water NA 20.375 NA 
Taq standard buffer 10x 2.5 1x 
dNTPs 10 mM 0.5 200 µM 
Primer mix 10 µM, each 0.5 200 nM 
Taq DNA Polymerase 5 U/µl 0.125 0.625 U/25 µl 
Template cDNA < 1µg/µl 1  NA 
 
Table 12: Thermal protocol of the fusion oncogene PCR 
Step # Description Temperature (°C) Time (s) Comment 
1 Initiation 95 30  
2 Denaturation 95 30  
3 Annealing  52  60  
4 Elongation 68 30 Go to step 2, 39 times 
5 Final elongation 68 300  
 
The product was loaded with 5 µl 6x loading dye buffer on a 2% agarose gel with 100 bp 
ladder. Type 1 and 2 EWSR1-FLI1 fusion were easily to distinguish due to a 66 bp upwards-
shift of the EWSR1-FLI1 type 2 PCR product due to an additionally included and amplified 
exon.  
In case of unclear results in the gel electrophoresis, the product was cut out of the gel, 
cleaned-up and sent for sanger sequencing at Eurofins Genomics with one of the PCR 
primers as sequencing primer. 
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To test for the expression of a reciprocal fusion in EF1 positive EwS cell lines, which is 
frequently present when a reciprocal translocation resulted in EF1 instead of more complex 
genetic events (Anderson et al., 2018), primers were applied as described by Elzi et al. (Elzi 
et al., 2015). The components and the thermal condition of the PCR are listed in 
Table 13-14. 
 
Table 13: Components of the PCR for FLI1-EWSR1 fusion 
 Stock conc. Amount (µl) Final conc. 
Nuclease-free water NA 14.125 NA 
Taq standard buffer 5x 5 1x 
MgCl2  25 mM 3 3 mM 
dNTPs 10 mM 0.5 200 µM 
Primer mix 10 µM, each 1.25 500 nM 
Taq DNA Polymerase 5 U/µl 0.125 0.625 U/25 µl 
Template cDNA < 1µg/µl 1  NA 
 
Table 14: Thermal protocol of the PCR for FLI1-EWSR1 fusion 
Step # Description Temperature (°C) Time (s) Comment 
1 Initiation 95 120  
2 Denaturation 98 25  
3 Annealing  63-53  30 -0.5°C increment/ cycle 
4 Elongation 72 30 Go to step 2, 19 times 
5 Denaturation 98 25  
6 Annealing  56  30  
7 Elongation 72 30 Go to step 5, 19 times 
8 Final elongation 72 300  
 
For reciprocal type 1 fusion, products were expected at 100 bp (primer mix#1) and 180 bp 
(primer mix#2), for type 2 only at 149 bp (primer mix#2). 
 
3.2.13. Gel electrophoresis and clean-up 
For size separation of DNA and detection of PCR products of distinct sizes, agarose gel 
electrophoresis was employed. To this end, 1-2% (higher percentage for smaller DNA 
fragments) agarose were mixed with Tris-acetate-EDTA (TAE) electrophoresis buffer, boiled 
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in a microwave until agarose was completely dissolved, and then cooled to about 60°C 
before either ethidium bromide, or in later experiments SYBR Safe as DNA stainer, was 
added and the gel was casted. Electrophoresis with samples in loading dye and DNA ladder 
was run in a TAE filled chamber at 90-120 V. Stained DNA was made visible with UV light. 
 
10X TAE: 48.4 g Tris base, 11.4 ml of glacial acetic acid (17.4 M), 3.7 g EDTA in 800 ml 
deionized water, filled up to 1 L 
 
To extract the DNA of a specific lane in the gel electrophoresis, the lane was cut out of the 
gel and DNA was cleaned-up using the Macherey Nagel NucleoSpin Gel and PCR Clean-up 
kit according to the manufacturer's protocol. In short, the gel was dissolved in 200 µl NTI 
buffer at 50°C, then the DNA was bound to a column's membrane during centrifugation at 
11,000 g for 30 s, the membrane was washed with 700 µl NT3 buffer by centrifugation, then 
it was tried by one further minute of centrifugation, before DNA was eluted with 20 µl 
nuclease-free water. 
 
3.2.14. Whole genome sequencing analyses 
3.2.14.1. Sample preparation and sequencing 
To generate a multi-dimensional comprehensive dataset characterizing EwS cell line models, 
whole genome sequencing (WGS) was performed. EwS cell lines planned for WGS were 
tested for cell line identity by STR profiling. Then, from cells grown on 25 cm² culture surface, 
genomic DNA was extracted. The quality of the DNA was first controlled with a NanoDrop 
spectrophotometer (high 260 nm:280 nm absorbance ratios, 260 nm:230 nm absorbance 
ratio around 1.8) and quantified with Qubit. 
50 µl of DNA with 50 ng/µl concentration was sent for sequencing at the High Throughput 
Sequencing Unit (W190) of the Core Facilities Genomics and Proteomics at the German 
Cancer Research Center (DKFZ, Heidelberg, Germany). The genomic DNA integrity was 
assessed as DNA Integrity Number (DIN) at the DKFZ, before library preparation with a 
PCR-free protocol. Sequencing was performed on an Illumina HiSeq X ten platform (Illumina, 
San Diego, CA, USA) with 150 bp paired-end reads. 
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3.2.14.2. Alignment 
Alignment of the resulting FASTQ files from the sequencing was performed according to a 
protocol by Wright et al. (Wright et al., 2017), which is optimised for the applied sequencer. 
In the first step, accounting for 1% PhiX spike-in per lane, FASTQ files were aligned with 
Burrows Wheeler aligner (Li and Durbin, 2009) (v.0.7.15, bwa mem) to the PhiX reference 
genome provided by Illumina, simultaneously assigning the read groups read group identifier, 
platform unit, sample, platform, and library identifier. A SAM file with unaligned reads was 
generated and directly converted to BAM format with samtools (Li et al., 2009) (version 1.9). 
With picard (Picard Toolkit, 2019, Broad Institute, GitHub Repository, 
http://broadinstitute.github.io/picard/) RevertSam the BAM file was converted into an 
unaligned UBAM file, clearing alignment tags and additionally removing not paired reads. 
With picard MarkIlluminaAdapters sequenced library adapters were marked with an adapter-
trimming tag (XT). The UBAM file was then converted into FASTQ format again with picard 
SamToFastq, which did additionally clip adapter sequences. FASTQ files were aligned to the 
hg19 reference genome from the UCSC genome browser with bwa mem. Read information 
and metadata lost during the conversion of the UBAM file to FASTQ were enclosed to the 
newly generated BAM files by merging with the UBAM files using picard 
MergeBamAlignment. Duplicates were marked and removed with picard MarkDuplicate. 
Base quality scores were recalibrated for variant calling with GATK (Van der Auwera et al., 
2013) (version 4.1.0.2) from the Broad Institute, building first a statistical model for known 
sites from the 1000 Genomes Project (1000 Genomes Project Consortium et al., 2010) and 
the dbSNP database (Sherry, 2001) with BaseRecalibrator and then adjusting the scores 
with ApplyBQSR. Finally, quality was controlled with FastQC (Andrews, 2019) (v.0.11.5) and 
displayed merged with MultiQC (Ewels et al., 2016). Coverage per position was count with 
samtools depth and displayed as average of 100 kb bins. 
 
3.2.14.3. Variant calling and annotation 
Single nucleotide variants were called with bcftools, using mpileup (Li, 2011) (version 1.9) 
followed by call process and position normalization, and GATK Mutect2, run for somatic 
mutations. ANNOVAR (Wang et al., 2010) and SnpEff (Cingolani et al., 2012) were 
employed for annotation. To control SNPs at specific positions of interest, the predicted 
SNPs were cross-checked with calls from VCMM (Shigemizu et al., 2013), which takes the 
pileup file of samtools as input, and freebayes (Garrison and Marth, 2012; Liu et al., 2019).  
Copy number variation (CNV) was estimated from the WGS data using CNVnator (Abyzov et 
al., 2011), extracting reads, building histograms, statistics, generating 1000 bp bins for 
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segments and 100 bp bins for specific sequences, before call and genotyping process. 
Additionally, CNVkit (Talevich et al., 2016) with 300 bp bins and exclusion of not accessible 
chromosomal regions was applied on the data.  
Genomic transchromosomal fusions were assessed with BreakDancer (Chen et al., 2009). 
Further structural variants were called with LUMPY (Layer et al., 2014), giving split and 
discordant reads as input and using a "blacklist" of non-accessible chromosomal regions, 
and GRIDSS (Cameron et al., 2017, 2020). 
Potential rearrangements by chromoplexy were extrapolated from copy number (CNVnator) 
and structural variation (GRIDSS) data using ChainFinder (Baca et al., 2013).  
Ploidy was estimated with an algorithm from the ploidyNGS tool (Augusto Corrêa dos Santos 
et al., 2017) comparing the most and second most frequent allele of heterozygous loci for 
read numbers, expecting a nearly 1:1 distribution in case of euploidy. Due to high ram 
consumption, the tool was not directly applied on the WGS data, but the method was utilized 
on read counts already generated by VCMM. 
When the tools were not capable of processing all samples together, they were processed 
independently, but in parallel with GNU parallel (Tange, Ole, 2020). 
 
3.2.14.4. GGAA-mSat genotyping 
For genotyping of GGAA mSats in EwS cell line WGS data, first a mSat library was built. The 
hg19 reference genome was used as input for the tool Tandem Repeats Finder (Benson, 
1999) (version 4.09) with parameters match weight 2 (not overrating any match), mismatch 
weight 5 (medium penality for mismatches, three correct bases in the GGAA motif can 
compensate one mismatch), InDel (insertion or deletion) penality 7 (strong penality, one full 
GGAA motif can compensate the penality for an InDel), match probability 80 (maximum), 
InDel probability 10 (low), minscore 32 (the product of minimal required correct sequence 
length multiplied with the match weight), and max period size 4 (as four bases GGAA motif is 
searched). 
From the resulting data file, entries with four consecutive GGAA or TTCC motifs were 
selected and filtered for high rates (39% each) G and A or T and C in the respective mSat. 
Overlapping sequences were matched with bedtools intersect (Quinlan and Hall, 2010). 
Thus, the created data file should comprise all GGAA-mSats with at least five repeats, shown 
as minimal number for enhancer activity (Gangwal et al., 2008), and GGAA-mSats with four 
repeats, but otherwise only small deviation(s) from the motif, so that small genetic variations 
~ 42 ~ 
 
might form even longer GGAA stretches in the EwS cell lines. The list was converted into 
BED format. 
Using HipSTR (Willems et al., 2017) on the aligned WGS data of the EwS cell lines and the 
GGAA-mSat library in BED format, the mSat positions were genotyped for each cell line. A 
PCR stutter model was not given as input, as library preparation for sequencing was done 
with a PCR-free protocol. Readouts of poor quality were removed with the tool dumpSTR 
with minimal call rate for each locus of 30%, minimal call depth per locus of 10 and minimal 
supporting reads per allele of 3, maximum InDel probability in mSat flanking regions of 0.15 
and minimal call quality of 90%. Synoptic statistics were calculated with qcSTR. Both tools 
are included in the TRTools package (Mousavi et al., 2020). 
 
3.2.14.5. Motif calling 
Enrichment for transcription factor binding sites was investigated using HOMER (Heinz et al., 
2010), giving random sequences from the reference genome as control when no comparison 
group was present, or mSat-flanking regions of not fusion bound mSats and promoters of not 
fusion regulated genes when probing the fusion bound mSats and promoters of fusion 
regulated genes. Predicted transcription factor motifs were inspected manually for alignment 
with enriched sequences. 
 
3.2.15. Chromatin immunoprecipitation and high-throughput sequencing  
(ChIP-Seq) 
3.2.15.1. ChIP 
To assess interactions of the EwS fusion oncogenes with the genome and the chromatin 
state of EwS cell lines, ChIP-Seq was performed. The following ChIP protocol is based on 
the iDeal ChIP-Seq kit for Transcription Factor from Diagenode. It was refined for EwS by 
Didier Surdez (Institut Curie, Paris, France) and taught to the author of this thesis. The 
author established this protocol at the Institute of Pathology of the LMU Munich. 
For chromatin immunoprecipitation (ChIP), 4x106 cells for transcription factors and 106 cells 
for histone marks were needed. Cells were seeded 48 h before ChIP in duplicates and 
controlled to be adherent, not fully confluent, and to grow in still fresh medium before use to 
avoid any loss or bias due to metabolic changes. One culture flask per cell line was 
harvested for counting the cell number. The other flask was used for ChIP. First, medium 
was changed to fresh medium with 1% methanol-free formaldehyde for crosslinking of 
protein and DNA. After 10 min incubation at room temperature, formaldehyde was quenched 
with 1 ml gylcine (2 M) per 10 ml medium for 5 min.  
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Culture surface was washed three times with 20 ml ice-cold PBS. Cells were lysed with as 
many millilitres lysis buffer IL1B as million cells were counted for the complete culture flask. 
Lysate and cells were scratched from the culture surface and incubated on ice for 20 min. 
The lysate was spinned down at 4°C and 500 g for 5 min, supernatant was decanted, and 
pellet was resuspended in 6 ml IL2 per 106 cells to break the nuclear membranes. After 
10 min incubation on ice and 5 min centrifugation at 4°C and 500 g, supernatant was 
decanted and the pellet of lysed cells was resuspended in 333 µl IS1b shearing buffer with 
1:200 protease inhibitor per 5x106 cells. 333 µl lysate were sonicated in a Bioruptor Plus, 
high power, 30 sec on/off. The optimal number of sonication cycles was tested before ChIP 
for each cell line (see Table 15) to achieve genomic fragments between 200 and 600 bp, 
hence long enough for sequencing, but not too long for pulldown or reducing information in 
the sequencing. Sonicated DNA was centrifuged for 10 min at 4°C and 16,000 g and the 
supernatant was transferred into new reaction tubes. 
 
Table 15: Sonication cycles tested and applied for optimal DNA fragmentation of EwS cell lines 
for ChIP 





























Magnetic beads were washed three times for 5 min with 1 ml washing buffer (3.2 ml 
ChIP-Seq-grade water, 800 µl IC1b, 80 µl BSA) on ice, and then resuspended in the initial 
volume. 30 µl beads were coupled to antibodies by addition of 1.8 µl proteinase inhibitor 
cocktail, 6 µl BSA, 20 µl of 5x buffer IC1b and maximum 2 µg of the antibody (see Table 16). 
The bead mix was filled up to 100 µl with ChIPseq-grade water and incubated 4 h at 4°C on 
a rotation wheel. 
For transcription factor binding antibodies, 250 µl sheared chromatin were added to the 
magnetic beads, for histone marks 66 µl sheared chromatin and 174 µl shearing buffer. For 
binding of the antibodies, the mixture was incubated at 4°C over night. 
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Table 16: Antibodies for ChIP 
Target Antibody Concentration 
(µg/µl) 
Volume (µl) Amount in ChIP 
(µg) 
EWSR1-FLI1 Abcam 15289 0.2 10 2 
EWSR1-ERG Abcam 92513 0.361 4.16 1.5 
H3K4me3 Diagenode C15410003 1.4 1 1.4 
H3K27ac Abcam 4729 1 1 1 
H3K27me3 Diagenode C15410069 1.45 µg/ml 2 2.9 
 
The bead-antibody-protein-DNA suspension was washed with 350 µl of iW1, iW2, iW3, and 
iW4 for 5 min on the rotation wheel at 4°C, each. Then, DNA was eluted from the beads with 
100 µl iE1 during 30 min incubation at room temperature on a rotation wheel. 
DNA was decrosslinked with 4 µl IE2 at 65°C for 4 h. As control for unspecific bindings, 
2.5 µl of sheared chromatin (input) was filled up with iE1 to 100 µl and processed from the 
decrosslinking step on in parallel with the other samples. 
DNA was purified by addition of 2 µl Carrier, 100 µl isopropanol (100%) and 10 µl iPure 
beads v2. After 10 min incubation on a rotation wheel to enable binding of the DNA to the 
beads, the beads were washed with 100 µl wash buffer 1 and 2 for 3 min on a rotation wheel, 
each. 
Lastly, chromatin was eluted from the iPure beads with 25 µl of elution buffer C for 15 min on 
a rotation wheel. The elution step was repeated and the eluate was pooled. 
10 µl of the eluate were diluted with 190 µl nuclease-free H2O and used for qRT-PCR, 
following the standard qRT-PCR protocol using primers for CCND1-CTCF (CTCF binding 
site), CCND1-EF1 (EWSR1-ETS binding site), CDKN1A, CUL1, GATA2, IGF2, SEC14L2. A 
relatively high amount of DNA template for the CCND1-EF1 and SEC14L2 primers was 
expected for FLI1/ERG and H3K27ac ChIP products. Additionally, GATA2, CDKN1A, and 
CUL1 primers were designed as positive control for H3K27ac ChIP. CCND1-CTCF served 
for control of the promoter mark H3K4me3 ChIP. IGF2 is normally repressed (also by CTCF) 
and was hence used for control of the repressive histone mark H3K27me3 ChIP. As the input 
control was 1% of the DNA used for FLI1/ERG ChIP, the same Cq value for input and 
FLI1/ERG could be interpreted as 1% of the in qRT-PCR detected sequence was actually 
immunoprecipitated. Knowing, that 66/250 sheared chromatin was used for histone marks, 
the same Cq for input and histone marks could be interpreted as 3.79% immunoprecipitation. 
In this way, the immunoprecipitated DNA sequences were quantified relative to input. 
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To test for sufficient chromatin shearing, 50 µl sheared chromatin were mixed with 150 µl 
PBS and decrosslinked with 1.5 µl proteinase K (20 mg/ml) for 4 h at 65°C. DNA was 
cleaned up with 201.5 µl phenol/chloroform/isoamlyalcohol 25/24/1. After 10 min 
centrifugation at high speed, the aqueous phase was mixed with 200 µl 
chloroform/isoamylalcohol 24/1. After another 10 min of centrifugation, DNA was precipitated 
with 2 µl glycogen (20 mg/ml), 20 µl sodium acetate (3 M), and 400 µl ethanol (100%) at 
-20°C for at least 30 min. Precipitated DNA was spinned down at highest speed for 20 min at 
4°C, washed with 500 µl ethanol (70%), and spinned down again for 10 min. Supernatant 
was removed carefully. After the pellet was dried, DNA was resuspended in 20 µl nuclease-
free water. Potential RNA decontamination was digested with 2 µl of RNAse cocktail at 37°C 
for 30 min. DNA was quantified on a spectrophotometer and 2.5 µg were run on a 1.3% 
agarose gel.  
The ChIP product was quantified with Qubit. 10 ng DNA in 50 µl volume were sent for library 
preparation and sequencing at the Division for NGS of the Institut Curie, Paris, France. 
 
3.2.15.2. Sequencing, alignment and peak calling 
Libraries of the ChIP product were prepared at the Institut Curie and sequencing was 
performed on the Illumina HiSeq 2500 platform with 100 bp single end reads. For CHLA25, 
EW3, RDES, SKES1, and TC106 the read length was increased to 150 bp. EW24 ChIP was 
sequenced with NovaSeq 100 bp paired end reads. 
As for A673, CHLA10, EW1, EW7, MHHES1, MIC, POE, and TC71 ChIP products from 
Didier Surdez were already sequenced, the corresponding ChIP products of the author of 
this thesis were not additionally sequenced. The data were kindly provided for collaboration. 
Alignment was performed by Sandrine Grossetête-Lalami (Institut Curie). The FASTQ files 
from sequencing were aligned with Bowtie 2 (Langmead and Salzberg, 2012) to the hg19 
reference genome. Data were converted into BAM format and sorted with samtools. Peaks 
were called with MACS2 (Zhang et al., 2008), using input as control and the broad-flag 
option for histone ChIP. BedGraph files were normalized with the corresponding input file, 
and sorted and converted into bigWig format with the UCSC tools. 
 
3.2.15.3. Downstream analysis of ChIP-Seq peaks 
Genes nearby peaks, overlaps of peaks between samples and overlaps with specific 
genomic regions were identified with HOMER and bedtools (v.2.27) closest and intersect 
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(Heinz et al., 2010; Quinlan and Hall, 2010). So called super-enhancers (SE), regions with 
high H3K27ac described as relevant for cell identity, were identified by the ROSE algorithm, 
stitching regions with H3K27ac histone modification together to potential enhancer regions 
and ranking them by their coverage in ChIP BAM files, thereby separating super-enhancers 
of other enhancers (Lovén et al., 2013; Whyte et al., 2013). For cross sample normalisation 
of peak height, bigWig files were normalized to each other with the R tool ChIPIN (Institut 
Curie, not yet published), which uses across samples constantly expressed genes as 
markers for likely similar ChIP signals. The list of constantly expressed genes was extracted 
from microarray data (see below) of the same cell lines as used for ChIP, by sorting genes 
by their expression standard deviation among the cell lines and selecting those 10% with 
lowest standard deviation. The data were converted into bedgraph files with UCSC 
bigWigToWig to calculate cross-sample normalized read densities relative to transcriptional 
start sites and other ChIP peaks using HOMER. Additionally EnrichedHeatmap and circlize 
were employed for heatmap creation (Gu et al., 2014, 2018). 
 
3.2.16. Transcriptome analyses 
3.2.16.1. Sample preparation 
In order to investigate the effect of EwS fusion oncogenes on gene expression, DNA-
microarray analyses were performed. EwS cell lines with inducible fusion oncogene 
knockdown were plated in 6-well plates (10 cm²) with the ratios described in Table 17. The 
ratios were optimized to reach around 65% cell confluence at the time of cell harvest. Three 
wells were treated with 1 µg/ml Dox for fusion knockdown induction, three others served as 
control. After 48 h, the medium was refreshed and filled up to 4 ml. After 96 h, the samples 
were harvested in RA1 lysis buffer. 
For all samples, RNA was isolated, quantified with a NanoDrop spectrophotometer, partly 
reverse transcribed for quantification of fusion knockdown in qRT-PCR. The requirements for 
DNA microarrays were 1) volume higher/at least 10 µl, 2) amount 1 µg, concentration 50-200 
ng/µl. Hence, 11 µl of 100 ng/µl RNA was sent for DNA-microarray analysis. 
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Table 17: Cell splitting ratios for EwS cell lines to reach 65% confluence after 96 h 









A673shEF1 1:10 1:10 
 
MICshEF1 1:8 1:8 
CHLA10shEF1 1:5 1:5 
 
POEshEF1 1:10 1:10 
CHLA25shEE 1:10 1:10 
 
RDESshEF1 1:16 1:8 
EW1shEF1 1:24 1:8 
 
RH1shEF1 1:27 1:19 
EW22shEF1 1:8 1:8 
 
SKES1shEF1 1:9 1:4 
EW24shEF1 1:5 1:5 
 
SKNMCshEF1 1:12 1:10 
EW3shEE 1:8 1:6 
 
TC106shEE 1:19 1:19 
EW7shEF1 1:19 1:10 
 
TC32shEF1 1:19 1:19 
MHHES1shEF1 1:13 1:8 
 
TC71shEF1 1:38 1:13 
 
3.2.16.2. DNA-microarray and data normalisation 
DNA-microarray analysis was performed at IMGM Laboratories (Martinsried, Germany) on 
human Clariom D microarrays (Affymetrix, Santa Clara, CA, USA). The CEL files were 
processed with the Transcriptome Analysis Console (TAC 4.0, Thermo Fisher Scientific, 
Waltham, MA, USA) and the Affymetrix human Clariom D annotation file (version 2) applying 
the Signal Space Transformation-Robust Multiarray Analysis (SST-RMA) method (including 
background reduction and intensity normalization). The readout comprises 135,754 transcript 
IDs. As the focus of this work is on genes transcribed and translated to potentially clinically 
relevant proteins, all IDs annotated with RNA, noncoding or pseudogene were removed. 
Furthermore, unmapped genes (hence not applicable for comparison with ChIP/WGS data), 
those only predicted by AceView and those not following the guidelines for naming genes 
from HUGE Gene Nomenclature Committee (only capital letters and numbers, no 
punctuation except for hyphens) were removed. The remaining genes were labelled with 
Entrez Gene IDs using DAVID (Huang et al., 2009a, 2009b). This resulted in a list of 25,962 
unique transcript IDs annotated with 25,237 unique genes. When several transcript-IDs 
represented one gene, the mean expression value was calculated and used for further 
investigations.  
 
3.2.16.3. Identification of regulated genes 
To define regulated genes, but avoid arbitrary cut-offs, the algorithm of SE identification from 
ROSE was adopted: Genes were displayed ranked by their fold change from highest 
negative to highest positive fold change upon fusion oncogene knockdown (x-axis) together 
with their fold-changes (y-axis). When normalizing fold changes and x-axis, all 
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downregulated genes, where the slope did not drop beneath one, and all upregulated genes, 
from when the slope reached 1, were defined as regulated. This corresponds to building a 
linear function between 0:0 and the most extreme fold change and then finding the gene, 
where a linear function with the same slope is tangential. 
 
3.2.16.4. Comparison of transcriptomes 
As comparison dataset to the cell lines, previously published expression data (Baldauf et al., 
2018b) on 21 cancers and 71 normal tissues were used. To eliminate batch effects, 
expression values of the different cohorts were normalized to each other using ComBat 
(Johnson et al., 2007). Similarities in and between the cohorts were assessed with t-
Distributed Stochastic Neighbor Embedding (t-SNE) in R. 
 
3.2.17. Proteome analyses 
3.2.17.1. Sample preparation 
Complementary to the transcriptome, the proteome of EwS cell lines was assessed. Cells 
were grown to about 60-70% confluence on 10 cm² culture dishes for 96 h with and without 
Dox treatment, as done for transcriptome analysis. Relatively high medium volume was 
applied to avoid any decrease in pH and accompanying potential metabolic effects. 
Afterwards, cells were washed to remove any proteins from the medium: First 4 ml medium 
without any supplements was added and directly aspirated, then cells were incubated with 
2 ml empty medium for 15-30 min at 37°C, then again washed with 2 ml empty medium. 
Cells were lysed in Nonidet-P40 buffer for 15 min at RT. Lysed cells were scratched into 
protein low-bind tubes, sonicated with 60% amplitude, 30 sec on, 6 cycles. Lysates were 
quantified with Bradford assay (see Western blot). 
 
Nonidet-P40 buffer: 1% Nonidet P40 in 10 mM NaCl, 10 mM Tris-HCl, pH 7.6; one complete 
protease mini tablette added per 10 ml lysis buffer immediately before use 
 
10 µg protein lysate were sent for mass spectrometry and protein quantification to the 
research unit Protein Science of the German Research Center for Environmental Health 
(Munich, Germany). 
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3.2.17.2. Imputation and interpretation 
Quantification data on 7,242 proteins were received. Quantification data were complete for 
3,248 proteins. Using the IterativeSVD algorithm of fancyimpute 
(https://pypi.org/project/fancyimpute/) for proteins with quantification data in at least 70% of 
samples, missing values were imputed for 1,336 proteins, leading to a total number of 4,584 
fully quantified proteins. Regulated proteins were identified with the same algorithm as 
regulated transcripts. Data were interpreted using gene set enrichment analysis. 
 
3.2.18. Methylation analyses 
3.2.18.1. Sample preparation 
To assess the effect of fusion oncogene knockdown on methylome, samples were prepared 
as described for transcriptome analysis, but were lysed in T1 buffer and genomic DNA was 
isolated. Concentration and purity were assessed using a NanoDrop spectrophotometer. 
1 µg of DNA in 17 µl volume were sent for analysis. 
 
3.2.18.2. Analysis and data normalisation 
Methylation analysis at CpGs was performed at the Genotyping Platform of the Genome 
Analysis Center at the German Research Center for Environmental Health (Neuherberg, 
Germany) using Illumina Infinium MethylationEPIC BeadChip arrays. Methylation levels were 
calculated from the raw data files (IDAT) using Illumina Genome viewer. 
 
3.2.18.3. Differential methylation analysis and comparative analysis 
For identification of differentially methylated regions in samples with fusion oncogene 
knockdown versus without knockdown, each cell line was analyzed using the R tool minfi 
(Aryee et al., 2014). For comparison of EwS cell line methylation profile with the methylation 
profile of various primary cancers, one IDAT file per sample was uploaded to the 
classification tool of MolecularNeuropathology.org (Capper et al., 2018). The same data were 
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3.2.19. Gene set enrichment analyses and gene ontology 
The gene set enrichment analysis (GSEA) tool is a knowledge based predictor of phenotypes 
associated with a specific gene expression profile (Subramanian et al., 2005). Previously 
described gene sets annotated with phenotypes were retrieved from the Molecular Signature 
Database (Broad Institute, c2.all.v6.2). Genes or proteins assessed in the DNA-microarrays 
or by mass spectrometry were ranked by their fold changes in different fusion states. The 
ranked list was compared with the database by the GSEA tool with 1,000 permutations. As 
the enrichment score increases, when a gene from the ranked list is present in a gene set, 
but decreases in the opposite case, only gene sets with many "hits" at the top or bottom of 
the ranked list reach a high absolute enrichment score. This value is further weighted by the 
position of the hits in the list, resulting in the normalised enrichment score (NES). 
The Gene Ontology Consortium curates gene annotations in the three ontologies molecular 
function, cellular component and biological process (Ashburner et al., 2000). By giving a 
gene list of interest to an overrepresentation tool based on gene ontology data, the genes get 
annotated, the number of genes expected in the list versus the observed number is 
compared and over- or underrepresentation documented. Here, PANTHER was employed as 
classification system (Mi et al., 2019). 
 
3.2.20. Survival analysis 
Survival analyses were performed with an in-house generated tool (GenEx) to identify 
potentially clinically relevant genes. This tool automatically assesses from gene expression 
data and corresponding clinical data survival association and significance level for each gene 
in short time. Significance calculations are based on the Mantel-Haenszel test. The option 
"best percentile" finds in a range between 20th and 80th percentile the optimal cut-off 
between the two groups with low and high expression of an individual gene based on 
maximum distance of the survival curves, thereby avoiding multiple testing. The survival data 
were published before (Sannino et al., 2019) and comprise 196 individual EwS cases from 
three cohorts with expression data on 13,253 genes. Cross-cohort normalization was 
performed with Combat. The data fulfill TCGA standards with at least 60% tumor purity. 
Survival analyses of GenEx were partly validated using Graph Pad Prism. 
 
3.2.21. Statistical analyses and graphical presentation 
Statistical analyses were performed with Graph Pad Prism, R and Microsoft Office Excel. 
The standard tests for assessing statistical significance were the two-sided independent 
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Student's t-test (between two groups comparison, normal data distribution assumed, based 
on the Kolmogorov-Smirnow test) and the Mann-Whitney-(U)-Test (between two groups 
comparison, no normal data distribution). When comparing two groups for two discrete 
categories, Fisher's exact test or Chi² test (for higher sample number than 5 per 
group/categorie) were applied.  
Data were represented using Graph Prad Prism, Microsoft Office, R ggplot2 (Wickham, 
2016), Circos (0.69) (Krzywinski et al., 2009), IGV (Thorvaldsdóttir et al., 2013), Benchling 
(2020, retrieved from https://benchling.com), BioVenn (Hulsen et al., 2008) or the respective 
data analysing software described in the respective Methods section.  




4.1. A EwS model cohort for studying the effects of EWSR1-ETS fusion 
oncogenes was generated 
4.1.1. EwS cell lines selection 
A relatively large cohort of EwS cell lines needed to be selected for fusion oncogene 
knockdown experiments and knockdown effect evaluation, as with only two or three cell lines 
the inter-patient heterogeneity cannot be modelled. One major selection criterion, among the 
30 cell lines available at the LMU Munich, was the respective fusion oncogene. As 85% of 
EwS tumors harbor an EWSR1-FLI1 (EF1) fusion, more EF1 type 1 than 2, and about 510% 
EWSR1-ERG (EErg), these fusions should also be represented by the cell lines. For EErg 
knockdown, all selected EErg positive cell lines should comprise the identical fusion 
transcript.  
To assure the presence of the fusion types described for the different cell lines, thereby 
performing a first identity check and exclusion of cross-contamination, PCRs for the fusion 
transcript were done on cDNA. Gel electrophoresis of the fusion transcript showed a clear 
up-shift of the lane for EF1 type 2 versus 1 (from 110 bp to 176 bp), reasoned by an 
additional FLI1 exon present in the fusion (Figure 4A). Whenever this method was not 
informative, the presence and type of fusion for each cell line was successfully validated by 
sanger sequencing of the transcript. This was especially important for the EErg positive cell 
lines to ensure identical transcript sequences. Chromatogramms of the sequencing of 
CHLA25, EW3 and TC106 showed identical fusions between exon 7 of EWSR1 and exon 6 
of ERG (here reverse complement due to sequencing with a reverse ERG primer, 
Figure 4B). Other fusion types identified in the 30 EwS cell lines were EWSR1(exon7)-
ERG(exon7) (COGE352), EWSR1(exon9)-FLI1(exon7) (EW16), EWSR1(exon10)-
ERG(exon6) (EW18), EWSR1(exon7)-ERG(exon9) (SKNPLI), EWSR1(exon7)-FEV(exon3) 
(TC205) and EWSR1(exon10)-FLI1(exon5) (ES7, ORS). As these fusion types were only 
observed once or twice, the available number of cell lines might be too less to test for the 
comparability of EwS positive for those fusions versus others and/or to test for fusion specific 
biology. Hence, cell lines with these rare fusion types were not further used. 
Next, cell lines were selected based on their growth under the same standard cell culture 
conditions, as different culture conditions might result in bias in later analyses. Similar 
doubling times, preferentially under 48 h were desired to achieve quickly sufficient cell 
numbers for later experiments. 
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Using these criteria, the 18 cell lines depicted in Table 18 were selected, 11 with EF1 type 1 
fusion, 4 with EF1 type 2 fusion and 3 with EErg fusion. 
 
 
Figure 4: PCR and sanger sequencing confirm the presence of pathognomonic EWSR1-ETS 
fusions in tested cell lines. A) Gel electrophoresis of PCR amplified EF1 fusion transcript; red 
dotted: expected size of EF1 type 1 transcript; orange dotted: expected size of EF1 type 2 transcript. 
B) Chromatogramm of reverse Sanger sequencing of the transcribed fusion between EWSR1 (exon 7) 
and ERG (exon 6) in three cell lines.  
 
Table 18: EwS cell lines selected for fusion oncogene knockdown and generation of the Ewing 
Sarcoma Cell Line Atlas 
EF1 type 1 EF1 type 2 EErg 
A673 EW1 CHLA25 
CHLA10 MHHES1 EW3 
EW7 RDES TC106 
EW22 SKES1  
EW24   
MIC   
POE   
RH1   
SKNMC   
TC32   
TC71   
 
For these cell lines, genomic DNA was sent for STR profiling. The achieved results were 
cross-checked with databases of cell line suppliers (ATCC and DSMZ (Dirks et al., 2010), 
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depicted as A and D in Table 19, respectively) and four publications comprising STR profile 
data on several EwS cell lines (Brohl et al., Deamen et al., May et al., and Ottaviano et al. 
(Brohl et al., 2014; Daemen et al., 2015; May et al., 2013; Ottaviano et al., 2010), depicted as 
1-4 in Table 19). Noteworthy, STR profiles from Ottaviano et al. did not comprise the here 
tested STR loci D13S317, D7S820 and CSF1PO. For the remaining cell lines without any 
reference, the COSMIC cell line project (Tate et al., 2019) was searched for STR results via 
cellosaurus (https://web.expasy.org/cellosaurus/, indicated as C in Table 19). 
For 16 cell lines, reference or comparison data were found. For A673, all references showed 
11 and 12 repeats at the D5S818 locus, but the here generated STR profile did only show 
one peak at 11 repeats. Interestingly, Ottaviano et al. listed this STR profile variant in their 
results, indicating that biallelic 11 repeats at D5S818 might be a common drift for A673. For 
SKNMC, the 11-repeat allele at the TPOX locus was not observed in the own data, but was 
consistently present in the reference data. For EW22, a 12-repeat allele was observed for the 
D16S239 locus, which was not described in the only reference (COSMIC). Interestingly, data 
for MHHES1 and TC71 were inconsistent. While Daemen et al. described, as here observed, 
biallelic 8 repeats at the D13S317 locus of MHHES1, DSMZ and COSMIC report one allele 
with 13 repeats. For TC71, three different references described three different loci as 
homozygous, while all others described this locus (as observed here) as heterozygous: 
Daement et al. missed seemingly the Y peak for amelogenin, Brohl et al. the 11 repeats at 
the CSF1PO locus, and Ottaviano et al. the 18 repeats at the vWA locus. 
Only for two cell lines, no reference or comparison data were found, namely MIC and POE. 
While there were no cell lines in the databases with >80% identity for the here observed POE 
STR profile (which comprised an 11-repeat allele at locus D13S317 in wildtype cells, which 
was later in a single cell clone not present, anymore), for MIC there was 89% overlap to the 
cell lines Calu-6 (anaplastic carcinoma) and NCI-H1838 (lung carcinoma), and 82% with 
NCI-H661 (lung carcinoma) and HCC1599 (breast carcinoma) at ATCC. As for MIC the 
pathognomic EF1 fusion was verified, confusion of this cell line with one of the hits from 
ATCC can be excluded. 
Thus, for 16 cell lines identity could be confirmed, only for three cell lines small drifts in one 
STR locus, each, were observed, and diversity between the cell lines was proven. Table 19 
can be used as a reference, and when working with the here generated cell lines, to control 
for genomic stability and sample purity. 
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Table 19: STR profiles for the selected EwS cell lines. The datasets used for comparison of own 
results are indicated with A (ATCC), D (DSMZ), 1 (Brohl et al.), 2 (Daemen et al.), 3 (May et al.), 4 
(Ottaviano et al.) and C (COSMIC). Alleles not detected in own data, but described in references, are 










































A673A,D,1,2,3,4 11 8 10 11 15 9.3 X 8 11 
-12 13 12 11 18 9.3 X 8 12 
CHLA103 12 12 9 11 16 7 X 11 12 
12 12 10 11 16 7 X 11 12 
CHLA251,3 10 10 8 11 15 7 X 8 10 
10 12 10 12 17 7 X 8 10 
EW1C 11 13 11 12 19 6 X 8 11 
15 14 12 12 19 9.3 Y 11 11 
EW34,C 12 12 8 11 15 9.3 X 8 11 
12 12 11 12 16 10 Y 9 12 
EW7C 10 8 9 12 16 6 X 8 12 
 
13 8 9 12 18 6 X 9 12 
EW22C 11 12 10 +12 17 6 X 9 11 
11 12 11 13 17 6 X 11 11 
EW24C 12 14 12 11 15 6 X 10 11 
12 14 13 11 16 9.3 X 12 12 
MHHES1D,2,C 13 8 9 11 16 8 X 8 11 
13 8/-13DC 11 11 17 9 X 8 11 
MIC  10 11 8 12 17 7 X 8 10 
12 11 10 13 20 9 Y 8 12 
POE 12 9 11 10 14 8 X 11 10 
13 -11 12 10 17 9 X 11 10 
RDESA,D,1,4 11 11 10 9 17 7 X 9 11 
11 12 10 11 17 7 Y 11 11 
RH1D 11 10 8 13 17 9.3 X 8 11 
11 10 12 13 17 9.3 Y 8 11 
SKES1A,D,1,4 12 8 10 11 14 6 X 8 11 
12 9 11 11 17 9.3 Y 8 11 
SKNMCA,D,1,3,4 11 11 8 12 17 9.3 X 9 10 
11 11 8 12 18 9.3 X -11 10 
TC321,3 12 10 8 13 15 6 X 9 11 
13 12 11 14 18 9.3 X 11 13 
TC71D,(1),(2),3,(4) 10 11 10 11 17 9.3 X 8 10 
10 12 10 14 17 9.3 Y 9 11 
TC1061 12 10 9 13 16 9.3 X 8 11 
13 11 10 13 18 9.3 X 10 13 
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4.1.2. Generation of EwS cell lines with inducible EWSR1-ETS knockdown 
To assess the effects of the fusion oncogene, knockdown experiments were planned. To this 
end, the cells were stably lentivirally transduced with doxycycline (Dox) inducible shRNA 
sequences. 
For EF1 type 1 several knockdown experiments have been described. But, to specifically 
target the fusion transcript, the potential target sequences are limited. Here, we tested target 
sequences similar to those described by Tirode et al. and Carrillo et al. (Carrillo et al., 2007; 
Tirode et al., 2007). 
In two experiments, the sequence of Carrillo et al. resulted in better knockdown 48 h after 
shRNA induction with 1 µg/ml Dox in three cell lines tested (Figure 5). Hence, this target 
sequence was used for all EF1 type 1 positive cell lines. 
 
 
Figure 5: shRNA sequences targeting EF1 type 1 reduce fusion transcription. Left: The EF1 type 
1 transcript sequence around the fusion point is depicted aligned with EWSR1 and FLI1, additionally 
the target sequence oriented to the work of Tirode et al. and adopted from Carrillo et al. are shown. 
Right: Dot plot indicating EF1 rest expression after knockdown induction in five tested cell lines in up 
to two experiments, bar indicates mean. 
 
For EF1 type 2 an attempt to target specifically the fusion has been described, but 
knockdown was only achieved by targeting FLI1 C-terminally (Chansky et al., 2004). The 
design of a specific shRNA against the fusion transcript is highly aggravated as the first exon 
from FLI1 in the fusion starts with GTTCA, as does the next EWSR1 exon, exon 8. The end 
of EWSR1 exon 7 again shares some bases with FLI1 exon 4 (Figure 6A). Two target 
sequences were tested as siRNAs. As no knockdown was achieved in two pilot experiments, 
even at 50 nM siRNA concentration and retransfection after 48 h, the possibility to target 
FLI1 instead was evaluated. To this end, high expression of wildtype FLI1 had to be 
excluded, as done by qRT-PCR (Figure 6B). Two target sequences predicted with good 
performance were tested, one targeting exon 5, the other exon 9 of FLI1. The latter clearly 
outperformed the other and was used for all EF1 type 2 positive cell lines (Figure 6C). 
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Figure 6: Targeting the EF1 type 2 transcript at fusion point does not sufficiently reduce EF1 
expression, while C-terminal FLI1 targeting is reasonable and effective. A) Alignment of the EF1 
type 2 transcript at the fusion point with EWSR1, FLI1 and two potential targeting sequences. B) Dot 
plot indicating the wildtype (not fused) FLI1 expression in EF1 type 2 positive cell lines compared to 
EF1 expression represented as -log10, interspaced line indicates 10%, dotted line indicates 1% 
relative expression, qRT-PCR, n=6. C) Dot plot indicating EF1 knockdown with two different shRNAs, 
targeting exon 5 and exon 9 of FLI1, in a pilot experiment with all four EF1 type 2 positive cell lines, 
horizontal bars indicate mean, qRT-PCR. 
 
For EErg a target sequence overlapping the fusion was selected with relatively high 
predicted knockdown efficiency (Figure 7). 
In the further text, the cell lines transduced with shRNA against EF1 and EErg are referred to 




Figure 7: Target sequence of the shRNA against EErg. The target sequence is depicted together 
with the EErg transcript at the fusion point aligned to EWSR1 and ERG. 
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To avoid any sample heterogeneity which might result over time in subclone overgrowth and 
less reproducible results, isogenic clones of the cell lines were generated. Only for EW1, 
RDES, EW24 and EW3 no clone was established. While for the first two cell lines clones 
were growing, but not with sufficient knockdown of the fusion oncogene, the last two did not 
form any clones, hinting that these cell lines might not be suitable for clonogenic growth 
assays. 
The knockdown over time was assessed to select a time point, when readouts of the 
knockdown effects should be generated. This experiment in four cell lines showed that 
knockdown of the EWSR1-ETS fusions (EEts) reaches its maximum after 48 h and stays 
stable, at least until 120 h, when Dox (1 µg/ml) was removed (Figure 8). As downregulation 
of the fusion oncogene took 48 h and the downregulation of its targets should be 




Figure 8: EEts is stably downregulated in shRNA transduced cell lines 48-72 h upon Dox 
treatment. Time curve of the EEts transcript level relative to time point 0, from 0-120 h Dox treatment, 
plus 72 h without Dox treatment. Cell lines are indicated by colors. Dots represent mean transcript 
level in n=3 experiments, whiskers indicate SEM, qRT-PCR. 
 
Four independent experiments showed successful knockdown of the respective fusion 
oncogene in all generated cell lines on the transcriptional level in qRT-PCRs (Figure 9, upper 
panel). The PCR results could be confirmed on the protein level by western blot analysis 
(Figure 9, middel panel). As the downregulation of the fusion oncogene upon Dox addition to 
the lentiviral transduced cells was consistent, those Dox treated cells are henceforth referred 
to as EEts-low cells, while those cells without Dox treatment are referred to as EEts-high.  
The applied FLI1 antibody was successfully tested for representing the dynamics of EF1 
expression with knockdown in A673shEF1 and overexpression in the same cell line and 
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HEK293T (which does normally not express EF1, see Figure 9, lower panel). The EF1 lane 
appears at around 80 kDa. Additionally, overexpression of EF1 in the not EF1 expressing 
osteosarcoma cell lines SAOS-2 und U2OS was tried for antibody validation, but the 
achieved expression levels were compared to that in HEK293T far less on the transcriptome 
level (factor 27 and 87 less, respectively), and the 80 kDa lane appeared only very weakly for 
U2OS. For EErg an ERG antibody described as suitable for the prostate cancer fusion 
TMPRSS2-ERG has been applied and showed EErg downregulation upon shRNA induction 
with lanes around 70 kDa. 
 
 
Figure 9: qRT-PCRs and western blot demonstrate successful knockdown induction of the 
fusion oncogene. Upper panel: Expression of the fusion in EEts-low state (fusion knockdown) vs. -
high in all 18 stably transduced cell lines, each experiment indicated as dot (n=4), bar indicates mean. 
Middle panel: Representative western blots of the indicated cell lines without and with (-/+) fusion 
oncogene knockdown induction, GAPDH is shown as loading control. Lower panel: Western blot of 
HEK293T (HEK) cells without and with overexpression of EF1, and of A673shEF1 without treatment, 
with fusion knockdown induction, and with EF1 overexpression. 
 
Lastly, the effect of the shRNAs on the fusion partners was controlled in four experiments on 
the transcriptional level. The ETS transcription factors were often relatively lowly expressed 
when compared to the fusion (<0.1% in EEts-high condition) and therefore considered as not 
abundant when such low expression was detected in three out of four experiments. 
Conversely, EWSR1 expression was even higher than the fusion expression level. In six of 
seven cell lines with abundant FLI1 expression (only detectable with primers for transcript 
variant 1-3, but not for variant 4), the FLI1 expression level increased upon fusion 
knockdown in each replicate. Strikingly, even in two of the EF1 type 2 positive cell lines, in 
which the shRNA targets FLI1, knockdown of the fusion oncogene leads to massive increase 
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in FLI1 expression. This effect was not observed for ERG. The shRNA against EErg showed 
interference with EWSR1, but the knockdown efficiency on the fusion oncogene was on 
average 46% stronger (Figure 10). 
 
 
Figure 10: Expression of wildtype fusion partners is mainly unaffected by fusion knockdown. 
The expression of not fused EWSR1 (black), FLI1 (green, TV1-3), ERG (purple) in EEts-low vs. high 
cells is depicted; when a gene was less than 0.1% expressed in EEts-high condition in three 
replicates, it was assumed as not expressed and not presented in the graph. Dots represent single 
measurements of biological replicates (n=4), columns mean. Dashed lines indicate 100%, meaning 
unaltered expression, qRT-PCR. 
 
To possibly test for unspecific effects of Dox treatment and lentiviral transduction, all used 
cell lines were stably transduced with inducible non-targeting shRNA (shControl), too, if the 
shControl cell line was not generated in the working group before. Namely, the following 
shControl cell lines were generated: CHLA10shControl, CHLA25shControl, EW1shControl, 
EW3shControl, EW22shControl, EW24shControl, EW7shControl, MHHES1shControl, 
MICshControl, RH1shControl, SKES1shControl, TC71shControl, TC106shControl. 
 
4.1.3. Tissue microarrays of the EwS cell line models enable fusion oncogene 
target regulation evaluation in situ 
Six cell lines were expanded in vivo to generate model tumors. For half of the tumors, 
knockdown was induced for 96 h. From the tumor material, two tissue microarrays (TMAs) 
were generated. These TMAs enabled the in situ validation of the effect of EF1 on described 
target genes on protein level, and can additionally be used for evaluating new antibodies 
against EF1 targets for immunohistochemistry. Interestingly, the fusion knockdown was even 
stronger in vivo than observed in vitro in qRT-PCR (Figure 11). 
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Figure 11: In vivo expansion of EwS cell lines with inducible fusion knockdown enables 
confirmation of regulatory effects in situ. A) Scan of one HE stained TMA comprising three cell 
lines, three tumors per condition (-/+ Dox), three cores per tumor. B) Exemplary micrographs from 
TMAs stained for FLI1, phospho-MYBL2, PAX7 and SOX6, the cell line is depicted in brackets, scale 




4.2. The Ewing sarcoma cell line atlas (ESCLA) 
 
 
Figure 12: Components of the ESCLA 
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To achieve a comprehensive multi-dimensional dataset on the cell lines, which were used 
and generated here, whole genome sequencing (WGS), chromatin immunoprecipitation and 
sequencing (ChIP-Seq), DNA-micrarray transcriptional, proteome and methylome analyses 
were performed (Figure 12). 
 
4.2.1. WGS 
WGS data were generated on an Illumina HiSeq X ten platform with 150 bp paired end 
reads. The estimated coverage was 37.8x, and when testing in bins showed a rather equal 
coverage across the genome, except for spikes, which were mainly observed nearby 
centromeres, and dips in regions of common copy number losses (Figure 13A). The initial 
FASTQ files already showed good quality parameters in FastQC (Andrews, 2019), but 
successive alignment and quality control steps further improved the parameters, as seen 
when controlling the final aligned BAM files. Especially adapter sequences were reduced, 
GC content adapted and overrepresented sequences were not detectable anymore 
(Figure 13B). Noteworthy, the final quality parameters were, in contrast to the initial phred 
scores, not estimates by the sequencers, but the result of base quality score recalibration 
based on known genomic variants. For variant calling, this recalibaration results in scores 
that are more representative.  
 
Based on the WGS data, rather low counts of single nucleotide variants (SNVs) and InDels, 
structural variants and copy number alterations (CNV) were observed (Figure 14A, left 
panel). The copy number variations comprised already described chromosome 1q, 8, and 12 
gain in 5, 14 and 7 cell lines, respectively (27.8%, 77.8%, 38.9; Figure 14A, middle panel, 
exemplary karyogram indicating CNVs for EW24 harboring all the recurrent variations in 
Figure 14B). In addition, the known frequent non-silent TP53 and STAG2 mutations were 
observed (Figure 14A, right panel). To test for euploidy, the method of ploidyNGS (Augusto 
Corrêa dos Santos et al., 2017) was adopted, which is the comparison of frequencies of the 
most common and second most common allele at heterozygous loci. Outputs from VCMM 
applied on WGS data indicated InDels and the number of reads per genotype. The rates of 
reads per allele at the first 100,000 heterozygous loci were plotted in a stacked histogram. 
Mainly equal distribution of the first and second most common allele at heterozygous loci 
indicated diploidy (Figure 14C). In case of higher numbers of chromosome sets (n), different 
ratios would have occurred (2:1 in 3n, 3:1 in 4n cells). 
As GGAA microsatellites (mSats) are known to be highly relevant in the interaction of 
EWSR1-ETS with the genome, potential GGAA mSats were searched in the reference 
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genome (yielding 8,311 potential loci), and were genotyped for all cell lines using HipSTR 
(Willems et al., 2017). 3,831 mSats (46.1%) were partially (≥6 cell lines), and 1,908 (22.3%) 
fully genotyped. As expected, high divergence in repeat numbers compared to the reference 
genome was observed. Noteworthy, mSats with 30-60 bp length appeared more often 
expanded than those with greater length, which might indicate limitations of HipSTR for 
genotyping mSats with more than 15 GGAA repeats. Nevertheless, mSats with maximum 24 
consecutive GGAA motifs were genotyped (Figure 14D). 
 
 
Figure 13: WGS resulted in >30x coverage and high-quality data. A) Coverage calculated across 
100 kbp bins, depicted is the minimal, mean and maximum coverage per bin in all 18 cell lines. B) 
FastQC quality check of WGS data before alignment (left) and after alignment and further processing 
(right); Seq: sequences; R1, R2: first and second in paired reads. 
 




Figure 14: WGS data on EwS cell lines reveal the presence of known genetic variations and 
genetic silence in EwS. A) Genetic variations in EwS cell lines. Left: Bar plots indicating the number 
of SNVs, structural variants (SV) and CNVs (mbp deleted/duplicated) for each cell line; middle: 
heatmap indicating log2 copy number ratios across the genome for each cell line; right: tile plot 
indicating basic characteristics of the cell lines and summing up common genetic variations. B) 
Exemplary karyogram with colour coded report of CNVs in EW24. C) Exemplary histograms of A673 
and TC106 indicating the number of reads supporting the most and second most common allele at 
heterozygous loci for InDels, indicating a nearly 1:1 distribution and thus euploidy. D) Quality 
indicators of HipSTR mSat genotyping. Left: Bar plot indicating number of alleles called with specific 
repeat number difference to the reference genome; middle: line graphs indicating the cumulative 
fraction of alleles (red) over reference mSat lengths and the mean length deviation of called mSats 
relative to the reference (blue); right: heatmap indicating counts of all observed genotypes described 
as numbers of consecutive GGAA repeats in the longest (vertical axis) and shortest (horizontal axis) 
allele. 
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4.2.2. ChIP-Seq 
As no antibodies are available, which are specific for the fusion oncogene, FLI1 and ERG 
antibodies were employed to test for the fusion oncogene binding to the genome. Hence, the 
data on not-fused FLI1/ERG expression displayed in Figure 10 were reinspected, showing 
only for EW24 two-digit percentage of FLI1 expression compared to the fusion (28.3%), and 
only for two other cell lines relative expression over 1% (A673 2.3%, RDES 1.7%), hinting to 
maximum small bias by the wildtype FLI1 in ChIP. For EWSR1-ERG positive cell lines, ERG 
expression ranges relatively to the fusion between 0.05% and <0.001%. The FLI1 antibody 
has been extensively tested for specificity by a collaborator (Didier Surdez, Paris, France), 
who saw strong decrease of ChIP product upon EF1 downregulation. As the ERG antibody 
was not yet described for this fusion oncogene, ChIP-PCR with and without knockdown of 
EErg in TC106shEE was performed, showing clearly a decrease in the fusion target site 
CCND1-EF1 and in the H3K27ac positive control sites CUL1, CDKN1A (Figure 15A), thus 
hinting towards antibody specificity. Interestingly, immunoprecipitation of the H3K4me3 
promoter mark control site (CCND1-CTCF), which was normally only observed at low level in 
PCR for FLI1/ERG-ChIP, dropped by factor 10 upon EErg knockdown. 
The number of ChIP peaks for the fusion per cell line ranged between 4,642 and 38,811 with 
one outlier on each extreme (1,253 peaks for TC32, 110,885 peaks for EW24, the only cell 
line, for which sequencing was performed with paired end reads). In sum, 156,092 distinct 
peaks for the fusion were detected (merging peaks with 200 bp width around the peak 
center). 280 consensus peaks for all cell lines were identified (Figure 15B). 82.1% of the 
consensus peaks overlapped with the previously published consensus EF1-binding sites for 
two EwS cell lines published by Riggi et al (Riggi et al., 2014). Also, nearly all other binding 
sites previously published in the consensus set were detected (1,499 of 1,555, 96.4%), but 
could not be confirmed as actual consensus sites, rather as "common" sites with on average 
12 cell lines (67%) yielding peaks on those sites. In contrast, 50 new consensus sites were 
detected (Figure 15C). Described GGAA mSats known to interact with NR0B1 and MYBL2 
(Beck et al., 2012; Musa et al., 2019) were covered in most cell lines. Interestingly, even after 
cross-sample peak height normalization, differential binding was observed between the cell 
lines (Figure 15D). 
Most binding sites were located in introns and intergenic regions (Figure 15E); 2.1% (3,241 
of 156,092) of sites were positioned at the locus of potential GGAA-mSat positions, for the 
consensus set even 65% (182/280), indicating a strong enrichment of GGAA mSats at the 
consensus versus all binding sites (P<0.0001).  
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Figure 15: ChIP for fusion oncogenes supports previous reports and yields a new consensus 
binding set. A) ChIP-PCR results of TC106 cells in fusion high and low state, given as % of input, 
names of the sites targeted by primer pairs are indicated. B) Bar plot indicating the number of 
identified EEts-binding sites found to be actually bound in # cell lines. C) Venn-Diagram displaying the 
overlap of EEts-binding sites observed as actually bound in at least 50% of cells, the consensus 
binding site set described by Riggi et al. based on two cell lines, and the here generated consensus 
set. D) Exemplary plots of peaks at published EEts binding sites, NR0B1 and MYBL2 associated loci, 
for all cell lines of the ESCLA. E) Distribution of the localization of EEts-binding sites in context of 
genes; TTS: transcriptional termination site. 
 
The median and average distance to the next transcriptional start sites (TSS) were 47 and 
106 kbp, respectively. Fusion binding was most enriched closely upstream of TSS and was 
colocalized with H3K27ac histone mark (Figure 16A,B). 
H3K27ac ChIP-Seq enabled super-enhancer calling (exemplary plot for TC71 in Figure 16C 
with highlighted super-enhancer sites nearby known EEts-regulated genes). 571 to 1,596 
super-enhancers were called per cell line, and, when merging their positions over cell lines, 
4,339 super-enhancer sites or clusters were detected. Only 58 of these 4,339 sites 
comprised super-enhancers of all cell lines. Noteworthy, 99.3% of super-enhancer sites 
overlapped with at least one EEts binding site, 53% with at least one site, where EEts 
binding was observed in half the cell lines or more. For the 58 super-enhancer sites shared 
~ 67 ~ 
 
across the cell line, the overlap rate with those frequently EEts-bound sites was even 84.5% 
(significant enrichment, P<0.0001). Moreover, genes closest to and/or overlapping these 58 
super-enhancers were significantly overrepresenting gene ontology terms in context of 
development, transcription and metabolism. 
 
 
Figure 16: H3K27ac is observed around EEts binding and enables super-enhancer calling. A) 
Heatmaps for the coverage of EEts and H3K27ac ChIP in a 10 kb window around EEts binding sites 
(sorted from top to bottom: sites with peaks in 18 cell lines to 9 cell lines) for RDES and TC106, and 
metaplots combining both heatmaps in line graphs. B) Histogram of read depth for EEts and H3K27ac 
relative to TSS, displayed is the mean depth for all cell lines with the solid line, dashed lines indicate 
read depth plus and minus standard deviation. C) Plot of stitched enhancers and their signal value 
calculated by ROSE for TC71, super-enhancers are displayed in red, arrows point to super-enhancers 
nearby the listed EEts-regulated genes. 
 
4.2.3. DNA-microarray transcriptome profiling 
More than 25,000 transcripts coding for proteins were quantified before and after fusion 
knockdown in 18 EwS cell lines. Fusion knockdown resulted in strong deregulation of the 
transciptome (Figure 17A), when looking on the average expression fold changes among all 
cell lines. In line with previous publications, described EEts targets were affected by fusion 
knockdown in most or even all cell lines (Figure 17B). Gene set enrichment analysis 
(Subramanian et al., 2005) on a ranked list (average rank calculated for each gene across 
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cell lines) computed as proof-of-principle the "Kinsey_Targets_of_EWSR1-FLI1_Fusion_Dn" 
set as the strongest enriched set among genes upregulated upon fusion knockdown. Several 
gene sets associated with proliferation and cancer were enriched among genes 
downregulated upon fusion knockdown (Figure 17C). Overt EEts independent effects of Dox 
treatment or the transduction process were not observed so far in previous projects on EwS 
in the working group. t-SNE analysis of shControl transduced cell lines (same dose Dox for 
the same time; analysed on ClariomD DNA microarray) confirmed the detectable treatment 
effect on the transcriptome as minor compared to the effect achieved with fusion targeting 
shRNA (Figure 17D). 
 
 
Figure 17: EEts knockdown leads to strong transcriptome alterations. A) Volcano plot indicating 
log2 fold change (FC) of individual genes (dots) upon EEts knockdown versus -log10 transformed P 
value for differential expression; genes with absolute FC>2 and P<0.001 are highlighted in red. B) Dot 
plot indicating log2 FC of the expression of listed genes upon EEts knockdown, each dot represents 
one cell line, the fusion type is color-coded. C) Exemplary GSEA graphs; NES: normalized enrichment 
score. D) t-SNE plot of transcriptome data from TC71shEF1, TC71shControl, SKNMCshEF1, and 
SKNMCshControl with (weak color) and without (strong color) Dox treatment, the shControl cells are 
circled and are much closer to each other than the treated versus untreated shEF1 cells. 
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To avoid an arbitrary cut-off for gene regulation, especially as different effect sizes of the 
fusion knockdown were expected due to different knockdown efficiency, a semi-quantitative 
approach was adopted from the ROSE super-enhancer call algorithm (Lovén et al., 2013; 
Whyte et al., 2013). In short, for each cell line all genes with either positive or negative fold-
change were listed on the x-axis with their fold-changes on the y-axis, both axes were 
normalized to each other. From the point, where the slope equals 1, all genes were denoted 
as regulated. This resulted in 5,925 genes denoted as downregulated and 4,686 genes as 
upregulated in at least one cell line (605 to 1,455 downregulated, and 324 to 1,124 
upregulated per cell line). Gene ontology analysis for downregulated genes yielded 
significant overrepresentations of several gene sets annotated with biological processes in 
context of DNA replication and cell cycle progression. Only four genes were downregulated 
in all EEts-low cells, indicating a uniform upregulation of these genes in EwS by the fusion 
oncogene, thus bearing potential as biomarkers for EwS. These genes were namely FEZF1, 
TRPM4, PAX7, and PPP1R1A. On the other hand, not any coding gene was upregulated in 
all EEts-low cell lines, only a long non-coding RNA, DNM3OS, known in the context of 
epithelial to mesenchymal transition (Mitra et al., 2017). However, already four genes 
(ATP9A, FSTL1, NRCAM, SRGAP1) were upregulated in 17 of the 18 cell lines, and another 
11 in 16 cell lines, indicating a rather uniform suppression in EwS of these genes, which 
might hint towards incompatibility with EwS growth/survival and could give inroads into new 
therapeutic targets. 
To test for an actual relevance of the apparent transcriptome rearrangement by the fusion 
oncogene, survival data of 196 EwS patients were compared with the transcriptome data. 
12,812 genes were represented in both datasets. Without correction for multiple testing and 
applying best-percentile method, either high or low expression of 5,723 genes was 
associated with survival (P<0.05; 44.7%). When only looking on the 6,132 genes, which were 
in both datasets and denoted as fusion regulated, 3,003 genes were associated with survival 
(49%), meaning a significant enrichment of survival associated genes among targets of the 
fusion knockdown (P<0.0001). When comparing the here generated transcriptome data with 
data from the DepMap project at the Broad Institute (Tsherniak et al., 2017) for seven EwS 
cell lines present in the ESCLA, again a significant enrichment of likely essential (score at 
least -1 for all cell lines) genes was observed in the EEts regulated genes (P=0.01). 
As the pathognomonic EEts fusion is the major driver of EwS, it was tempting to speculate, 
that EEts kockdown leads to a change in the transcriptome profile bringing the cells closer to 
the cell of origin. However, t-SNE analysis with 71 normal tissues (Baldauf et al., 2018b) 
showed EwS cells in EEts-high and -low state clearly clustered with each other and 
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separated from the normal tissues (see overlap of EEts-high (dark red) and EEts-low (dark 
blue) in center of Figure 18). 
 
 
Figure 18: t-SNE plot of EwS cell lines (center, circled) in EEts-high and -low state does not 
show any alignment of the EwS transcriptome with any of 71 normal tissues. 71 normal tissues 
are represented by 11 groups. CNS: central nervous system; n: number of samples; t: number of 
tissue types per group. 
 
4.2.4. Proteome analysis 
Protein quantification by mass spectrometry in all cell lines was successfully performed for 
3,248 proteins. Additional 1,336 proteins with scarce data across the samples were imputed, 
resulting in 4,584 proteins quantified for each cell line. 
The proteins showed, as the transcriptome, heterogeneous dynamics by fusion oncogene 
knockdown, even if less pronounced (Figure 19A). Actually, the protein levels were strongly 
and significantly correlated with the expression data on transcriptome level 
(Pearson's r=0.58, P<0.0001, Figure 19B). 
In line, GSEA on the proteins ranked by their fold-changes (rank calculated for each protein 
in each cell line, mean rank chosen for building the ranked list) yielded association with 
translation and, again, cell cycle (Figure 19C). When defining regulated proteins as done for 
transcriptome data (see above), cell cycle genes were again overrepresented among the 
downregulated proteins in gene ontology analysis. 
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Figure 19: The proteome is similarly affected by fusion knockdown compared to the 
transcriptome. A) Dot plot indicating protein level in EEts-high versus -low cells, red dots highlight 
significantly differentially expressed proteins. B) Dot plot indicating correlation of fold changes 
observed on the transcriptome leven and on the protein level for all genes, whose expression was 
quantified in both data dimensions; dotted red line indicates linear regression curve. C) Exemplary 
GSEA graphs; NES: normalized enrichment score. 
 
All these data hint towards a strong association of the transcriptome and proteome, and thus 
to transcriptional regulation as key factor for protein expression in EwS rather than post-
transcriptional processes. 
 
4.2.5. Methylome analysis 
Differential methylation of CpG island in EEts-high versus -low state was assessed with 
Illumina EpicArrays and data processing with the minfi package (bumphunter algorithm) 
(Aryee et al., 2014). While for each cell line regions of differential methylation upon fusion 
knockdown were identified (383 to 18,127 regions, median 1102.5; 27 to1,322 denoted as 
significant; Figure 20), calling failed when processing all cell lines together. In line, 
intersection testing for the differentially methylated regions (DMRs) yielded not any region 
modulated in all cell lines by EEts knockdown, only one modulated in 12 cell lines, and 26 
modulated in at least 50% of cells. For 23 of these 26 regions transcriptome data of the 
closest gene were available and revealed EEts-dependent expression regulation for 11 
genes. However, when testing for coincidence of expression regulation and identification of a 
nearby DMR in individual cell lines, no significance existed. Nevertheless, when testing EwS 
cell lines transduced with shControl construct and with/ without Dox treatment, less 
differentially methylated regions were called (78.3%, and 10.4%, for A673 and TC32, 
respectively), indicating that some detected sites are due to a real effect of the fusion 
oncogene, which is seemingly highly dependent on cell context. 
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Figure 20: Differentially methylated regions were identified across the genome, but without 
inter-cell line consistence. IGV track plot. Different fusion types and shControl cells are represented 
by different colors. Methylation-differences were called between conditions EEts-high and -low. 
 
In sum, the ESCLA includes data on a relatively large number of cell line models, is 
multidimensional and comprehensive for all cell lines, of good quality in each dimension, and 
displays genome wide alterations, fusion binding and histone marks, and transcriptome, 
proteome and methylome rearrangement upon fusion knockdown (Figure 21). 
 
~ 73 ~ 
 
 
Figure 21: Circos plot displaying various aspects of the ESCLA, as genome wide proteome, 
transcriptome and methylome rearrangement upon EEts modulation, EEts binding sites and 
super-enhancers, and CNVs. DMR: Differentially methylated region; SE: super-enhancer; CNV: 
positions of gains are represented in blue, losses in black. 
 
 
4.3. Applicability of the ESCLA as model for EwS 
Research on cellular mechanisms and functional experiments are based on experimental 
models like immortalized cell lines. The quality of each model has to be carefully considered 
before translating any conclusion made on a model to clinics. 
Thus, similarities of the cell line models in the ESCLA to primary EwS tumors were 
assessed. Additionally, potential differences between cell line models with distinct fusion 
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types were investigated as indicator whether the data can be used in conjunct analyses or 
demand subgrouping. 
 
4.3.1. ESCLA transcriptional and methylation profiles are close to, but not 
overlapping with primary EwS 
Curated transcriptome data of 50 primary EwS and 11 further morphological mimics were 
present (Baldauf et al., 2018b). The data were corrected for batch effects together with the 
ESCLA data and t-SNE was performed. Interestingly, EwS cell lines did not merge with the 




Figure 22: t-SNE plot of EwS cell lines (ESCLA), primary EwS and other sarcomas does not 
show transcriptional EwS identity for cell lines.  
 
The MolecularNeuropathology.org platform provides prediction of sample identity by the 
methylation profile (Capper et al., 2018). For six cell lines, the methylation profile was 
calculated as being closest to EwS (CHLA10, CHLA25, MHHES1, MIC, RDES, TC32), while 
for the remaining cell lines the methylation profile was assigned to a bin of unclear identities. 
Noteworthy, for the cell lines with methylation profile closest to EwS, the metric was smaller 
for EEts-low samples compared to EEts-high samples. Additionally, a t-SNE plot with the 
same data, kindly provided by Dr. Martin Sill (DKFZ, Heidelberg, Germany), displayed close 
vicinity of the cell line methylation profiles with EwS profiles, but no overlap (Figure 23). 
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Figure 23: t-SNE of the ESCLA and other neoplasms indicates distinct methylation profile of 
EwS cell lines. Left-down: overview of the complete t-SNE, ESCLA data in circle, dashed lines are 
borders for the excerpt. Right: excerpt of the t-SNE plot around ESCLA cell lines. 
 
In sum, cell lines resemble genomic variations observed in primary tumors (see Figure 14A), 
but depict an only similar, not identical transcriptional and methylation profile. Hence, any 
results drawn from the ESCLA are likely to resemble actuality in EwS, but require extensive 
validation in further models and potentially other models closer to the actual EwS biology 
(e.g. patient derived xenografts). 
 
4.3.2. Distinct fusion types do not strongly differ in gene expression, expresion 
regulation, super-enhancers and methylation 
Differences of EwS with distinct fusion types were often discussed in the context of 
prognosis, but poorly investigated in cell line models. Actually, high similarities in the biology 
and effects of the different fusions are a prerequisite to transfer results of studies based on 
only few fusion types, most often solely EF1 type 1, to all EwS, and to perform joint analyses 
as done here.  
Therefore, EwS cell lines with different fusion types were compared as to their transcriptional 
profile of all regulated genes in t-SNE analysis, which displayed no separation or clustering 
of any fusion type from others (Figure 24A). Next, the regulated genes of each individual cell 
line were compared with those of all other cell lines. As a minimum 605 and 324 genes were 
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down- and upregulated, respectively, per cell line, for each cell line the top 603 and 321 
down- and upregulated genes (in total 924) were selected as the comparison dataset. To 
avoid low overlap rates due to false positives, the 33% of the selected genes with highest 
fold changes (most likely truly EEts regulated, n=308) of one cell line were compared to the 
the 924 top-regulated genes of each other cell line. All comparisons showed far higher 
overlap than the rate expected by chance (3.7%). Only EF1 type 2 and EErg positive cells 
showed a higher overlap of regulated genes in their respective cohort than compared to cells 
of other fusion types (Figure 24B). As EF1 type1 positive cells had nearly the same overlap 
with other type 1 positive cells as with type 2 positive cells, and type 2 positives shared 
similar numbers of genes with type 1 and EErg positive cells, likely all cell lines comprise a 
consensus set of often and strongly regulated genes, but EF1 type 2 and even more EErg 
fusion seemingly results in additional fusion-type private regulated genes.  
 
 
Figure 24: EwS cell lines with distinct fusion types do not differ in expression profile and 
regulation on the transcriptome and proteome level. Upper panel: results for transcriptome. Lower 
panel: results for proteome. A/D) t-SNE of the expression profile of EEts-high cell lines, distinct fusions 
are color-coded. B/E) Box plot indicating overlap of top-regulated genes in cell lines of specified fusion 
type with regulated genes in other cell lines, line represents median, box interquartile range, whiskers 
10th-90th percentile; EF1t1/2 EF1 type 1/2. C/F) Venn diagram of top 100 (NES as metric) gene sets 
correlated with genes downregulated upon EEts knockdown. 
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In line, among the top 100 enriched gene sets correlated with genes downregulated upon 
EEts knockdown (likely EEts driven) in GSEA, separated by fusion type again applying 
ranked lists with mean rank for the regulation of each gene, an overlap of 65% was observed 
(69-85% overlap for two individual fusion types; Figure 24C). Leading edge analysis of the 
fusion-specific called gene sets did not reveal any genes, which were present in more than 
50% of the fusion-specific sets and exclusively regulated by the respective fusion type, 
except for two proteasome subunits in EF1 type1 cells (PSMA2, PSMD8). 
Highly similar results were achieved on the protein level (overlaps for GSEA 60%, all fusion 
types, 65-72% for two individual fusion types; Figure 24D,E,F). 
As super-enhancers are considered to define cell identity, commonalities in called super-
enhancers were also investigated. Because of high diversity in the number of called super-
enhancers, and the lowest number being 571, only the top 500 super-enhancer regions were 
tested for overlap. It has to be noted, that super-enhancers span several thousand base 
pairs and were identified individually per cell line. Hence, there might be a relatively high rate 
for random overlaps. This is why here all 500 top super-enhancers were compared to all 
others (in contrast to similar analyses for transcriptome and proteome) to avoid that a few 
random hits might be sufficient to corrupt the results. Similar to the results on regulated 
genes, nearly uniform rates of commonality between the cell lines independent of fusion type 
were observed (Figure 25A).  
 
 
Figure 25: EwS cell lines with distinct fusions share several super-enhancers and similar 
methylome profiles. A) Box plot indicating the overlap of super-enhancer (SE) regions in one cell line 
compared to all others, separated by fusion; box indicates interquartile range, whiskers 10th to 90th 
percentile; EF1t1/2 EF1 type 1/2. B) t-SNE for the CpG methylation in the ESCLA; cell lines harboring 
different fusion types are color-coded. 
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Moreover, when comparing the CpG methylation profiles (more than 800,000 sites) of the 
different cell lines, again no clustering and separation of any fusion type was observed 
(Figure 25B). 
 
A possible explanation for the observed differences of EErg positive cell lines might be that 
the fusion is always generated by chromoplexy, which affects also other genes. Other fusion 
types can be the result of simple reciprocal translocation. Under this aspect, the number of 
EF1 type 1 and 2 positive cell lines with fusions by reciprocal translocation versus 
chromoplexy was assessed. As 52% of EF1 positive tumors with reciprocal translocation 
express the second fusion product (Anderson et al., 2018), FLI1-EWSR1, this reverse fusion 
was probed with two primer pairs (Elzi et al., 2015) in PCR on cell-line cDNA. For EF1 type 1 
positive cell lines both primer pairs were expected to bind, for type 2 positive cells only one. 
In line, two lanes were found for A673 and POE, single lanes for MHHES1 and RDES 
(Figure 26A). BreakDancer (Chen et al., 2009) readout of the whole genome sequencing 
detected reads supporting the EF1 fusion on the plus and minus strand of EWSR1 in these 
cell lines, what can only be observed in case of reciprocal fusion (Figure 26B). The same 
was seen for EW1, EW7, MIC, SKES1, and TC32. For RH1 and TC71 the highest 
confidence score for the one-sited detected fusion hinted toward non-reciprocal 
translocation. ChainFinder (Baca et al., 2013) for detection of chromoplexy revealed 
rearrangement loops forming the fusion in EW24 and SKNMC (Figure 26C) and an EWSR1 
rearrangement in EW22. Although for the remaining cell lines the fusion development was 
not displayed by chainfinder, it is likely that once chromoplexy occurred in these cells as 
other rearrangement loops were detected. In consideration of standard usage of chainfinder 
with multi-step healthy control filtered samples, the achieved output once more corroborated 
the data quality of the ESCLA. Considering also CHLA10, the only cell line without any high 
confidence results for chromoplexy or reciprocal translocation, as product of chromoplexy, 
the rates of chromoplexy as developmental process of the fusion oncogenes in the ESCLA 
were 55, 0 and 100% for EF1 type 1, 2 and EErg, respectively (Figure 26D). 
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Figure 26: Cell lines with distinct fusion types in the ESCLA differ in their rate of chromoplexy. 
A) PCR product gel electrophoresis for the reverse EF1 fusion. B) Scheme explaining the identification 
of reciprocal EF1 fusions by sequencing reads on the plus and minus strand of EWSR1 extracted by 
BreakDancer. C) Circos plots indicating rearrangement loops in EwS cell lines, loops affecting or 
generating the fusion oncogene are highlighted in purple. D) Overview of cell lines with reciprocal and 
complex fusion development per fusion type; EF1t1/2: EF1 type 1/2. 
 
 
4.4 Parameters affecting gene expression regulation by EWSR1-ETS 
As the proteomics data were strongly correlated with the transcriptome data, but the latter 
were by far more extensive, proteomics data were neglected for further analyses. Equally, 
the missing concordance of differential CpG island methylation upon fusion knockdown 
suggested not any strong uniform effect of those methylation islands and the data were, 
hence, not integrated in the further analyses.  
The number of GGAA repeats in GGAA mSats has often been described as determining 
factor of EEts-mediated enhancer activity, but has only been tested at a few loci and 
experimentally validated in an artificial mono-allelic approach (reporter assays). Of 8,311 
potential GGAA-mSat loci, 3,377 loci were partially, 251 of them even always bound by EEts 
in ChIP-Seq analysis. Of note, this numbers differ from the previously mentioned count of 
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EEts-binding sites harboring GGAA mSats, as one binding site can cover more than one 
mSat when they are closely adjacent, and as the binding sites were inferred from peaks in all 
cell lines with 200 bp width around peak center, while here each cell line and full-sized peak 
was probed individually. As mentioned before, HipSTR genotyped 3,831 mSats, including 
844 of the partially and 152 of the always EEts-bound mSats. 
When combining the ChIP-Seq and HipSTR data, the average and maximum number of 
consecutive GGAAs of both alleles per locus correlated, indeed, with the rate of observed 
EEts binding (Pearson's r²=0.98 and 0.99, P<0.0001; Figure 27A). As expected, the increase 
of the EEts-binding rate over the count of maximum consecutive GGAA repeats of both 
alleles had a slight latency when compared with the average count, indicating that long 
consecutive GGAA mSats on both alleles increase the probability of EEts-binding detection 
in ChIP compared to the presence of only one allele with such a long mSat. Only for mSats 
with up to 18 consecutive repeats, mean or maximum per locus, more than 100 genotypes 
were called. Hence, for longer mSats the number of observations was rather scarce and no 
conclusion were made for those. Interestingly, although the absolute number of genotyped 
GGAA mSats dropped at first dramatically with increasing consecutive-motif numbers, there 
was a second maximum at about 12 to 14 motifs (mean and maximum allele length), which 
might represent an enrichment of such longer and more often bound mSats in EwS.  
However, as the results were not binary and not any steep increase of binding rates was 
observed at a specific GGAA-repeat length, likely additional factors influence, whether EEts 
binds or not. The tested mSat regions were selected by an algorithm with Tandem Repeats 
Finder. Of course, these mSats had recurrent motifs, but these could also be interspersed 
with other bases (Figure 27B). To account for the number of additional GGAA motifs and 
interspersed bases besides the longest GGAA stretch within the called mSat-region, 
henceforth referred to as mSat architecture, their potential as enhancers or suppressors of 
EEts binding was tested. As metric the rate of finding a mSat with a specific architecture 
bound versus not bound was used, normalized by the same metric of a mSats with the 
identical number of consecutive GGAA motifs, but without any further bases called. As for 
heterozygous loci an assignment of binding to one of the alleles was not possible, the 
analyses were carried out solely on homozygous mSats. Furthermore, to build ratios as 
metric, only mSats at least once observed as bound and not bound were investigated. 
Additionally, mSats with a specific architecture observed less than 8 times (50% of the 
average count of all bound and not bound mSats with distinct architectures) were not 
included to avoid strong effects of seldom and possibly random observations. The metric was 
normalized to 1 as value for no preference for EEts binding. Applying all these filters to 
reduce bias, mSat architectures were investigated for the number of bases flanking the 
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longest GGAA stretch before another GGAA motif, the average number of interspersed 
bases between additional GGAA motifs, the number of additional GGAA motifs, the longest 
consecutive repeat number among them, and the number of GGAA stretches. 
 
 
Figure 27: The number of consecutive GGAA motifs, additional nearby motifs and nearby 
transcription factor binding enhance EEts binding probability. A) Bar plots of alternately absolute 
count and relative count of GGAA mSats EEts-bound in ChIP versus unbound, stratified by the mean 
(top panel) and maximum (lower panel) number of consecutive GGAAs of both alleles per locus; 
cons.: consecutive. B) Top: Scheme of the called mSat "architecture": Besides the longest consecutive 
GGAA stretch additional single motifs and repeats with interspersed bases were called. Below: 
Subsetting of all genotyped GGAA mSats for different characteristics of the mSat architecture, bars 
indicate value of the metric ratio of observing the respective mSat EEts-bound or -unbound in ChIP, 
normalized to 1 and here additionally to the effect of the longest consecutive GGAA stretch; 1 
indicates no effect, >1 favoring EEts binding, <1 EEts-binding impairment; cons.: consecutive. C) 
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Those 10% mSat architectures with the lowest metric (see B) and highest metric were transformed to 
a stacked motif, illustrating differences between rarely and often bound EEts mSats. D) Plot of the 
metric (see B) for each mSat architecture, in grey without any correction for any observed effect of the 
mSat architecture, red after correction for the longest consecutive GGAA stretch, flanking alternate 
bases, additional GGAAs and further interspersed bases, each dot represents one mSat architecture. 
The area under the curve is filled with light color and indicates how much determinants of EEts binding 
were calculated out of the metric. E) Exemplary stacked motif of de novo calling for enriched motifs 
nearby EEts-bound mSats and the matched GATA2 binding motif; bg: background. F) Density plot 
indicating the distance distribution between an EEts-bound GGAA mSat to any other (red) versus an 
unbound mSat (blue). G) Stacked motif of the most significantly enriched de novo called motif at EEts 
binding sites externally of GGAA mSats; bg: background. 
 
All characteristics of the mSat architecture indicated complementary to each other, that 
additional GGAA motifs increase the probability of binding, especially when only a few 
interspersed bases were present, leading to more consecutive GGAAs. Moreover, closer 
vicinity of the additional GGAA motifs to the longest stretch seemingly increase the EEts-
binding probability (Figure 27B,C). However, although values for characteristics with rather 
low overall counts of observations (<50) were not included in the Figures, several outliers 
were evident. Nevertheless, combination of the characteristics as percentage of GGAA 
bases of all bases in the called mSat, despite the longest consecutive GGAA stretch, led to a 
significant correlation with EEts binding (Pearson's r²=0.99, P=0.0007; Figure 27B). Obvious 
differences between the mSat architecture up- and downstream of the longest consecutive 
GGAA stretch were not observed.  
As the applied metric (rate of EEts-binding observation) was normalized to 1 (log10 
transformed zero), adjusting the initial metric for all factors affecting binding probability 
should reduce the area under the curve of all observed metric values, optimally to zero. 
However, when successively normalizing the applied metric for the differences observed for 
the longest consecutive GGAA stretch, the number of flanking bases before another motif, 
the number of additional motifs, and the rate of interspersed further bases, the area under 
the curve decreased by 22.2% only - with the strongest effect already observed by the 
highest number of consecutive GGAA motifs (18.9%; Figure 27D). 
As another potential influencing factor on EEts binding, nearby co-bound transcription factors 
can be considered. Therefore, mSats always bound in EEts ChIP were compared with those 
never bound for transcription factor binding motif enrichment 1 kb (standard promoter size) 
up- and/or downstream. No motif was found to be present nearby most bound mSats, but not 
nearby the unbound. The only significantly identified motifs matching known transcription 
factor binding motifs, present in about 5% of the tested target regions and at least by factor 
10 less nearby unbound mSats, were those for GATA2/6 (Figure 27E) and FOXF2 
downstream, and RUNX1 and MIXL1 upstream of the mSats. Interestingly, GATA2 was 
downregulated in 8 cell lines upon EEts knockdown, which might indicate that in EwS EEts 
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promotes co-binding with GATA2 in the rare cases of motif colocalization. Even distant 
GGAA mSats might affect EEts binding to another mSat, as within a 100 kb window always 
EEts-bound GGAA mSats were closer to another mSat than not EEts-bound mSats 
(Figure 27F). Additionally, copy number gains of mSats seemingly favor EEts-binding 
detection at the respective site. Each of the 3,377 GGAA mSats at least once bound in EEts 
ChIP was inspected for EEts binding per cell line and for CNV. 32,480 times a mSat was not 
bound, 28,306 times bound. 11.9% of unbound mSats showed copy number loss, but only 
8.3% of bound mSats. Vice versa, 16.5% of unbound mSats showed copy number gain, but 
21.7% of bound mSats (P<0.0001). 
Motif finding was also performed for EEts-binding sites observed in at least 50% of cell lines 
externally of mSats. As expected, de novo motif calling resulted as top hit with by far highest 
significance in a GGAA motif not flanked by another GGAA, hinting towards binding 
capability of EEts also to a single GGAA motif or small repeats (reverse complement in 
Figure 27G). 
 
To see the effect of EEts binding to GGAA mSats on expression regulation of nearby genes, 
Figure 27A was rebuilt, subsetting the bound and unbound mSats by the effect of EEts 
knockdown on the closest gene (Figure 28A). Surprisingly, the overall rate of nearby 
downregulated genes was already 6.7% for four consecutive GGAA motifs (mean allele 
count) and did not show a constant increase over the number of consecutive repeats 
(Figure 28B). Even more, when comparing the rates of nearby downregulated genes for EEts 
bound versus unbound mSats, there was no significance for higher rates of regulated genes 
nearby bound mSats. Similiar results were achieved for upregulated genes upon EEts 
knockdown, besides a significance of slightly higher rates of upregulated genes (P=0.016) 
nearby bound mSats, which was not expected as insulator function of EEts at GGAA mSats 
has not been described, yet. Nevertheless, in previous ChIA-PET data (generated by Didier 
Surdez, Paris, France; not yet published) associations of promoters with GGAA mSats even 
1 Mbp distant were shown. This means, that a gene might be regulated via EEts binding to a 
mSat far apart, what suggests that the rate of regulated genes might be much higher than 
displayed in Figure 28A. Indeed, when testing a 2 Mbp window around each GGAA mSat, 
99% of all genes in the transcriptome data were overlapping.  
When testing vice versa genes, that appeared as likely regulated upon EEts knockdown 
among all cell lines (defined as regulated in one direction in at least 33% of cell lines and 
never regulated in the opposite direction), the distance to the next GGAA mSat was 
significantly smaller for downregulated genes versus not regulated genes (P<0.0001), while 
the next GGAA mSat for upregulated genes was more upstream (Figure 28C). When again 
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looking more specifically for genes regulated per cell line and the nearest in the respective 
cell line EEts-bound GGAA mSat, the results were even more pronounced (Figure 28D). The 
closest EEts-bound GGAA mSat was little more often on the opposite strand of the gene 
body (50.1, 51.2 and 52.5% for not, up- and downregulated genes), more often downstream 
when on the opposite strand (54.7, 52.8 and 58.2% for not, up- and downregulated genes), 
and upstream when on the same strand (56.8, 61.3 and 61.9% for not, up- and 
downregulated genes). As the differences were most pronounced for genes downregulated 
upon EEts knockdown, even highly significant (P<0.0001) when compared to not regulated 
genes, strandness might be relevant for EEts-mediated gene regulation. The number of 
GGAA mSats per 2 Mbp-window around transcriptional start sites was higher for 
downregulated genes than for not regulated genes (on average 6.70 versus 5.96 GGAA 
mSats, 12.3% difference), and even more when focusing on EEts-bound GGAA mSats (on 
average 1.41 versus 0.98 EEts-bound GGAA mSats, 43.5% more, P<0.0001 for both 
differential rates). Those differences were less for genes upregulated upon EEts knockdown, 
but again there was a difference between binding localization relative to the TSS as 11.4% 
more GGAA binding upstream than downstream of the TSS was observed. In contrast to 
bound GGAA mSats, the distance to the next EEts binding externally of a GGAA repeat was 
rather downstream for genes upregulated upon EEts knockdown (Figure 28E). Of note, 
EW24 was excluded from this analysis because of the relatively very high number of 
identified binding sites. Thus, the actual distance to EEts-bound GGAA mSats versus single 
GGAA motifs differentially affect gene expression regulation. 
Promoters of regulated genes were tested for transcription factor binding motif enrichment 
versus promotors of not regulated genes, subgrouping them into up- and downregulated 
upon fusion knockdown. These analyses did not reveal a motif exclusively or in most cases 
seen in the promoters of regulated genes, but not in the not regulated. Nevertheless, 12.8% 
of upregulated genes harboured a NFAT5 binding motif (versus 4.3% of not regulated 
genes). For the downregulated genes NFY binding motif was found in 27.7% of promoters 
and a motif highly similar to E2F4, 2, and 1 binding site in 11.1% (versus 15% and 4.1% in 
not regulated genes, respectively; Figure 28F). Noteworthy, NFAT5 was upregulated in three 
cell lines, NFY subunit C was downregulated in 6 and E2F4, 2, and 1 in 1, 15 and 12 cell 
lines upon fusion knockdown. Hence, likely NFAT5 is suppressed and NFYC, E2F1 and 
E2F2 are promoted in EwS, decreasing expression of genes with NFAT5 binding site in their 
promoters and increasing expression of genes with NFY and E2F family binding sites. 
 
Hence, high numbers of consecutive GGAA motifs adjacent to further GGAA repeats 
increase the probability of EEts binding, despite nearby transcription factor binding sites 
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(GATA2), further mSats, copy number gains, and still unknown factors. Enrichment of nearby 
EEts-bound GGAA mSats influence the effect of EEts on gene expression dependent on the 
actual distance and relative localization to the TSS, partly together with specific EEts-
regulated transcription factor motifs in the promoter region. 
 
 
Figure 28: Genes up- and downregulated upon EEts knockdown differ in their distance to the 
next EEts-bound GGAA mSat and in transcription factor binding motifs in their promoters. A) 
Bar plots of alternately absolute count and relative count of GGAA mSats EEts-bound in ChIP versus 
unbound, further subsetted for the effect of EEts knockdown to the closest gene, stratified by the 
mean (upper panel) and maximum (lower panel) number of consecutive GGAAs of both alleles per 
locus; cons.: consecutive. B) Percentage of closest genes to a GGAA mSat that are regulated upon 
EEts knockdown, stratified by mean number of consecutive GGAA motifs for both alleles per locus; 
cons.: consecutive. C) Density plot indicating distance to the next GGAA mSat for genes not, up- or 
downregulated upon EEts knockdown. D) Density plot as in C, but for the distance to the next EEts-
bound GGAA mSat in the respective tested cell line. E) Density plot as in D, but for the distance to the 
next EEts binding externally of a GGAA mSat. F) Exemplary stacked motifs of frequently observed 
transcription factor binding sites in promoters of genes upregulated (top) and downregulated (bottom) 
upon EEts knockdown; bg: background. 
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4.5. EWSR1-ETS heterogeneously regulates clinically relevant genes 
One main motivation for creating the ESCLA with 18 cell lines was to overcome the present 
lack of studies on the overt inter-patient heterogeneity. Thus, in the next step the applicability 
of the ESCLA to model heterogeneity and the transferability of the results to clinically 
relevant genes were initially tested. First, genes with heterogeneous expression regulation 
were selected. Several cells per group (strong versus weak/no differential expression in 
transcriptome data upon EEts knockdown) were needed to reinforce statistical power, and 
between those groups a grey zone for the resolution of the here applied analyses might exist. 
Hence, heterogeneously regulated genes in the ESCLA were defined as being strongly 
regulated (top 33% of regulated genes of the respective cell lines) in at least 33% of cell 
lines, and being not or weakly regulated (lower 33% of regulated genes of the respective cell 
lines) in another 33% of cell lines. This approach found 256 genes in the ESCLA to be 
heterogeneously regulated upon EEts knockdown. 
Second, to identify potentially clinically relevant and thus potentially clinical heterogeneity-
mediating genes, the list of heterogeneously regulated genes was crossed with survival data. 
Of the heterogeneously regulated genes 209 were represented in the survival dataset. 
Applying best-percentile algorithm and Bonferroni correction, 22 genes were significantly 
associated with worse overall survival in the EEts-mediated expression state (high 
expression when downregulated upon EEts knockdown, hence likely driven by EEts in 
patients; low expression when upregulated upon EEts knockdown, hence likely suppressed 
by EEts in patients) (Table 20). 
The inter-quartile range of gene expression values in the survival dataset was utilized as 
metric for heterogeneous expression. Actually, for 15 of the 22 identified heterogeneously 
regulated and survival associated genes (68%) the inter-quartile ranges were over the 80th 
percentile of the patients' cohort.  
Many factors influencing EEts binding to GGAA mSats and gene expression, described 
above, are not suitable to explain the heterogeneity, as they do not differ between cell lines. 
The total number of GGAA mSats in a 1 Mbp window around the TSS of a gene, the distance 
to the next GGAA mSat, transcription factor binding sites nearby the GGAA mSat and in the 
promoter are unlikely to account for heterogeneity, except for cases of binding-motif 
perturbed or de novo generated SNVs and large InDels. 
More likely, the binding rate of nearby GGAA mSats, their length and CNVs, and CNVs of the 
gene body might differ between the cell lines. However, when comparing all these factors for 
each gene in the group of cell lines with strong effect of fusion knockdown on the expression 
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of the respective gene and in the group without strong effect, either no difference or no 
uniform difference between groups was observed (Figure 29). 
 
Table 20: Genes heterogeneously regulated in the ESCLA and survival associated. P value is 
Bonferonni corrected; Surv. corr: expression status correlating with worse survival; IQC perc.: 
percentile of the inter-quartile range in the expression data of the survival cohort. 




AIF1 Actin binding protein regulating immune cells 0.001 high 88 
CDC20 Cell cycle regulator 0.0004 high 91 
CDC25A Dual-specific phosphatase, DNA damage 
responder 
0.0028 high 50 
CDC25C Cell cycle regulator, triggers mitosis 0.0194 high 88 
CENPI Centromere protein; E2F target <0.001 high 79 
DSEL Dermatan sulfate epimerase-like 0.0002 low 90 
DUSP26 Dual-specific phosphatase 0.0161 high 66 
E2F1 Transcription factor, cell cycle regulator 0.0001 high 34 
EXO1 Exonuclease <0.001 high 94 
GPN3 GTPase 0.0002 high 68 
GTSE1 Cell cycle dependent protein 0.0003 high 80 
KIF14 Microtubule regulator involved in mitosis 0.019 high 90 
KIF15 Microtubule regulator involved in mitosis 0.0075 high 90 
KIF2C Microtubule regulator involved in mitosis <0.001 high 88 
MYBL2 Transcription factor, involved in cell cycle 0.0004 high 87 
NEK2 Protein kinase involved in mitosis <0.001 high 79 
NUF2 Centromere associated protein 0.0011 high 97 
SELENBP1 Selenium binding protein 0.0039 low 99 
SPAG5 Associated with mitotic spindle apparatur 0.0093 high 89 
TP53INP1 p53 interactor <0.001 low 74 
TPX2 Microtubule regulator involved in mitosis 0.0014 high 89 
TRIP13 ATPase involved in cell cycle progression 0.0084 high 90 
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Figure 29: Heterogeneous regulation upon EEts knockdown for genes, which are 
heterogeneously expressed in patients and associated with overall survival, cannot be 
explained by CNV of the respective gene, number of GGAA mSat binding up to 1 Mbp distant 
from the TSS, CNV of mSats in 1 Mbp distance to the TSS, or the number of consecutive GGAA 
motifs in the nearest mSat, alone. All calculations were performed for the two groups of cell lines 
with strong effect of EEts knockdown on the gene expression and with no or weak effect. All values 
were normalized to the number of cells per group; reg.: regulation. 
 
Thus, the ESCLA is capable to identify heterogeneously regulated genes, which are also 
heterogeneously expressed in patients. However, the many known and here partially 
described and evaluated factors influencing EEts-binding to GGAA mSats and mechanisms 
of EEts-dependent gene-expression regulation are not sufficient to identify, whether EEts 
binds to a GGAA mSat, and how this binding affects gene expression. Hence, further 
investigations are demanded to identify determinants of patients' heterogeneity. The ESCLA 
is likely a rich resource for this research journey.  
  




EwS is an aggressive bone-associated cancer mainly affecting children and young adults 
(Grünewald et al., 2018). Prognosis for localized disease is favorable, but it is poor for 
patients with non-localized disease (Bosma et al., 2018). The clinical heterogeneity is in 
contradiction to the few recurrent mutations in EwS (Tirode et al., 2014).  
Actually, the EEts fusion appears as the major, if not single driver of EwS. It reprograms the 
genomic accessibility (Patel et al., 2012; Tomazou et al., 2015), binds to the genome (Guillon 
et al., 2009; Monument et al., 2014), and drives the expression of several genes, which were 
shown to promote cancer aggressiveness (Grunewald et al., 2012; Musa et al., 2019; Smith 
et al., 2006; Surdez et al., 2012). Moreover, expression of EF1 in embryonal stem cells 
resulted in a highly similar phenotype to EwS (Gordon et al., 2016). Thus, a better 
understanding of the biology of the fusion oncogene, and parameters which affect the biology 
of the fusion oncogene and might explain inter-patient heterogneity, is highly important. This 
constituted the rationale to generate the ESCLA. The ESCLA not only comprises data of 18 
EwS cell lines to model heterogeneity, but was also generated with focus on the EEts fusion 
biology. The WGS platform was purposely selected as Illumina 150 bp paired-end reads 
were described to enable high accurracy microsatellite calling (Willems et al., 2017), like 
GGAA mSats described as main binding sites of EEts (Gangwal et al., 2008; Guillon et al., 
2009). The ChIP experiments were performed for distinct fusion types. Moreover, for 
comparative analyses transcriptome, proteome and methylome data were generated for all 
cell lines in fusion-high and -low state. 
 
The cell lines were selected to represent the most common fusion types, EF1 type 1, 2 and 
EErg. 93% of EwS are positive for one of these fusions (Berger et al., 2013). A fusion 
oncogene knockdown, but not knockout approach was chosen to evaluate effects of the 
fusion oncogene on gene expression. As EwS is dependent on the fusion, fusion knockout 
might have been lethal for EwS cell lines (Patel et al., 2012; Smith et al., 2006). For the same 
reason, an inducible shRNA construct was employed. CRISPRi (Qi et al., 2013) might be 
used as complementary strategy on the genome level to test in synopsis with the here 
generated data for fusion specifity of the observed effects. The achieved knockdown led to 
EEts rest-expression of 16 to 60% (mean 31%). Whereas knockdown of the EF1 type1 and 2 
fusion did not impair the expression of non-fused wildtype EWSR1 and FLI1, the EWSR1 
expression was reduced upon shEErg expression. However, the knockdown effect on the 
fusion was stronger (46%) than on EWSR1 and the EWSR1 expression level twice as high 
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as for the fusion. Furthermore, an interaction of EF1 with EWSR1 has been described that 
interfers with the EWSR1-mediated transcriptional repression (Gorthi et al., 2018). Therefore, 
EWSR1 is presumably not physiologically active in EwS and any effects of the shRNA-
mediated EWSR1 impairment on the transcriptome, which was the readout of the knockdown 
experiments, are unlikely. Strikingly, even in two EF1 type 2 positive cells, in which the 
applied shRNA for fusion knockdown targeted FLI1 in exon 9, a massive increase of non-
fused FLI1 was observed upon fusion knockdown. Actually, a delicately balanced expression 
regulation of ETS transcription factors in EwS might explain known differences in the 
proliferative versus metastatic capacities of EwS cell lines dependent on the fusion 
expression (Aynaud et al., 2020; Chaturvedi et al., 2012; Franzetti et al., 2017; Katschnig et 
al., 2017). Moreover, suppression of ETS transcription factors, which are known mediators of 
differentiation (Kar and Gutierrez-Hartmann, 2013), might stabilize the undifferentiated 
phenotype of EwS (Fletcher, 2014; Grünewald et al., 2018). 
TMAs were generated from six xenografted cell lines. These TMAs enabled in situ validation 
of described EEts-regulated genes like PAX7 and SOX6 (Baldauf et al., 2018b; Charville et 
al., 2017; Marchetto et al., 2020). The TMAs add value to qRT-PCR and western blot 
analyses in 2D culture models. First, gene regulation can be evaluated in 3D-developed 
tumors grown in a mammal instead of in an artifical 2D culture. Second, the subcellular 
distribution of staining is an additional specificity indicator which is missing in whole cell 
lysate western blot analyses. 
 
WGS, and consciously not whole exome sequencing as in a few former studies (Sand et al., 
2015), was performed to cover regulatory regions with GGAA mSats. For library preparation, 
a PCR-free protocol was used to avoid any PCR-stutter artifacts. The achieved coverage 
with 150 bp paired-end reads was 37x. WGS data depticted mutation rates for TP53, 
STAG2, and rate of CDKN2A deletion of 78%, 50%, and 28%, respectively. Thus, at least for 
the cell lines in ESCLA, rates of genetic alterations are far higher than reported in patients 
(7%, 17% and 12%, respectively) (Tirode et al., 2014). Of note, the proposed mutual 
exclusivity of STAG2 mutation and CDKN2A deletion (Tirode et al., 2014) was not observed 
for TC32. Additionally, frequent copy number alterations like chr1q (Mackintosh et al., 2012), 
chr8 and chr12 gain and chr16q loss were displayed by the data (Tirode et al., 2014). From 
this qualitative WGS data, HipSTR (Willems et al., 2017) inferred genotypes of 3,831 GGAA 
mSats from 8,311 potential sites. The potential sites were retrieved from the reference 
genome (hg19) demanding at least four consecutive GGAA motifs. Thus, sites potentially 
expanded to five repeats in EwS, described as minimal number for EEts-mediated enhancer 
activity (Gangwal et al., 2008), were also called. Actually, 132 of 1,593 GGAA mSats with 
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four motifs in the reference genome had at least five repeats in some EwS cell lines. Up to 
24 consecutive motifs were genotyped by HipSTR. However, this tool is limited to call 
maximum mSat length close to the read length. 1,895 (23%) of potential GGAA mSats were 
at least 150 bp long in the reference genome. This warrants long-read sequencing to 
increase knowledge about GGAA-mSat genotypes in EwS. Unfortunately, although these 
methods have been improved, they have still relatively high error rates compared to 
sequencing on an Illumina HiSeq Xten platform (De Roeck et al., 2019; Fu et al., 2019). Such 
error rates might result in falsely called mSat-interrupting bases, which can heavily corrupt 
association studies of mSat length and effects on genes, especially as the consecutive 
GGAA number was the most important factor for EEts binding in the here generated results. 
Described EF1 binding and additionally EErg binding to GGAA mSat (Gangwal et al., 2008; 
Guillon et al., 2009; Monument et al., 2014) was confirmed in the ChIP-Seq data. Actually, 
most consensus sites from two cell lines (Riggi et al., 2014) were present in most, if not all 
cell lines. Having 18 cell lines analysed with various numbers of called peaks, probably 
several consensus sites were missed out due to false negatives, so that further studies on 
EEts-genome interaction should not be limited to consensus sites, but also include common 
sites. Still, 280 consensus sites were identified for the 18 EwS cell lines, including 50 sites 
which were not described in the previous consensus set. As a high overlap of the 280 sites 
with the consensus set of Riggi et al. was observed, and as TC32 was an outlier with only 
1,253 peaks for the fusion, these 280 consensus site likely represent a conserved set of 
EEts-genome interactions in EwS and not random hits. Furthermore, reported NR0B1 and 
MYBL2 associated mSats were bound in most cell lines (Johnson et al., 2017a; Musa et al., 
2019). Interestingly, even after application of a cross-cell line normalization method, based 
on the assumption of equal peaks for genes expressed at the same level in all cells, peak 
heights showed strong inter-cell line heterogeneity. For all cell lines, at least 100 bp-read 
sequencing was performed, as peaks in mSats were expected and standard 50 bp reads 
might have not been sufficient for qualititative mapping (Zhang et al., 2016). For EW24, the 
only cell line whose ChIP products were sequenced with paired-end reads, far more peaks 
were called than for any other cell line. Further experiments in the same and other cell lines 
with paired-end sequencing have to clarify whether the multitude of peaks were the result of, 
for instance, a contamination, or if several true peaks were missed out by single-end 
sequencing. 44% of EEts binding sites were located in intergenic regions, 47% in introns. 
Actually, EEts-mediated enhancer activity by binding to an intron, instead of a distant mSat, 
has been already published (Dallmayer et al., 2019; Marchetto et al., 2020). EEts binding 
was colocalized with the H3K27ac enhancer mark. This observation is in line with the 
described enhancer activity of and H3K27ac at EEts-bound GGAA mSats (Monument et al., 
2014; Patel et al., 2012; Riggi et al., 2014; Tomazou et al., 2015). Super-enhancers (SEs) 
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were called with the ROSE algorithm (Lovén et al., 2013; Whyte et al., 2013). SEs often 
overlapped with known targets of the EwS fusion oncogene, like PRKCB, SOX6 and GLG1 
indicated for TC71 in Figure 16C (Baldauf et al., 2018a; Marchetto et al., 2020; Surdez et al., 
2012). For those 58 super-enhancers which were found in all cell lines, the overlapping and 
nearby genes overrepresented gene ontology terms in context of development, transcription 
and metabolism, including eight of 98 genes involved in embryonic skeletal system 
morphogenesis. Super-enhancers are described as determinating cell identity (Whyte et al., 
2013). Therefore, the overrepresented genes might be an indicator of the cell of origin. 
Indeed, the identified gene ontologies are in line with the current hypothesis that EwS origins 
from mesenchymal stem cells (Sheffield et al., 2017; Tirode et al., 2007). Nevertheless, the 
EwS cell origin is still a matter of debate. As EEts drives the expression of a multitude of 
genes, fusion knockdown might result in a transcriptome profile more similar to the cell of 
origin. Thus, a t-SNE plot with transcriptome data of EwS cell lines without and with fusion 
knockdown and 71 published normal tissue types (Baldauf et al., 2018b) was generated. 
However, the fusion knockdown was not sufficient to change the transcriptome profile of the 
cell lines strong enough to reach higher similarity of EEts-low cells with any normal tissue 
than with EEts-high cells.  
Described targets of EEts mediated gene expression regulation were reidentified or 
confirmed for EErg-positive cell lines. However, EEts-knockdown in EwS cell lines was 
heterogeneous, hence comparative analyses were performed (semi-)rank based. The 
proteome data were strongly and significantly correlated with the transcriptome data, thus 
mutually validating each other. The strong correlation of transcriptome and proteome 
suggests that transcriptional regulation is of higher relevance in EwS than posttanscriptional 
modifications. Indeed, publications on posttranscriptional modification in EwS are rare 
(Baumuratova et al., 2010). Surprisingly, the overlap of genes regulated in all cell lines was 
very limited. Actually, only four genes were identified, namely FEZF1, TRPM4, PAX7 and 
PPP1R1A. The transcription factor PAX7 is known to be highly expressed in EwS (Baldauf et 
al., 2018b), but its function in EwS is still unclear. Unfortunately, the PAX7 expression is not 
fully specific for EwS, thus not suitable as diagnostic marker (Baldauf et al., 2018a). 
PPP1R1A was very recently described to regulate cell cycle progression in EwS (Luo et al., 
2020). FEZF1 represses transcription, is involved in neuronal development, and has been 
already implicated in the context of cancer (Lan et al., 2018). TRPM4 is a cation channel 
expressed in various normal tissues and cancers (Wong and Hussain, 2020). Nevertheless, 
integration of all transcriptome data by building average ranks for gene regulation across cell 
lines and subsequent GSEA led to enrichment of gene sets annotated with cell cycle and 
proliferation. These gene sets were in line with known EF1 mediated proliferation (Franzetti 
et al., 2017) and the previous notion that one third of EF1 regulated genes are involved in 
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cell cycle (Patel et al., 2012). The overrepresented gene ontology terms in context of DNA 
replication and cell cycle matched well several reports on the proliferative activity of EwS with 
still quiet genomic landscaping (Franzetti et al., 2017; Patel et al., 2012; Tirode et al., 2014), 
demanding a precise cell cycle regulation. In line, EwS is highly susceptible to inhibition of 
DNA damage repair via CDK12/13 (Iniguez et al., 2018). This implies a common biology of 
EwS cell lines, that is seemingly mediated by different genes in the different cell lines. 
Hence, targeting a single gene might be less efficient in EwS than targeting pathways, what 
further emphasize the importance of understanding the biology of EEts.  
An EwS specific, but highly inter-tumor heterogeneous methylation profile was reported 
(Sheffield et al., 2017). When comparing the methylation profile of the cell lines with data on 
primary tumors (Capper et al., 2018), the metric of all six cell lines depicting an EwS profile 
decreased upon fusion knockdown, indicating an effect of the fusion on the EwS-specific 
methylome. However, not any uniform differentially methylated region was identified upon 
fusion knockdown. Furthermore, the cell lines clearly clustert apart from primary EwS in 
t-SNE analysis of the methylome, although an overlap of methylation profiles of cell lines and 
primary EwS was shown in a previous study (Sheffield et al., 2017). The same was observed 
for the transcriptome data. At least, EwS cell lines were neighboring to primary EwS in both 
datasets. Possibly the observed methylation profile in cell lines is one extreme of the 
reported methylation spectrum of EwS which is favored for growth in vitro and rather not 
depicted in vivo. The biological meaning of the different methylation profiles identified by 
Sheffied et al. is not elucidated. However, in synopsis of the ChIP-Seq data, histone 
modifications appear to be the more relevant epigenetic marks for EwS. Hence, more ChIP-
Seq experiments in EEts-low status should be performed to further outline the epigenetic 
effects of EEts. Successful identification of epigenetic EwS characteristics by this approach 
has been demonstrated already (Tomazou et al., 2015). 
 
The clear clustering of EwS cell lines in t-SNE plots for both transcriptome and methylome 
challenge the validity of the cell lines as model for EwS. Additionally, current publications 
question the value of cell lines due to poor reproducibility of cell-culture based results (Hirsch 
and Schildknecht, 2019; Niepel et al., 2019). However, alternative models are scarce. 
Furthermore, EwS is genomically rather stable, thus the cell biology of cell lines might stay 
closer to the primary tumors in EwS than in many other tumor entities. Eventually, other 
culture conditions, e.g. 3D growth, might already improve similarity of cell-line biology to the 
tumor (Kapałczyńska et al., 2016). Alternatively, patient-derived xenografts (PDX) are on the 
rise (Siolas and Hannon, 2013), and first EwS PDX were established (Marchetto et al., 2020; 
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Rokita et al., 2019). Future studies have to elucidate their value as tumor model compared to 
cell lines.  
 
For the first time, cell lines with distinct fusion types were systematically compared. 
Previously, several studies discussed differences of fusion types in regard of the phenotype 
prognosis, first assuming (de Alava et al., 1998) and later reject the hypothesis of any fusion-
type specific effect (Le Deley et al., 2010). Indeed, neither for transcriptome and proteome 
nor for methylome clustering of one fusion type from others was observed in t-SNE plots. 
Despite the similarities in t-SNE analyses, high overlaps of top results in GSEA and of 
shared regulated genes and SEs were detected. Still, EF1 type 2 positive cell lines displayed 
higher overlaps with EF1 type 2 postive cell lines, as did EErg positive cells with others EErg 
positive cells. The reason for those seemingly fusion-type privately regulated genes might be 
simply a stochastic phenomenon, as far less EF1 type 2 and EErg positive cell lines were 
tested than for EF1 type 1 (4 and 3 cell lines versus 11). Hence, the risk for any outlier 
reducing the overlap rate was far less for these fusion types. Nevertheless, there might be 
differences between EwS with distinct fusion types as a consequence of the developmental 
history of the fusion oncogene. The EErg fusion cannot be explained by simple reciprocal 
translocation, as the fusion partners are localized on opposite strands. Thus, likely the EErg 
fusion arises from chromoplexy (Anderson et al., 2018). The developmental process of the 
EwS cell lines' fusions were assessed with three methods, PCR of the inverse fusion 
transcript, read counts from BreakDancer (Chen et al., 2009) on the plus and minus strand of 
EWSR1, and rebuilding rearrangement loops with ChainFinder (Baca et al., 2013). For all 
EF1 type 2 positive cells a reciprocal fusion was detected. In contrast, six of the eleven 
(55%) EF1 type 1 positive cells did not yield any evidence for reciprocal translocation, but for 
chromoplexy. Hence, in nine of 18 cell lines (50%) chromoplexy occured. The rate was 
slightly higher than in a published cohort of primary EwS (42%) (Anderson et al., 2018). 
Noteworthy, chromoplexy always affects at least one other genomic locus. For EW24 even 
several loci were identified as involved in rearrangement loops. Studies on a large series of 
primary EwS might elucidate whether chromoplexy often affects the same genes in EwS or 
rather random loci. This could imply distinct biology of EwS dependent on the developmental 
history of the fusion, and in consequence the necessity of EwS-treatment stratification by 
chromoplexy versus reciprocal translocation. The here generated ChainFinder results were 
based on the cell line data solely, while usually such tools are used after extensive data 
quality adjustment with available normal controls (Anderson et al., 2018; Baca et al., 2013). 
On the one site the successful identification of rearrangement loops in the cell lines 
corroborate the data quality of the ESCLA, on the other site some rearrangements might not 
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have been fully called. Additionally, chromothripsis has been described to cause gene 
fusions (Anderson et al., 2018; Stephens et al., 2011). As chromothripsis affects rather more 
genes on individual chromosomes than chromoplexy, there might be differences between 
EwS with chromothripsis versus chromoplexy as genomic rearrangement event. Thus, also 
this mechanism of fusion development should be further investigated for EwS.  
In sum, the EwS cell lines with distinct fusions depicted many similarities and not any clear 
difference. Except for proteasome subunits in EF1 type 1 positive cell lines, not any gene 
was recurrently represented in fusion-private gene sets (GSEA), but not regulated by other 
fusions. Thus, all cell lines were jointly analysed. The further analyses were conducted 
combining readouts of the several datasets included in the ESCLA to investigate EEts-
mediated gene regulation and potential factors of heterogeneity. 
 
When it comes to heterogeneity, very little is known for EwS. As EwS is genomically silent, 
but the fusion oncogene interacts with highly polymorphic GGAA mSats (Gangwal et al., 
2008; Mirkin, 2007), likely these mSats cause heterogeneity. Indeed, of 3,831 mSats 
genotyped across at least 6 cell lines with HipSTR, 1,467 (38%) corresponded to the 
reference, but nearly as many (1,297; 34%) mSats had even more than two alternative 
alleles. Actually, examples for the clinical impact of GGAA-mSat length were published. A 
SNP, whoose A allele is more frequent in Caucasions than Africans, connects two adjacent 
GGAA mSats creating one long consecutive repeat stretch. This GGAA mSat has enhancer 
activity for EGR2, a susceptibility gene. In line, the EwS incidence in Caucasians is 10x 
higher than for Africans (Grünewald et al., 2015). In 2019, the relevance of a GGAA-mSat 
length for prognosis was shown in a publication coauthored by the author of this thesis 
(Musa et al., 2019). MYBL2 was higher expressed in patients with longer GGAA mSats and 
was associated with survival (Musa et al., 2019). Actually, MYBL2 was reidentified in the 
ESCLA as heterogeneously regulated and survival associated gene.  
In line with previous publications, higher numbers of consecutive GGAA repeats displayed 
higher rates for EEts binding (Gangwal et al., 2008; Guillon et al., 2009; Monument et al., 
2014). Yet, a sweet spot for EEts binding was not observed, although in luciferase reporter 
assays a strong enhancer activity increase was seen at 18-26 repeats before a dip and later 
increase at about 50 repeats (Johnson et al., 2017a; Monument et al., 2014). However, only 
once 24 repeats were genotyped. Thus, the read length was too small to achieve many 
genotypes with the length of the "sweet spot" or even beyond. Nevertheless, the here 
generated data are based on a diploid human genome and not on an artifical mono-allelic 
model. Therefore, this data, as far as sufficient calls are availabe, should be more reliable. 
Besides higher binding rates with increasing number of GGAA repeats, also the absolute 
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number of genotyped mSats accelarated again beyond seven to nine GGAA-motif repeats. 
Rerunning the analysis with other tumor entities and/or normal tissues is necessary to 
evaluate if the mentioned increase in mSat calls with more than seven to nine repeats is 
specific for EwS and might indicate higher EwS susceptibility for children with longer mSats. 
Even more, this analysis could clarify whether GGAA mSats expand in EwS or if the 
observed mSat diversity is actually germline variants. Current data clearly favor the 
hypothesis of germline variants. For instance, the frequency of the risk allele at rs79965208 
is higher in Caucasians than in Africans. Thus EwS susceptibility due to high EGR2 
expression is likely the consequence of a germline variant (Grünewald et al., 2015). 
Furthmermore, mSat instability was not observed for EwS (Monument et al., 2014). 
Moreover, the MYBL2 associated mSat was tested in 76 matched pairs of EwS patients' 
normal and tumor samples, and no differences in the pairs were detected (Musa et al., 
2019).  
Despite the longest consecutive GGAA stretch, also additional nearby motifs with few 
interspersed bases correlated with higher EEts-binding rates. This association was most 
apparent when simply calculating the percentage of GGAA bases of all bases called by 
HipSTR besides the longest consecutive stretch. Another still unresolved issue is connected 
to these results: What should be considered as GGAA mSat in EwS? Several authors refer 
to consecutive GGAA repeats as a GGAA mSat (Gangwal et al., 2008; Guillon et al., 2009). 
Others allow also interruptions up to 20 bases between each motif (Johnson et al., 2017b), 
aggravating the exact definition of the start and end position of a mSat. Here, the mSat 
regions were defined with the parameters given to Tandem Repeats Finder. At least four 
consecutive GGAA repeats were demanded, and whenever the motif was interrupted by an 
alternate base, three motif bases compensated the mismatch, and one full GGAA motif an 
InDel. Other thresholds will result in other start and end positions of the mSats and the here 
described associations of the mSat architecture with EEts binding might differ. Hence, the 
number of consecutive GGAA motifs enables most precise and reproducible description of a 
GGAA mSats, and it was also strongest correlated with fusion binding (Pearson's r=0.99). 
Thus, in further analyses only the longest consecutive GGAA mSat was included. 
Despite the number of GGAA motifs, higher rates of copy number gains in EEts-bound 
GGAA mSats were observed. This might be due to the applied method, as the more copies 
are present the more likely a binding might be precipitated and sequenced. Contrarily, it 
might be a hint that the recurrent CNVs in EwS, whose relevance was not investigated 
except for prognosis association (Mackintosh et al., 2012), supports EwS tumor initiation 
and/or progression. For instance, NFAT5, whose binding motif was found in 12.8% of genes 
upregulated upon EEts knockdown, hence likely downregulated in EwS, is located on chr16q 
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which is frequently lost in EwS (Tirode et al., 2014). Additionally, in few cases specific 
transcription factor binding sites nearby the mSat and the distance to the next GGAA mSat 
might have effect on the EEts-binding probability. However, only factors influencing the EEts 
binding probability were affirmed here, as the number of consecutive GGAA motifs, or newly 
introduced, but not any determinant was identified. Consequently, it remains to be elucidated 
whether EEts binding to GGAA mSats is a probabilistic event favored by some factors, or if 
there are more, still unknown influencing factors. 
EEts binding externally of GGAA mSats to a single GGAA motif, as observed in the ESCLA, 
has been described previously (Guillon et al., 2009; Riggi et al., 2014). In context of the 
hypothesis, that fusion oncogene versus ETS transcription factor expression is tightly 
regulated, the occupation of the ETS transcription factors' binding sites might be another 
mechanism to reduce their effects. As ETS transcription factors in the EEts fusion lack one of 
normally two p300 binding domains, their transcriptonal activator potential is less than for 
wildtype ETS transcripton factors (Riggi et al., 2014). 
The investigation of the above-mentioned factors influencing EEts-binding probability was 
motivated by the association of EEts binding to GGAA mSats with enhancer activity on 
nearby genes (Gangwal et al., 2008; Musa et al., 2019; Patel et al., 2012; Riggi et al., 2014). 
Indeed, the described GGAA-mSat enhancer activity seems to be dependent on EEts and 
thus exclusive for EwS: In a study on mSats associated with nearby gene regulation, the 
GGAA motif was not enriched in the regulative mSats compared to other mSats (OR 0.79, 
P=0.018). Moreover, of 1,380 fine-mapped mSats with associated gene regulation, only eight 
consisted out of the GGAA motif (Fotsing et al., 2019). 
Surprisingly, when focusing on the closest gene for each GGAA mSat, the rate of regulated 
genes was not higher for bound than for unbound GGAA mSats. At a first glance, this 
appears contradictionary to previous studies, which successfully searched fusion-specific 
ChIP-Seq peaks nearby the candidate gene, and actually found a correlation of the mSat 
length with enhancer activity on the candidate gene (Gangwal et al., 2008; Marchetto et al., 
2020; Musa et al., 2019). However, wide range enhancer activity of GGAA mSats was 
described (Guillon et al., 2009). Unpublished ChIA-PET data found enhancer to promoter 
looping with even 1 Mbp distance. Actually, virtually each gene is close enough to a GGAA 
mSat in the human genome to be regulated by such a mSat. Again in line with reports on the 
enhancer activity of EEts-bound GGAA mSats (Gangwal et al., 2008; Wei et al., 2010), the 
distance to the next GGAA mSat, especially an EEts-bound GGAA mSat, was smaller for 
genes downregulated upon EEts knockdown versus not regulated genes. Additionally, the 
number of bound GGAA mSats up to 1 Mbp distant from TSS was 43% higher nearby 
downregulated genes. The enhancer activity of the mSats might affect more genes 
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downstream than upstream, as the nearest bound GGAA mSat was more often upstream on 
the same, and downstram on the opposite strand. Although the closest bound GGAA mSats 
were slightly more often on the opposite strand and downstream, more GGAA mSats were 
found upstream in 1 Mbp distance. Besides these observations on the relative localization of 
GGAA mSats to regulated genes, transcription factor binding sites for NFAT5, NFY, and E2F 
family members were identified in the promoters of 13% of genes upregulated, and 28% and 
11% of genes downregulated upon fusion knockdown, respectively. Interestingly, genes 
coding for these transcription factors appeared regulated by the fusion into the same 
direction as their targets. A potential synergism of EEts and transcription factors has been 
already described for E2F3 as well as an E2F enrichment in EF1 target genes (Schwentner 
et al., 2015; Tomazou et al., 2015). 
Thus, the here presented data support an enhancer activity of EEts-bound GGAA mSats, but 
indicate a multifactorial and probabilistic enhancer effect on target genes. For EEts binding, 
already several factors were identified, like the longest consecutive GGAA stretch, additional 
motifs, nearby mSats, and CNV. For the enhancer effect of EEts binding to GGAA mSats, 
additional factors were identified, like distance to TSS, relative position to TSS dependent on 
the strand, enrichment of nearby EEts-bound mSats, and transcription factor binding motifs 
in promoters. In light of all these parameters, some published experiments might need critical 
reevaluation. For instance, published luciferase reporter assays on GGAA mSats, cloned 
together with their flanking bases, were interpreted as indicator for the enhancer activity of 
the respective GGAA mSat (Dallmayer et al., 2019; Marchetto et al., 2020; Musa et al., 
2019). Another more general interpretation, in line with the here presented data, might be 
that actually any GGAA mSat, independent on the flanking region, has EEts-mediated 
enhancer activity. This could be further investigated in reporter assays with synthetic GGAA 
mSats without flanking regions. As another example, CRISPRi for specific GGAA mSats was 
shown to impair target gene expression (Johnson et al., 2017a; Musa et al., 2019). However, 
as the results here did not support the concept of one GGAA mSat regulating one gene, 
probably also other genes might be affected by such CRISPRi experiments. Identification of 
those genes might further elucidate the interactions among GGAA mSats and with genes. 
The most relevant experiments to understand those interactions are likely chromosome 
conformation capture experiments. Unfortunately, these experiments currently lack precise 
positional resolution (Pal et al., 2019). 
The mechanism of EEts mediated gene suppression was not further clarified, as the 
associations seen for genes downregulated upon EEts knockdown were usually far stronger 
than for the upregulated genes. Nevertheless, identification of the suppressive EEts effect on 
NFAT5, located on the recurrently lossed chr16q arm, might already explain the upregulation 
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of 13% of upregulated genes. The observed EEts binding to single GGAA motifs might also 
reason suppression of ETS transcription factor family targets. However, NFAT5 has not been 
described to be regulated by ETS transcription factors. Additionally, an alternate localization 
of bound GGAA mSats for genes upregulated upon fusion knockdown was observed. The 
next bound GGAA mSats was more often upstream than downstream located, and more 
distant to the TSS. How such relative positions in the genome might translate into gene 
suppression, remains to be elucidated. Again, chromatin conformation capture might shed 
light on potential interactions of GGAA mSats with genes upregulated upon EEts knockdown, 
hence, likely in EwS suppressed genes.  
 
Finally, 22 genes were identified as being heterogeneously regulated by EEts and associated 
with overall survival. Notably, 14 of these 22 genes were involved in cell cycle regulation. 
This further supports the notion that EwS requires strictly regulated cell cycle progression to 
stay genomically silent (Gorthi et al., 2018; Iniguez et al., 2018). Furthermore, the 
heterogeneous regulation and expression of these genes hint towards the employment of 
different cell-cycle regulating processes in distinct EwS tumors. Moreover, two transcription 
factors were among the 22 heterogeneously regulated genes, namely E2F1 and MYBL2. The 
regulation of E2F1 is in line with the enriched E2F family binding site in 11% of promoters of 
genes downregulated upon EEts knockdown. Furthermore, in each cell line with strongly 
affected E2F1 expression upon fusion knockdown, the known E2F target CENPI 
(Thangavelu et al., 2017), another cell-cycle associated gene among the 22 genes, was at 
least moderately affected. As above-mentioned, MYBL2 was reidentified and its clinical 
relevance for EwS has been already published (Musa et al., 2019). However, factors 
described in this thesis to impact EEts-mediated gene regulation were not sufficient to 
explain inter-cell line heterogeneity in the expression regulation of the 22 survival associated 
genes.  
 
In summary, the ESCLA is a high-quality dataset and likely a rich resource for further 
investigations, which already reidentified and supported previous findings on EEts-fusion 
binding and genes regulated by EEts. Additionally, the ESCLA provided new insights into a 
rather probabilistic model of EEts-mediated gene regulation, new impulses for further 
investigations, emphasized the importance of chromatin conformation capture to better 
understand EEts interactions, and highlights the relevance of a well understood EEts biology 
to promote personalized medicine.  
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6. Conclusions and limitations 
 
6.1. Conclusions 
• Numerous EwS cell line models with inducible EWSR1-ETS fusion knockdown were 
generated as a resource for further investigations of fusion-mediated effects. 
 
• A tissue microarray with in vivo expanded EwS cell lines with and without fusion 
knockdown (EF1) was constructed and enables in situ evaluation of fusion regulated 
proteins. 
 
• The Ewing Sarcoma Cell Line Atlas - ESCLA - was generated with all constructed cell 
line models. The ESCLA is multidimensional and comprehensive with high quality 
data, enabling assessment of gene regulation, fusion binding, epigenetics and 
genetics of the cell line models. 
 
• Analyses of the ESCLA corroborated previously described mutations, targets of 
EWSR1-ETS, EWSR1-ETS binding sites and colocalization with histone acetylation 
and super-enhancers. Furthermore, GGAA mSats were genotyped, additional 
(consistently) EWSR1-ETS regulated genes and consensus EWSR1-ETS binding 
sites were identified. 
 
• First time systematic evaluation of commonalities between EwS cell lines with three 
distinct fusion types, EF1 type 1, 2 and EErg, showed highly similar super-enhancer 
landscape, methylation profile and expression regulation, but different rates of 
chromoplexy.  
 
• The number of consecutive GGAA motifs as main determinant of EWSR1-ETS 
binding to a GGAA mSat was validated by the ESCLA data. Additionally, copy 
number gains and transcription factor binding sites of e.g. GATA2 were identified to 
favor EWSR1-ETS binding. Previously reported differences in the distance of 
EWSR1-ETS regulated genes to EWSR1-ETS binding sites were refined. Moreover, 
the position of the GGAA mSat relative to the stand and transcription start site was 
shown to differ for genes regulated by EWSR1-ETS. Combination of transcriptome, 
ChIP and WGS data revealed that EWSR1-ETS regulated genes are enriched for 
binding sites of transcription factors, which were as well regulated by EWSR1-ETS, 
namely NFAT5, NFYC and E2F family members. 
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• Expression regulation heterogeneity was demonstrable in the ESCLA, in line with 
observations in primary EwS associated with survival.  
 
• Hence, the ESCLA constitutes a rich resource for the Ewing sarcoma research 
community, promotes biomarker identification, models heterogeneity and, thus, might 




• This thesis bases on cell line models, which were shown here to be only similar, but 
not equal to primary EwS tumors regarding transcriptome and methylome. Hence, the 
results might be not fully representative for EwS and likely several true interactions in 
EwS are not ascertainable by the ESCLA. Further efforts should be made to find 
alternative EwS models and test them for their representativity for EwS. Additionally, 
culture conditions other than 2D (e.g. sphere formation, in vivo expansion) should be 
tested for their potential to adapt cell line behavior closer to primary EwS tumors. 
 
• The fusion knockdown efficiency highly differed among the cell lines and had 
inconsistent effects on cell viability. Hence, some regulation was possibly missed out 
and artefacts might have occurred due to selective pressure. To increase the rate of 
accurately identified fusion regulated genes, similar knockdown levels are desirable, 
and might be achieved by further generation and testing of single cell clones and/or 
retransfection. 
 
• The ESCLA was built with sequencers, analysers and processing pipelines in 
accordance with state of the art. Nevertheless, all analyses have limitations that will 
be, at least partly be overcome with technical improvements. The sequencing was 
performed with 150 bp reads; GGAA mSats near to this length or even longer can 
only be predicted with a certain rate of specificity. Long-read sequencing will enable 
the identification of far longer mSats and a clear phasing, but have currently still high 
error rates. ChIP is notoriously difficult to normalise. The results should be validated 
with independent replicates and sequencing with a uniform protocol. Additionally, the 
optimal ChIP-Seq protocol for read mapping to GGAA mSats has not been 
systematically evaluated yet. The microarray data were already filtered for 
~ 102 ~ 
 
(presumably) translated genes, but several gene models are already deprecated and 
other predicted, here not considered genes have been experimentally validated. 
Thus, reanalyses of microarray data with updated gene lists as well as updated chip 
description files promise discovery of further fusion driven genes.    
 
• All analyses on the ESCLA were performed with computational and statistical tools, 
most of which are based on several assumptions. Especially when running several 
analyses in a row, thus making many assumptions, false interpretations can easily 
occur. Hence, although analyses were done with appropriate tools and parameters, to 
the best of my knowledge, all results are and have to be understood as correlations 
and predictions which demand extensive experimental validation before translation 
into clinics. 
 
• The analyses based on the ESCLA were focused on gene expression, especially for 
genes with clinical relevance, and further investigation of previously described and 
presumed expression regulating factors. Hence, many other potential regulatory 
aspects in EwS were not considered, but can partly be assessed in the ESCLA. For 
instance, ClariomD microarray also quantifies various long non-coding RNAs whose 
relevance for EwS was not investigated here. Network analysis might identify most 
relevant hubs in regulatory circuits. Additionally, the ESCLA might be extended, as 
the cell line models were stably generated. For instance, drug response assays in 
EEts-high versus -low cells and metabolomic analyses warrant further insights into 
the biology of EwS. 
 
• Although previous reports on factors influencing EWSR1-ETS binding to GGAA 
mSats and EWSR1-ETS mediated gene expression regulation were confirmed and 
refined, and additional factors were identified, still binding and expression regulation 
were not fully predictable. Hence, some influencing factors were not detected and are 
still unknown. The genome-wide analyses counterspeaked the assumption of direct 
enhancer activity of an EWSR1-ETS bound GGAA mSat on the nearest gene. 
Instead, the here presented results hint towards a complex regulatory network over a 
relatively wide genomic range. Thus, to identify interacting sites in this regulatory 
network the ESCLA should be augmented with chromosome conformation capture 
analyses. Additionally, genome editing of GGAA mSats and subsequent genome 
wide ChIP-Seq and transcriptome analyses might elucidate the relevance of single 
mSats in EWSR1-ETS mediated gene expression regulation. 
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• The survival dataset was relatively large for a rare cancer, but small compared to 
studies on for example mamma carcinoma. Additionally, the overlap of genes 
described in the survival dataset and investigated by ClariomD microarray was 
50.8%. A larger, possibly multi-centric survival cohort on the same microarray 
platform as the ESCLA or RNAseq analysis will likely increase the number of correctly 
identified differential fusion driven clinically relevant genes. 
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